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Abstract 
Flavoenzymes are a widely diverse group of enzymes that are able to catalyze a 
variety of different chemical reactions. A growing interest in flavoenzymes 
capable of reducing aromatic nitro groups may be attributed to their ability to 
reduce anticancer prodrugs such as CB 1954. Similarly, quinone 
oxidoreductases are able to activate anticancer prodrugs such as mitomycin 
derivatives by reducing the quinone derivative to the hydroxyl derivative. 
Some oxidoreductases are able to reduce nitro aromatic compounds. These 
enzymes may be either mammalian such as NQO1 and NQO2 which are over 
expressed in certain cancerous cells or bacterial which can be introduced into 
the cancerous growth. The bacterial nitroreductases have been previously well 
characterized and were found to share several similarities. On the other hand, 
other nitro reducing enzymes have not been investigated to determine the 
presence of any shared similarities. Another aim of this thesis is to identify the 
differences between the structure of the oxidized and reduced forms of NQO2. 
The similarities shared between the flavoenzymes which are known to reduce 
nitroaromatic compounds to their hydroxylamine or amine derivative were 
investigated in this thesis. Both the sequences and 3D structures of the selected 
proteins were compared and investigated using a variety of bioinformatics tools 
such as sequence and structure alignment, in addition to homology modelling. 
It was discovered that there are several aromatic residues conserved in different 
positions, relative to the flavin cofactor, in the catalytic sites of the proteins. 
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Abstract 
The 3D structure of the reduced NQO2 was determined using X-ray 
crystallography. The oxidized and reduced protein structures were compared to 
determine the structural differences. The expression, purification and 
crystallization of the NQO2 protein, as well as the reduction of the protein 
crystals are described in this work. The determination of the structure of the 
reduced protein provided new insights into the mechanism of electron transport 
to and from the flavin cofactor. Moreover, kinetics studies were undertaken on 
the purified NQO2 protein using fluorescence spectroscopy. These resulted in 
the identification of several new substrates for NQO2. 
11 
Acknowledgments 
Firstly, I would like to thank my supervisor Dr. Cristina DeMatteis for her 
guidance and understanding through out my PhD. I would also like to thank the 
International Office and the School of Pharmacy at the University of 
Nottingham for funding. 
I would also like to add my sincere appreciation for all the help provided by all 
my colleagues in the crystallography and modelling labs. Special thanks to 
Dr. Elizabeth Hooley for her help in collecting data at Diamond Light Source 
and to Dr. Paul McEwan for his guidance during data processing. I would also 
like to add my appreciation for the technical support given by Dr. Ian Withers, 
Dr. Huw Williams, Dr. Jed Long and Lee Hibbet. I would also like to thank 
Graham Coxhill from the School of Chemistry for help provided on mass 
spectroscopy work carried out. 
I would also like to thank my friends for their good company, encouragement, 
and laughs, as well as many lunches, coffees and greatly needed chocolate 
breaks. I would also like to thank my friends abroad for their encouragement 
and many long phone conversations at the oddest times of the day. 
Last but not least I would like to express my gratitude to my parents and 
brother for all their financial, moral and emotional support. I would also like to 
thank them for their continuous encouragement and never ending belief in me 
without which I would have not been able to carry out my PhD. 
Rana H. Refaey 
iii 
Table of Contents 
Abstract 
..................................................................................................... 
i 
Acknowledgments 
.................................................................................. 
iii 
Table of Contents 
................................................................................... 
iv 
List of Figures 
.......................................................................................... 
x 
List of Tables ' 
Abbreviations 
........................................................................................ 
xv 
1. Introduction to Flavoenzymes and their Role in Bio-reductive 
Cancer Chemotherapy 
............................................................................ 
1 
1.1 Flavoenzymes 
.......................................................................................... 
1 
1.1.1 Regulation of Flavoenzymes 
........................................................... 
3 
1.1.2 Recurrent Characteristics in Flavoproteins 
.................................. 
5 
1.1.3 Classification of Flavoproteins 
....................................................... 
6 
1.2 Quinone Oxidoreductases 
...................................................................... 
7 
1.2.1 Quinones 
........................................................................................... 
8 
1.2.1.1 Sources of Quinones 
............................................................................. 
8 
1.2.1.2 Cytotoxicity of Quinones 
....................................................................... 
8 
1.2.3 Primary Structure of NQOs 
........................................................... 
9 
1.2.4 Secondary Structure of NQOs 
...................................................... 
10 
1.2.5 Catalytic Site of NQOs 
.................................................................. 
12 
1.2.6 Mechanism of Action of NQOs 
..................................................... 
13 
1.2.7 Cosubstrates, Substrates and Inhibitors of NQOs 
...................... 
16 
1.2.7.1 Cosubstrates 
....................................................................................... 
16 
1.2.8 Distribution of NQOs 
.................................................................... 
17 
1.2.9 Physiological functions of NQOs 
.................................................. 
17 
1.2.10 Medical Applications of NQOs 
................................................... 
18 
1.3 Bacterial Nitroreductases 
..................................................................... 
19 
1.4 Cancer 
.................................................................................................... 
20 
1.4.1 The Development of Cancer 
......................................................... 
20 
1.4.2 Hypoxia in Tumours 
...................................................................... 
20 
1.5 Cancer Treatment 
................................................................................. 
22 
1.5.1 Anticancer Targeted Prodrug Therapy 
....................................... 
22 
1.5.1.1 ADEPT 
................................................................................................ 
23 
1.5.1.2 GDEPT 
............................................................................................... 
23 
1.5.2 Bioreductive Anticancer Drugs 
.................................................... 
24 
1.5.2.2 Nitroaromatics 
.................................................................................... 
28 
1.6 Aims of the Thesis 
................................................................................. 
32 
iv 
Table of Contents 
2. Introduction to X-ray Crystallography 
.......................................... 
33 
2.1 Introduction 
........................................................................................... 
33 
2.2 Protein Crystallization 
......................................................................... 
35 
2.2.1 Protein crystallization techniques 
................................................ 
36 
2.2.2. Cryocrystallography 
..................................................................... 
37 
2.2.3 Nature of the Crystal 
..................................................................... 
38 
2.2.3.1 Lattice planes and Miller indices 
....................................................... 
40 
2.2.4 X-ray Diffraction by Crystals 
....................................................... 
41 
2.2.4.1 Bragg's Law 
....................................................................................... 
41 
2.2.4.2 Reciprocal lattice and Ewald's Sphere 
............................................... 
42 
2.3 Data collection 
....................................................................................... 
43 
2.4 Data Processing 
..................................................................................... 
44 
2.4.1 Indexing and Integration of Images 
............................................. 
44 
2.4.2 Scaling and Merging of Reflections 
.............................................. 
45 
2.4.2.1 Assessing Data Quality 
....................................................................... 
46 
2.4.3 The Structure Factors and the Phase Problem 
........................... 
47 
2.4.3.1 Molecular Replacement 
...................................................................... 
48 
2.4.4 Electron Density Maps 
.................................................................. 
49 
2.4.5 Refinement of the Model 
............................................................... 
49 
2.4.5.1 Refinement Indicators 
......................................................................... 
50 
2.4.6 Model Quality 
................................................................................. 
51 
3. Sequence analysis and Structural Studies of Nitroaromatic 
Reducing Enzymes 
................................................................................ 
53 
3.1 Introduction 
........................................................................................... 
53 
3.2 Methods and Materials 
......................................................................... 
56 
3.2.1 Summary of Methods Used 
........................................................... 
56 
3.2.2 Identification of Enzymes 
............................................................. 
57 
3.2.3 Strategy for Obtaining Sequences and 3D Structural Data....... 57 
3.2.4 Extraction of Active Site Residues from 3D Structures 
............. 
57 
3.2.5 Sequence Alignment 
...................................................................... 
58 
3.2.5.1 Alignment parameters used in alignments with Clustal W2 
............... 
59 
3.2.6 The 3D Structural Alignment of the Active Site Residues......... 59 
3.2.7 Sequence Alignment for Enzymes within Different Structural 
Groups 
..................................................................................................... 
60 
3.2.7.1 Calculation of percentage identity & similarity between sequences of 
group members 
............................................................................................... 
60 
3.2.8 Homology Modelling 
.................................................................... 
61 
3.2.8.1 Choice of model 
.................................................................................. 
61 
3.2.8.2 Template examination and group identification 
................................. 
62 
3.2.8.3 Percentage identity and similarity calculation for modelled proteins 62 
3.2.8.4 Validation of group identification 
...................................................... 
63 
3.2.9 Structural and Sequence Alignment for Proteins Groups......... 63 
3.2.9.1 Structural alignment 
........................................................................... 
63 
3.2.9.2 Sequence alignment 
............................................................................ 
63 
3.2.9.3 Secondary sequence alignment 
........................................................... 
63 
3.2.10 Identification of Conserved Residues 
......................................... 
64 
V 
Table of Contents 
3.3 Results 
.................................................................................................... 
64 
3.3.1 Obtaining the Sequences and 3D Structural Data 
...................... 
64 
3.3.2 Active Site Residue Extraction from 3D Structures 
................... 
64 
3.3.3 Sequence Alignment for All Enzymes 
.......................................... 
67 
3.3.4 The 3D Structural Alignments of Active Site Residues 
.............. 
67 
3.3.4.1 Group I active site structural alignment 
............................................. 
68 
3.3.4.2 Group II active site structural alignment 
........................................... 
69 
3.3.5 Sequence Alignment for Enzymes within Identified Groups 
.... 
70 
3.3.5.1 Calculation of identity and similarity within identified groups.......... 70 
3.3.5.2 Sequence alignment of group I 
........................................................... 
71 
3.3.5.3 Sequence alignment of group 11 
.......................................................... 
72 
3.3.6 Homology Modelling 
..................................................................... 
73 
3.3.6.1 Template examination and group identification 
................................. 
74 
3.3.6.2 Comparison of models produced by homology modelling 
.................. 
75 
3.3.6.3 Percentage identity and similarity calculation between modelled and 
previously identified group I members 
........................................................... 
76 
3.3.6.4 Percentage identity and similarity calculation between modelled and 
previously identified group II members 
.......................................................... 
77 
3.3.7 Structural and Sequence Alignment for Group I Proteins........ 77 
3.3.7.1. Structural alignment 
.......................................................................... 
77 
3.3.7.2 Sequence alignment 
............................................................................ 
78 
3.3.7.3 Secondary Structure prediction and alignment 
.................................. 
80 
3.3.8 Structural and Sequence Alignment for Group II Proteins 
...... 
81 
3.3.8.1 Sequence alignment 
............................................................................ 
81 
3.3.8.2 Structural alignment 
........................................................................... 
82 
3.3.8.3 Secondary Structure prediction and alignment: 
................................. 
82 
3.3.9 Structural and Sequence Alignment for Group III Proteins..... 83 
3.3.9.1 Identification of group III members 
.................................................... 
83 
3.3.9.2 Percentage identity and similarity between group III members......... 83 
3.3.9.3 Sequence alignment 
............................................................................ 
85 
3.3.9.4 Secondary Structure prediction and alignment 
.................................. 
85 
3.3.10 Structural and Sequence Alignment for Group IV Proteins 
... 
86 
3.3.10.1 Structural alignment 
......................................................................... 
86 
3.3.10.2 Sequence alignment: 
......................................................................... 
88 
3.3.10.3 Secondary Structure predication and alignment 
.............................. 
89 
3.4 Discussion and Conclusion 
................................................................... 
89 
4. Kinetic Studies for NQO2 I: Methods and Materials 
.................... 
96 
4.1 Introduction 
........................................................................................... 
96 
4.1.1 Enzyme Reactions 
.......................................................................... 
96 
4.1.2 Enzyme Kinetic Constants 
............................................................ 
97 
4.1.3 Potential NQO2 Substrates 
......................................................... 
100 
4.1.3.1 Novel substrate, GC201 
.................................................................... 
100 
4.1.3.2 Coenzyme Q0, Coenzyme QI and Coenzyme Q2 
............................. 
100 
4.1.4 Experimental Methods for Determining Michealis-Menten 
Constants 
............................................................................................... 
101 
4.2 Experimental Methods and Materials 
.............................................. 
102 
4.2.1 Cloning of NQO2 
......................................................................... 
103 
4.2.2 Expression and Harvesting of NQO2 
......................................... 
103 
4.2.3 Purification of NQO2 
.................................................................. 
104 
V1 
Table of Contents 
4.2.4 Assessment of Protein Purity 
...................................................... 
105 
4.2.4.1 Preparation of gel 
............................................................................. 
106 
4.2.4.2 Preparation of samples and running of the gel 
................................ 
107 
4.2.5 Concentrating and Storage of NQO2 
......................................... 
107 
4.2.6 Optimizing Enzyme Kinetics Protocol 
....................................... 
108 
4.2.6.1 UV visible absorbance scans 
............................................................ 
108 
4.2.6.2 Fluorescence emission and excitation spectrums 
............................. 
108 
4.2.6.3 Effect of air exposure on the fluorescence of NBDH 
........................ 
108 
4.2.6.4 Fluorescence emission controls for other reaction components 
...... 
109 
4.2.7 Calibration Curve Relating Concentration of NBDH to its 
Fluorescence 
.......................................................................................... 
109 
4.2.8 Optimization of Published Reaction Conditions 
....................... 
110 
4.2.8.1 Enzyme concentration optimization 
.................................................. 
111 
4.2.8.2 Temperature choice 
.......................................................................... 
111 
4.2.8.3 Reproducibility testing 
...................................................................... 
112 
4.2.9 K. Determination for Novel Substrates 
..................................... 
112 
4.2.9.1 Determination of linear relationship between enzyme concentration 
and reaction rate 
.......................................................................................... 
112 
4.2.9.2 K, 
n 
determination 
.............................................................................. 
113 
4.2.9.3 Substrate-cosubstrate reaction controls 
........................................... 
114 
5. Kinetic Studies for NQO2 II: Results and Discussion 
................. 
115 
5.1 Protein Preparation 
............................................................................ 
115 
5.1.1 Assessing Protein Purity Using SDS-PAGE 
.............................. 
115 
5.2 Optimizing Enzyme Kinetics Protocol 
.............................................. 
115 
5.2.1 UV Visible Spectrum of NBDH 
.................................................. 
115 
5.2.2 Fluorescence Emission Spectrum of NBDH 
.............................. 
117 
5.2.3 Effect of Air Oxidation on the Fluorescence of NBDH 
............ 
117 
5.2.4 Fluorescence Emission Measurements for Other Reaction 
Components 
........................................................................................... 
118 
5.2.5 Calibration Curve for NBDH 
..................................................... 
119 
5.3 Protocol Development 
........................................................................ 
121 
5.3.1 Choice of Enzyme Concentration 
............................................... 
121 
5.3.2 Effect of temperature on reaction of menadione and K. 
......... 
122 
5.3.3 Determining the Reproducibility of Results Using the Optimized 
Parameters 
............................................................................................. 
123 
5.4 Enzyme Kinetics for Substrates 
........................................................ 
124 
5.4.1 Substrate%osubstrate Mixture Fluorescence Monitoring 
....... 
124 
5.4.2 Relationship between enzyme and reaction rate 
...................... 
125 
5.4.3 K. determination for Substrates 
................................................ 
127 
5.4.3.1 Coenzyme QO 
.................................................................................... 
127 
5.4.3.2 Coenzyme Q] 
.................................................................................... 
129 
5.4.3.3 Coenzyme Q2 
.................................................................................... 
130 
5.4.3.4 GC201 
............................................................................................... 
132 
5.5 Discussion and Conclusion 
................................................................. 
133 
vii 
Table of Contents 
6. Determination of the Crystal Structure of Reduced NQO2 I: 
Methods and Material 
........................................................................ 
135 
6.1 Introduction 
......................................................................................... 
135 
6.2 Methods and Materials 
....................................................................... 
136 
6.2.1 Protein Production 
...................................................................... 
137 
6.2.2 Protein Crystallization 
................................................................ 
137 
6.2.3 Crystal Reduction & Cryoprotectant Solution Optimization. 139 
6.2.4 Data Collection 
............................................................................. 
140 
6.2.4.1 Dataset one 
....................................................................................... 
140 
6.2.4.2 Dataset two 
....................................................................................... 
141 
6.2.4.3 Datasets three, four and five 
............................................................. 
141 
6.2.5 Data Processing 
............................................................................ 
142 
6.2.5.1 Indexing and integration of images 
.................................................. 
142 
6.2.5.2 Scaling and merging of images 
......................................................... 
142 
6.2.5.3 Molecular replacement 
..................................................................... 
143 
6.2.5.4 Refinement of model 
......................................................................... 
144 
6.2.6 Identification of Unknown Electron Density in the Binding 
Pocket 
..................................................................................................... 
145 
6.2.6.1 Automated ligand identification 
....................................................... 
145 
6.2.6.2 Refinement of probable molecules into the electron density 
............ 
145 
6.2.7 Model Validation 
......................................................................... 
147 
7. Determination of the Crystal Structure of Reduced NQO2 II: 
Results and Discussion 
........................................................................ 
149 
7.1 Protein Production 
.............................................................................. 
149 
7.2 Protein Crystallization 
....................................................................... 
149 
7.3 Crystal Reduction and the Choice of Cryoprotectant 
..................... 
150 
7.3.1 Crystal Reduction 
........................................................................ 
150 
7.3.2 Cryoprotection Solution Choice 
................................................. 
152 
7.4 Data Processing 
................................................................................... 
152 
7.4.1 Space Group and Cell Dimension Determination 
.................... 
152 
7.4.2 Data Processing Statistics for Different Datasets 
..................... 
153 
7.5 Molecular Replacement 
...................................................................... 
154 
7.6 Model Examination 
............................................................................ 
155 
7.7 Refinement and Ligand Identification 
.............................................. 
159 
7.7.1 Refinement Statistics After Manual Adjustments in COOT... 159 
7.7.2 Identification of Unknown Electron Density 
............................. 
159 
7.7.2.1 Automated ligand identification 
....................................................... 
163 
7.7.2.2 Refinement of probable molecules into the electron density 
............ 
164 
7.7.2.3 Analytical work 
................................................................................ 
166 
7.8 Discussion 
............................................................................................ 
166 
7.8.1 Structural Differences Between Oxidized & Reduced NQO2.166 
7.8.2 Unidentified Electron Density 
.................................................... 
171 
8. Conclusions and Future work 
........................................................ 
173 
viii 
Table of Contents 
Bibliography 
........................................................................................ 
178 
Appendices 
........................ 
xviii 
Al. Amino acid abbreviations 
.................................................................. 
xviii 
A2. Composition of solutions used in experimental procedures 
............... 
xix 
A3. Sequence alignments 
............................................................................. 
xx 
A4. Ramachandran plots 
........................................................................ 
xxviii 
ix 
List of Figures 
Figure 1.1 Structure of flavins and numbering of isoalloxazine ring 
................ 
2 
Figure 1.2 Different oxidation states of isoalloxazine ring 
............................... 
3 
Figure 1.3 The chemical properties of the isoalloxazine ring 
........................... 
5 
Figure 1.4 Structures of different quinones 
....................................................... 
9 
Figure 1.5 Sequence alignment of NQO1 and NQO2 
..................................... 
10 
Figure 1.6 Superimposed structures of hNQO1 and hNQO2 
.......................... 
11 
Figure 1.7 Cartoon representation of the structure of NQO2 
.......................... 
12 
Figure 1.8 The overlaid catalytic sites of hNQOI and hNQO2 
...................... 
13 
Figure 1.9 Aromatic residues in the catalytic sites of hNQOI and hNQO2 
... 
14 
Figure 1.10 Schematic representation of the mechanism of action of NQOs 
. 
14 
Figure 1.11 Proposed mechanism of hydride transfer in NQO1 
..................... 
15 
Figure 1.12 Stepwise reduction of nitroaromatic compounds 
......................... 
20 
Figure 1.13 Cancer development models 
........................................................ 
21 
Figure 1.14 Representation of ADEPT 
............................................................ 
24 
Figure 1.15 Representation of GDEPT 
............................................................ 
25 
Figure 1.16 Reduction of MMC and formation of DNA cross links 
............... 
26 
Figure 1.17 Structures of E09 and AZQ 
......................................................... 
27 
Figure 1.18 Release of active drug upon reduction of indolequinone 
............. 
28 
Figure 1.19 Structure and bioactivation of CB 1954 
........................................ 
30 
Figure 2.1 Processes involved in X-ray Crystallography 
................................ 
34 
Figure 2.2 Phase diagram for crystallization 
................................................... 
36 
Figure 2.3 Schematic representations of sitting and hanging drop 
.................. 
37 
Figure 2.4 Schematic representation of crystal parameters 
............................. 
39 
Figure 2.5 Lattice planes and their designated Miller indices 
......................... 
40 
Figure 2.6 Constructive interference as defined by Bragg's law 
..................... 
41 
Figure 2.7 Construction of Ewald's sphere 
..................................................... 
43 
Figure 2.8 Schematic representation of varying degrees of crystal packing 
... 
45 
Figure 2.9 Backbone of protein, showing c and '1' angles 
............................. 
52 
Figure 3.1 Overlaid extracted active sites of group I members 
....................... 
68 
Figure 3.2 Overlaid extracted active sites of group II members 
...................... 
69 
Figure 3.3 T-Coffee sequence alignment of identified group I members........ 72 
Figure 3.4 Clustal W2 sequence alignment of identified group I members 
.... 
72 
X 
List of Figures 
Figure 3.5 T-Coffee sequence alignment of identified group II member........ 73 
Figure 3.6 Clustal W2 sequence alignment of identified group II members... 73 
Figure 3.7 Overlaid active site of all group I members 
.................................... 
78 
Figure 3.8 Sequence alignment of all group I using T-Coffee 
........................ 
79 
Figure 3.9 Sequence alignment of all group I using Clustal W2 
..................... 
79 
Figure 3.10 Secondary structure alignment of all group I 
............................... 
80 
Figure 3.11 Overlaid active site of all group II members 
................................. 
81 
Figure 3.12 Sequence alignment of all group II using T-Coffee 
...................... 
82 
Figure 3.13 Sequence alignment of all group II using Clustal W2 
.................. 
82 
Figure 3.14 Secondary structure alignment of all group II 
.............................. 
83 
Figure 3.15 Overlaid active site of all III members 
......................................... 
84 
Figure 3.16 Sequence alignment of all group III using T-Coffee 
.................... 
85 
Figure 3.17 Sequence alignment of all group III using Clustal W2 
................ 
85 
Figure 3.18 Secondary structure alignment of all group III 
............................ 
86 
Figure 3.19 Overlaid cartoon representation of the structures of group IV..... 87 
Figure 3.20 Overlaid active site of all group IV members 
.............................. 
87 
Figure 3.21 Sequence alignment of all group IV using T-Coffee 
................... 
88 
Figure 3.22 Sequence alignment of all group IV using Clustal W2 
................ 
88 
Figure 3.23 Secondary structure alignment of all group IV 
............................ 
89 
Figure 3.24 Residues of mechanistic importance in group I members............ 91 
Figure 3.25 Residues of mechanistic importance in group IV members......... 94 
Figure 3.26 The orientations of the conserved residues in different groups 
... 
94 
Figure 4.1 Progress curve of an enzyme reaction 
............................................ 
97 
Figure 4.2 Representation of Michealis-menten & Lineweaver-Burke plot.. 99 
Figure 4.3 Reduction of GC201 
..................................................................... 
100 
Figure 4.4 Structures of coenzymes Q0, coenzyme Q1 and coenzyme Q2 
.. 
100 
Figure 4.5 Structure of NBDH 
....................................................................... 
101 
Figure 5.1 Example of SDS-PAGE 
............................................................... 
116 
Figure 5.2 UV/visible absorbance spectrum of NBDH 
................................. 
116 
Figure 5.3 Emission spectrum of NBDH 
...................................................... 
117 
Figure 5.4 Decrease in fluorescence of NBDH due to air oxidation 
............. 
118 
Figure 5.5 Fluorescence of NQO2, coenzyme Q seris and menadione 
......... 
119 
Figure 5.6 Calibration curve of NBDH at low concentration 
........................ 
120 
Figure 5.7 Calibration curve of NBDH at high concentration 
....................... 
121 
X1 
List of Figures 
Figure 5.8 Effect of enzyme concentration on the menadione reaction rate. 122 
Figure 5.9 Michealis-Menten plots for NQO2/menadione reaction 
.............. 
123 
Figure 5.10 Reproducability testing of NQO2/menadione reaction 
.............. 
124 
Figure 5.11 Fluorescence decay of cosubstrate/substrate mixtures 
............... 
125 
Figure 5.12 Effect of enzyme concentration on reaction rate 
........................ 
126 
Figure 5.13 Michealis-Menten plot for NQO2/coenzyme QO reaction......... 127 
Figure 5.14 Hanes-Woolf plot for NQO2/coenzyme QO reaction 
................. 
128 
Figure 5.15 Lineweaver-Burke plot for NQO2/coenzyme QO reaction 
........ 
128 
Figure 5.16 Michealis-Menten plot for NQO2/coenzyme Q1 reaction 
......... 
129 
Figure 5.17 Lineweaver-Burke plot of NQO2/coenzyme Q1 reaction.......... 130 
Figure 5.18 Michealis-Menten plot for NQO2/coenzyme Q2 reaction......... 131 
Figure 5.19 Lineweaver-Burke plot of NQO2/coenzyme Q2 reaction.......... 131 
Figure 5.20 Michealis-Menten plot for reaction of GC201 with NQO2....... 132 
Figure 6.1 Side view of isoalloxazine ring showing bend N5-N10 
............... 
136 
Figure 6.2 Oxidation of DTT 
......................................................................... 
146 
Figure 7.1 Photographs of NQO2 crystals 
..................................................... 
151 
Figure 7.2 Reduced NQO2 crystal mounted on goniometer 
......................... 
151 
Figure 7.3 Cartoon representation of NQO2, showing mobile loop 
.............. 
156 
Figure 7.4 Active site of NQO2 showing the unidentified electron density. 157 
Figure 7.5 Different orientations of the active site electron density maps of 
dataset 4 
......................................................................................................... 
158 
Figure 7.6 The active site electron density maps of data set 5 
...................... 
159 
Figure 7.7 Side view of unidentified electron density of different data sets. 161 
Figure 7.8 Top view of unidentified electron density of different data sets.. 162 
Figure 7.9 Overlaid active site electron density maps of data sets 1,2 & 3... 163 
Figure 7.10 Structures of 4- hydroxycinnamic acid and palmitic acid.......... 164 
Figure 7.11 Different molecules refined in the unidentified electron density 165 
Figure 7.12 Overlaid cartoon representation of oxidized & reduced NQ02.167 
Figure 7.13 Overlaid FAD molecules of the oxidized & reduced NQO2 
..... 
168 
Figure 7.14 Overlaid structures of oxidized & reduced thioredoxin reductase 
........................................................................................................................ 
169 
Figure 7.15 Hydrogen bond between Tyr-155 residue and 02 of FAD........ 170 
Figure 7.16 Overlaid Tyr-155 & FAD of the oxidized & reduced NQO2 
.... 
170 
X11 
List of Tables 
Table 1.1 Reported substrates and inhibitors of NQOI and NQO2 
................. 
17 
Table 3.1 Different parameter combinations used for Clustal W2 alignments 59 
Table 3.2 Final list of enzymes, accession code & associated species............ 65 
Table 3.3 Final list of enzymes, accession & pdb codes & associated species66 
Table 3.4 Conserved residues of group I 
......................................................... 
69 
Table 3.5 Conserved residues of group II 
........................................................ 
70 
Table 3.6 Percentage similarity between group I members 
.............................. 
70 
Table 3.7 Percentage similarity between group II members 
........................... 
71 
Table 3.8 Symbols & colours used in Clustal W2 & T-Coffee alignments 
.... 
72 
Table 3.9 List of templates used in homology modelling 
............................... 
74 
Table 3.10 RMSD values between the different homology models 
................. 
76 
Table 3.11 Percentage similarities between identified & modelled group I 
members 
............................................................................................................ 
76 
Table 3.12 Percentage similarities between identified & modelled group II 
members 
............................................................................................................ 
77 
Table 3.13 Conserved residues in modelled group I proteins 
.......................... 
78 
Table 3.14 Conserved aromatic residues in all group III members 
.................. 
83 
Table 3.15 Percentage similarity between all group III members 
.................... 
84 
Table 3.16 Conserved residues in group IV members 
...................................... 
88 
Table 3.17 Percentage similarity between group IV members 
........................ 
88 
Table 4.1 Elution protocol of NQO2 from Ni-NTA resin 
............................. 
105 
Table 4.2 Preparation of resolving and stacking gels of SDS-PAGE............ 106 
Table 4.3 Samples in gel lanes 
...................................................................... 
107 
Table 4.4 Optimum reaction conditions 
........................................................ 
112 
Table 6.1 Previously published crystallization conditions 
............................ 
138 
Table 6.2 Parameters used for collection of dataset 1 
................................... 
141 
Table 6.3 Parameters used for collection of dataset 2 
................................... 
141 
Table 6.4 Parameters used for collection of datasets 3,4 and 5 
.................... 
141 
Table 6.5 Combined parameters for determination of nominal resolution.... 142 
Table 6.6 Structures of probable molecules refined into the unidentified 
electron density 
............................................................................................... 
147 
Table 7.1 Optimized conditions for NQO2 crystallization 
............................ 
150 
X111 
Table 7.2 Average cell dimensions for the different cell units 
...................... 
152 
Table 7.3 Data processing statistics for crystals with chunky morphology 
.. 
153 
Table 7.4 Data processing statistics for crystals with plate like morphology 154 
Table 7.5 Space group, solvent content, Z-scores & LLG values 
................. 
154 
Table 7.6 Refinement statistics for datasets one, two and three 
.................... 
160 
Table 7.7 Refinement statistics for datasets four and five 
............................. 
160 
xiv 
Abbreviations 
Degree 
2xYT Two times yeast-tryptone media 
3D Three dimensional 
A Angstrom 
ADEPT Antibody directed enzyme prodrug therapy 
APS Ammonium persulphate 
C Celsius 
CB 1954 5-(azrindin- l 
-yl)-2,4-dinitrobenzamide 
CCP4 Collabrative computing project number 4 
DMSO Dimethylsulphoxide 
DNA Deoxyribonucleic acid 
DTT Dithiothreitol 
E. cloacae Enterobacter cloacae 
E. coli Escherichia coli 
ESRF European Synchrotron Radiation Facility 
FAD Flavin adenine dinucleotide 
FMN Flavin mononucleotide 
FRase Flavin oxidoreductase of Vibriofischeri 
FRP NADPH: FMN Ooxidoreductase of Vibrio harveyi 
FrxA NAD(P)H flavin oxidoreductase of Helicobacter pylori 
FUDR 5-fluorodeoxyuridine 
GDEPT Gene Directed Enzyme Produrg Therapy 
GSH Glutathione 
GTN Glycerol trinitrate reductase 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HPLC High pressure (performance) liquid chromatography 
K degree kalvin 
kDa Kilodalton 
1 Litre 
m Milli 
M Molar 
xv 
Abbreviations 
MAO Monoamine oxidase 
MMC Mitomycin C 
n Nano 
NADPH Nicotinamide adenine dinucleotide phosphate 
Na-HEPES 4-(2-Hydroxyethyl)piperazine- l 
-ethanesulfonic acid 
sodium salt 
NBDH N-benzyldihydronicotinamide 
NbzA Nitrobenzene nitroreductase 
NEC E. cloacae nitroreductase 
NemA N-ethylmaleimide reductase 
NfsA Major nitroreductase of Escherichia coli 
NfsB Minor nitroreductase of Escherichia coli 
Ni-NTA Nickel-nitrilotriacetic acid 
NMR Nuclear Magnetic Resonance 
NOX NADH oxidase of Thermus thermophilis 
NQO1 NAD(P)H: quinone oxidoreductase 
NQO2 Quinone reductase 2 
NRH N-ribosyl-1,4-dihydronicotinamide 
OD Optical Density 
OYE Old yellow enzyme 
PDB Protein database 
PETN Pentoerythritol tetranitrate reductase 
PnrA Pseudomonas putida nitroreductase 
RBCs Red blood cells 
RMSD Root mean square deviation 
Rnr Retro-nitroreductase 
RPM Revolution per minute 
SAXS Small angle X-ray scattering 
SDS Sodium dodecyl sulphate 
SDS-PAGE sodium dodecyl sulphate polyacrylamide gel 
electrophoresis 
sec Second 
SnrA Oxygen-insensitive NADPH reductase 
TEMED N, N, N', N'-Tetramethylethylenediamine 
xvi 
Abbreviations 
TNT Trinitrotoluene 
Tris Tris(hydroxymethyl)aminomethane 
UV Ultra violet 
V Volts 
VDEPT Virus Directed Enzyme Prodrug Therapy 
XenA Xenobiotic reductase A 
XenB Xenobiotic reductase B 
9 Micro 
xvii 
Chapter One 
Introduction to Flavoenzymes and their Role in 
Bio-reductive Cancer Chemotherapy 
1.1 Flavoenzymes 
Flavoenzymes are very versatile and catalyze a wide variety of biochemical 
reactions, including energy production, oxidation, reduction, light emission and 
biodegradation. They depend on the presence of a flavin cofactor to be able to 
catalyze enzymatic reactions. Flavins are derivatives of vitamin B2, riboflavin; 
which can be synthesized de novo in plants and bacteria, but not in animals, 
and thus must be provided from dietary sources (De Colibus and Mattevi, 
2006, Sinnott et al., 1997). The two most common flavins utilized by proteins 
are flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD), 
where FAD is the phosphoryl adenosine derivative of FMN. Flavin cofactors 
consist of two moieties, a tricyclic isoalloxazine ring and a side chain 
(Figure 1.1) (Sinnott et al., 1997). The side chain is responsible for anchoring 
the cofactor, usually via non-covalent bonds to the protein, while the 
isoalloxazine ring is the reactive moiety of the flavin cofactor. 
The isoalloxazine ring is responsible for the chemical versatility of the flavin 
cofactor. The flavin cofactor is able to undergo both one and two electron 
reduction to produce the semiquinone and fully reduced flavin, respectively 
(Miura, 2001). Flavoprotein redox reactions typically involve two separate 
steps, a first reduction step followed by an oxidation step. The reduction step in 
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many flavoenzymes occurs in one step involving the transfer of two electrons 
to the flavin from an electron donor to produce the fully reduced flavin. The 
second oxidation step may occur in either one step involving the transfer of 
two electrons to produce the fully oxidized cofactor directly, or two steps 
involving the transfer of one electron per step producing the fully oxidized 
cofactor via the semiquinone derivative (Figure 1.2) (Massey, 2000). 
Figure 1.1 Structure of flavins and numbering of isoalloxazine ring. 
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H3C 
H3C 
H 
(C) 
Figure 1.2 Different oxidation states of isoalloxazine ring of flavins where (a) is the fully 
oxidized state; (b) is the fully reduced state and (c) is the semiquinone form. 
The ability of flavoenzymes to participate in both one and two electron transfer 
reactions is unique among known redox enzymes. This property is due to the 
chemical nature of the isoalloxazine ring, where the semiquinone form can be 
stabilized under biological conditions. Enzymes utilizing pyridine nucleotides, 
such as nicotinamide nucleotides, can only catalyze the transfer of two 
electrons while metalloenzymes can only catalyze the transfer of one electron. 
This unique ability allows flavoproteins to act as an intermediate between 
pyridine nucleotide utilizing enzymes and metalloenzymes in electron transfer 
chains (Miura, 2001). 
1.1.1 Regulation of Flavoenzymes 
Although, as a group, flavoenzymes are very diverse in the reactions they 
catalyze, each enzyme shows high specificity towards the cosubstrates and 
substrates utilized in the electron transfer process. In addition, flavoenzymes 
are also selective with regards to the type of reaction they catalyse (Ghisla and 
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Massey, 1986, Miura, 2001). This suggests the presence of several mechanisms 
by which the reactions of flavoenzymes are regulated and controlled. These 
may include hydrogen bonding between the enzyme and the isoalloxazine ring 
of the flavin cofactor, the electrostatic environment in the catalytic site of the 
enzyme, the formation of charge-transfer complexes between the flavin and the 
substrate, as well as the regulation of the position of the substrate in the 
binding pocket in relation to the flavin cosubstrate (Sinnott et al., 1997, Miura, 
2001). 
The electrostatic environment in the catalytic site of the enzyme is regulated by 
controlling the accessibility of the solvent to the binding site and thus 
maintaining the hydrophobicity of the binding site. In several proteins 
catalyzing dehydrogenation reactions the catalytic site is shielded from the 
solvents, by a mobile loop, which allows the entrance of the substrate to the 
catalytic site and then closes. Alternatively, the catalytic site of the enzyme 
may be narrow and hence the binding of the substrate expels any solvent 
molecules previously present in the binding site (Fraaije and Mattevi, 2000, 
Miura, 2001, Sinnott et al., 1997). 
The amphipathic chemical nature of the isoalloxazine ring allows many 
different interactions. The xylene like portion of the molecule is hydrophobic 
and thus is more likely to interact with hydrophobic portions of the protein and 
substrates. On the other hand, the pyrimidine moiety is hydrophilic and 
electron deficient and thus more likely to interact with electron rich portions of 
the enzyme and substrates (Figure 1.3). The chemical properties of the 
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isoalloxazine ring are affected by the redox state of the flavin, where the 
basicity of the N5 atom increases upon the reduction of the flavin from the 
oxidized state to the semiquinone state, and shows a dramatic increase upon 
further reduction to the fully reduced state. Likewise, the pyrimidine moiety 
becomes electron rich when in the reduced state compared to being electron 
deficient in the oxidized state (Ghisla and Massey, 1986). Moreover, there are 
several sites on the flavin that could participate in hydrogen bonds as donors or 
acceptors, which are also affected by the redox state of the cofactor. In the 
oxidized state Ni, 02,04 and N5 act as hydrogen bond accepting sites, while 
N3 acts as both hydrogen bond donating and accepting site. On the other hand, 
in the reduced state 02 and 04 act as hydrogen bond accepting sites, while NI 
and N5 can act as both hydrogen bond accepting and donating sites (Figure 1.1 
and Figure 1.3) (Miura, 2001). 
Hydrophobic 
region 
Hydrophilic 
region 
Figure 1.3 The isoalloxazine ring of flavins, showing the chemical 
properties of the ring and the position of hydrogen bond interactions, 
represented by dashed lines. 
1.1.2 Recurrent Characteristics in Flavoproteins 
Although flavoenzymes are very diverse in their functions, they share several 
recurrent characteristic. FMN binding proteins tend to exhibit an (a/ß)8 barrel 
folding topology; on the other hand, FAD binding proteins generally exhibit 
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more diverse binding topologies (Fraaije and Mattevi, 2000, Sinnott et al., 
1997). Flavoenzymes catalyzing dehydrogenation reactions share several 
similarities in both the flavin and substrate binding pocket. Firstly, the presence 
of a positively charged residue in proximity to NI and C2 flavin atoms 
stabilizes the anionic form of the reduced flavin. Secondly, the presence of the 
N5 atom of the flavin in close proximity to an enzyme hydrogen donor atom, 
typically a nitrogen atom from a side chain or protein backbone (Fraaije and 
Mattevi, 2000). 
1.1.3 Classification of Flavoproteins 
Flavoproteins can be classified according to their biological functions and the 
nature of the substrates involved in both the reduction and oxidation reactions 
into five major classes; 
1. Transhydrogenases, catalyze the transfer of two electrons, as well as the 
appropriate hydrogen ions, from one organic substrate to another. These 
can then be further classified according to the atom types from which 
the electron pair is transferred to the flavin cofactor and that to which 
the electron is transferred. 
2. Dehydrogenases/oxidases, transfer electrons from an organic substrate 
to molecular oxygen generating hydrogen peroxide without any 
measurable intermediates. 
3. Dehydrogenases/oxygenases, transfer electrons from an organic 
substrate to molecular oxygen but unlike oxidases, they generate two 
water molecules and incorporate oxygen into another organic substrate, 
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forming the hydroxide derivative. In addition, a flavin hydroperoxide 
intermediate is observed. 
4. Dehydrogenases/electron-transferases, transform a two-electron transfer 
into a one-electron transfer, where the reduction step involves the 
transfer of two electrons simultaneously to the flavin cofactor. On the 
other hand, the oxidation step occurs in two sequential steps, each 
involving the transfer of one electron to a different substrate. 
5. Pure electron-transferases, involving only the transfer of one electron 
between an electron donor and an electron acceptor. This group of 
flavoenzymes have the ability to strongly stabilize the semiquinone 
form of the flavin cofactor (Massey and Hemmerich, 1980, Massey, 
1995). 
1.2 Quinone Oxidoreductases 
Quinone oxidoreductases are flavoenzymes involved in the detoxification of 
quinones through a strict two electron reduction to the hydroquinone 
derivative, and thus avoiding the semiquinone derivative. Quinone 
oxidoreductases can be divided into three classes according to their sequence, 
the first class contains an extended C-terminal domain, such as NQO1, the 
second class have a shorter sequence, lacking the extended C-terminal domain, 
such as NQO2. The third class, which in addition to lacking the extended C- 
terminal domain, also have a deletion of approximately 18 residues between 
residues 64 and 82, such as Escherichia coli and Saccharomyces cerevisiae 
quinone reductases. Bacterial flavodoxins also have a similar deletion pattern 
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and lack the same amino acids and thus these quinone reductases are known as 
flavodoxin-like (Bianchet et al., 2004, Deller et al., 2008). 
1.2.1 Quinones 
1.2.1.1 Sources of Quinones 
Quinones are abundant naturally occurring components of the electron 
transport chain, present in plants, bacteria and fungi. Moreover, quinones may 
be produced by the in vivo metabolism of naturally occurring compounds such 
as dopamine and adrenaline, as well as xenobiotics. Quinones are also present 
in the air as a result of pollution caused by cigarette smoke, car exhaust and 
burnt organic material. Moreover, quinones are also widely used as drugs for 
the treatment of various infections and cancer. Thus humans are regularly 
exposed to high amounts of these chemicals either through food intake or 
inhalation. Quinones may occur in different forms including monocyclic 
structures, such as benzoquinones, extended structures, such as 
diethylstilbestrone or condensed forms, such as benzo[a]pyrene-1,6-dione 
(Figure 1.4) (Monks et al., 1992, Obrien, 1991). 
1.2.1.2 Cytotoxicity of Quinones 
The one electron reduction of quinones, such as that carried out by cytochrome 
P450, results in the production of the semiquinone derivatives, which mostly 
exist as radicals at physiological pH. The semiquinone radicals may then react 
with molecular oxygen resulting in the production of oxygen radicals, and 
regenerating the oxidized quinone, which can be reduced to the semiquinone 
derivative once again. The accumulation of the radical oxygen species 
interferes with the cellular oxidative defensive mechanisms by depleting 
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cellular stocks of glutathione (GSH), resulting in oxidative stress. Furthermore, 
oxygen radicals may also react with protein thiol and amine groups as well as 
DNA functional groups. This leads to the disruption of biological functions. 
The complete two electron reduction of the quinone results in the production of 
the hydroquinone derivative which is then conjugated with UDP-glucuronic 
acid, glutathione or sulphate ions and thus avoiding cellular toxicity caused by 
the semiquinone form (Monks et al., 1992, Obrien, 1991). 
(a) 
(c) 
0 
(b) 
0 
(d) 
Figure 1.4 Structures of benzoquinones (a, b), diethylstilbestrone (c) 
and benzo[a]pyrene-1,6-dione (d). 
1.2.3 Primary Structure of NQOs 
NQO1 and NQO2 share a sequence homology of approximately 50 per cent. 
The main structural difference between the two enzymes is the presence of an 
additional 44 residues forming the extended C-domain tail in NQO1. The 
alignment of NQO1 and NQO2 sequences shows a region that is highly 
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conserved between residues 94 and 115 in human NQO2 and NQO1 from 
various species (Figure 1.5). 
mNQO1 MAAFi-ALIVLAHSE}: TSFNYAM'EEAAVEALF"h: F'GWEVLESDLYAMNFNPIISiNDITGEL 60 
rNOQ1 MAVkb: ALIVLAHAEkTSFNYAMti: EAAVEALF: i: KGWEVVESDLYAMNFNPLISRNDITGEP 60 
hNQO1 MVGRRALIVLAHSERTSFNYAMKEAAAAALKKKGWEVVESDLYAMNFNPIISRKDITGKL 60 
hNQO2 MAGKKVLIVYAHQEPKSFNGSLKNVAVDELSRQGCTVTVSDLYAMNFEPRATDKDITGTL 60 
mNQO1 KDSKNFQYPSESSLAYKEGRLSPDIVAEHKKLEAADLVIFQFPLQWFGVPAILKGWFERV 120 
rNOQ1 KDSENFQYPVESSLAYKEGRLSPDIVAEQKKLEAADLVIFQFPLYWFGVPAILKGWFERV 120 
hNQ01 ý"DPANFQYPAESVLAYKEGHLSPDIVAEQKKLEAADLVIFQFPLQWFGVPAILKGWFERV 120 
hNQO2 SNPEVFNYGVETHEAYKQRSLASDITDEQKKVREADLVIFQFPLYWFSVPAILKGWMDRV 120 
mNQO1 LVAGFAYTYAAMYDNGPFQNh: F'TLLSITTGGSGSMYSLQGVHGDMNVILWPIQSGILRFC 180 
rNOQ1 LVAGFAYTYATMYDKGPFQNKKTLLSITTGGSGSMYSLQGVHGDMNVILWPIQSGILRFC 180 
hNQO1 FIGEFAYTYAAMYDKGPFRSKKAVLSITTGGSGSMYSLQGIHGDMNVILWPIQSGILHFC 180 
hNQO2 LCQGFAFDIPGFYDSGLLGýýLALL: 'VmTG; TAEMYTKTGVNGDSR. YFLWPLQHGTLHFC 180 
mNQ01 GFQVLEPQLVYSIGHTPPDA: 'rMQILE:, W : LETVWEETPLYFAPSSLFDLNFQAGFLMK 240 
rNOQ1 GFQVLEPQLVYSIGHTPPDARVQVLEGWr; KCZLETVWEESPLYFAPSSLFDLNFQAGFLLK 240 
hNQO1 GFQVLEPQLTYSIGHTPADARIQILEGWKKRLENIWDETPLYFAPSSLFDLNFQAGFLMK 240 
hNQO2 GFKVLAPQISFAPEIASEEERKGMVAAWSQRLQTIWKEEPIPCT---------------- 224 
mNQ01 
rNOQ1 
hNQ01 
hNQ02 
KEVQEEQKKNKFGLSVGHHLGKSIPADNQIKARK 
KEVQEEQKKNKFGLSVGHHLGKSIPADNQIKARK 
KEVQDEEKNKKFGLSVGHHLGKSIPTDNQIKAPK 
--------------- 
AHWHFGQ------------ 
274 
274 
274 
231 
Figure 1.5 Sequence alignment of mouse NQO1 (mNQO1, accession code: Q64669), 
rat NQO1 (rNQO1, accession code: P05982), human NQO1 (hNQO1, 
accession code: P16083) and human NQO2 (hNQO2, accession code: P15559). * 
The highly conserved area between sequences is underlined. Residue 104 
which plays a key role in the mechanism of action is highlighted in 
yellow, and will be discussed in section 1.5.2.2.1 
1.2.4 Secondary Structure of NQOs 
NQOI and NQO2 are both homodimeric structures with two identical catalytic 
sites situated at opposite ends of the protein. The superimposed structures of 
the two proteins show that, except for the extended C-terminal domain of 
NQOI, both proteins have identical folds (Figure 1.6). Unlike NQO1, crystal 
structures of NQO2 have revealed that it contains one metal binding site, co- 
ordinated with two histidine nitrogens, one cysteine sulphur and a main chain 
carbonyl group of the same histidine residue. The purified enzyme was found 
Sequence alignment was carried out using the default parameters of Clustal W2. 
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to contain Zn ions, but it is proposed to contain Cu ions in vivo due to the 
nature of the co-ordinating residues, which is most similar to type I Cu sites 
(Foster et al., 1999). 
Figure 1.6 Superimposed structures of hNQOI (pdb code: 1D4A (Faig et al., 2000), 
yellow) and hNQO2 (pdb code: IQR2 (Calamini et al., 2008), blue)', showing the overall 
structures of the NQO land NQO2 dimers and the extended C-terminal domain 
of NQO1. Figure was created using UCSF Chimera (Pettersen et al., 2004). 
The structure of the NQO2 monomer consists of two domains an N-terminal 
catalytic domain, which is similar to that of NQOI and a C-terminal domain. 
The N-terminal is composed of residues I to 220 and consists of five central 
parallel ß-strands surrounded by five a-helices that connect the consecutive 
t Structures were overlaid using Sybyl 8.0 using "align structures by homology" command. 
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strands in an alternating a/ß topology. This fold may be considered as a 
modified Rossman fold (Figure 1.7). The C-terminal domain of NQO2 consists 
of 10 residues which form a well defined loop, that co-ordinate with the metal 
ion in the protein (Bianchet et al., 2004, Foster et al., 1999). 
Figure 1.7 Cartoon representation of the structure of NQO2 showing five central parallel 
ß-strands surrounded by five a-helices connected in an alternating fashion 
and FAD molecule at the interface between the monomers. 
Figure was created using UCSF Chimera (Pettersen et al., 2004). 
1.2.5 Catalytic Site of NQOs 
The catalytic sites of both NQOI and NQO2 are pockets located at the dimer 
interface (Figure 1.7). Both enzymes have large catalytic sites that are able to 
accommodate a wide variety of substrates, as is characteristic of enzymes that 
catalyze the detoxification of xenobiotics. The catalytic sites of both enzymes 
are very similar, with differences seen in only three residues; His-161, Tyr-126 
and Tyr-128 in NQOI which are replaced by Asn-161, Phe-126 and Ile-128 
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respectively in NQO2. The substitution of Tyr-128 in NQO1 with Ile-128 in 
NQO2 renders the catalytic site of NQO2 slightly wider and more polar 
(Figure 1.8). Both binding pockets are lined with aromatic residues; Trp-105 
and Phe-106 are at the bottom of the pockets. Phe-178, in both NQO 1 and 
NQO2, Tyr-126 in NQOI (Phe-126 in NQO2) and Tyr-128 in NQOI (Ile-128 
in NQO2) are positioned above the FAD molecule at the back of the binding 
pocket (Figure 1.9) (Bianchet et al., 2004). 
, //, ý1' ýýN- VAL 
Figure 1.8 The overlaid catalytic sites of hNQO1 (teal) and hNQO2 (magenta) 
showing the three residue difference between the active sites (displayed as sticks). The 
Ile-128 of NQO2 is not included in the image as it is 10.4 A from the FAD molecule. 
Figure was created using PyMOL (Delano, 2008). 
1.2.6 Mechanism of Action of NQOs 
Quinone oxidoreductases are believed to function by a ping-pong mechanism, 
where two hydride transfer reactions occur without the cofactor leaving the 
catalytic site. The first hydride transfer is between the oxidized cofactor and 
the cosubstrate (electron-donor); the second is between the reduced cofactor 
and the substrate. Both the cosubstrate and the substrate bind in the same 
13 
Chapter One 
- 
Introduction to Flavoproteins 
catalytic site, and thus the cosubstrate must leave the catalytic site before the 
substrate can be reduced (Figure 1.10) (Bianchet et al., 2004). 
Figure 1.9 The aromatic residues in the catalytic sites of hNQO1 (teal) and hNQO2 
(magenta), key residues are displayed as sticks. Figure was created using PyMOL 
(Delano, 2008). 
E E-H E 
Figure 1.10 Schematic representation of the ping-pong mechanism of reaction between 
enzyme, cosubstrate and substrate, where E represents the oxidized enzyme and E-H 
represents the reduced enzyme, CoH represents the reduced cosubstrate and Co 
represents the oxidized cosubstrate, Sub represents the substrate, while Sub-H represents 
the reduced substrate. 
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The mechanism of hydride transfer in NQOI is believed to involve the N5 of 
the flavin cofactor, in addition to two residues in the catalytic site, His-161 and 
Tyr-155. The hydride is first transferred from the cosubstrate to N5 of the 
flavin, resulting in a negative charge which is stabilized by a hydrogen bond 
between 02 and the OH group of the Tyr-155 residue. On the other hand, the 
His-161 is constantly exposed to the solvent and is thus protonated. In the 
second half of the reduction reaction, one hydride and a proton are transferred 
to the substrate, from N5 of the flavin cofactor and the protonated His-161 
respectively. The hydrogen bond between the 02 of the flavin cofactor and the 
hydroxyl group of Tyr- 155 is broken (Figure 1.11). In NQO2, it is thought that 
Asn-161 and a bound water molecule play the same role as His-161 in the 
hydride transfer in NQOI (Bianchet et al., 2004). 
B-H ý 
N 
NH 
His-161 
Tyr-155 
OH 
OH 
Bý 
H: ýN 
%ý 
H 
Step 2 
0 
0 0 
Sub-H2 
HN G) 
NH Co-sub 
+ 
9 Step I 
Figure 1.11 Proposed mechanism of hydride transfer in NQO1. 
Adapted from (Deller et al., 2008) 
15 
Chapter One 
- 
Introduction to Flavoproteins 
1.2.7 Cosubstrates, Substrates and Inhibitors of NQOs 
Although NQOI and NQO2 share a high sequence identity and have similar 
3D structures and catalytic sites, they differ in the cosubstrates that they are 
able to utilise, in addition to different substrates and inhibitors. 
1.2.7.1 Cosubstrates 
NQO1 has the ability to utilize both nicotinamide adenine dinucleotide 
(NADH) and nicotinamide adenine dinucleotide phosphate (NADPH) in vivo. 
On the other hand, NQO2 utilizes either N-ribosyl- or N-alkyl- 
dihydronicotinamide as cosubstrates in vivo (Skelly et al., 2001, Deller et al., 
2008). It has also been reported that NQO2 may also be able to utilize 
tetrahydrofolic acid as a cosubstrate (Boutin et al., 2005). 
1.2.7.2 Substrates and inhibitors 
Furthermore to the difference in the cosubstrates utilized by both enzymes, 
they also differ in their substrates and inhibitors. It is reported that NQO2 is not 
able to catalyze the reduction of documented NQO1 substrates such as 
naphthoquinones. Similarly NQO2 is not inhibited by known NQO1 inhibitors 
such as oral anti-coagulants and phenindione. Similarly, NQO1 is resistant to 
inhibition by known potent NQO2 inhibitors, such as quercetin and 
chrysoeriol. Table 1.1 lists some of the reported substrates and inhibitors for 
both NQO1 and NQO2. The aromatic nature of the catalytic sites of both 
NQO1 and NQO2 suggests a preference towards conjugated systems that 
would be able to form additional n-n interactions. 
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NQO1 NQO2 
Quinones Ubiquinones 
Vitamin E Menadione 
Substrates 
Anti-cancer drugs Anticancer drugs 
(e. g. CB 1954 and mitomycin C) (e. g. CB 1954 and mitomycin C) 
Antimalarials 
Oral anticoagulants (e. g chloroquine and quinacrine) 
(e. g. dicoumarol and warfarin) Benzo(a)pyrene Inhibitors 
Cibacron blue Flavone derivatives 
Phenindone (e. g Quercetin) 
Resveratrol 
Table 1.1 Reported substrates and inhibitors of NQO1 and NQO2(Boutin et al., 2005). 
1.2.8 Distribution of NQOs 
NQO1 is widely distributed in the human body with the exception of the liver 
and blood cells, particularly red blood cells (RBCs), were NQO1 is expressed 
at very low levels. It has been observed that there are large variations in the 
levels of expressed NQO1 between individuals. A higher concentration of 
NQO1 was reported in certain tumour tissues such as breast, brain, colon, lung 
and liver tumours compared to normal tissues. On the other hand, NOQ2 is less 
widely distributed in the human body and is more selectively expressed in 
kidney, lung, liver, heart, skeletal muscles and RBCs. It has also been reported 
that NQO2 is more expressed in colorectal and liver tumours compared to non 
cancerous cells. Moreover, the levels of NQO2 expressed in known 
chemosensitive tissues such as bone marrow, were found to be very low (Wu et 
al., 1997, Knox and Chen, 2004, Vella et al., 2005). 
1.2.9 Physiological functions of NQOs 
The primary role of NQO1 is thought to be the detoxification of xenobiotics, 
such as quinones via two electron reduction. It is also thought to have a role in 
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the metabolism of endogenous quinones, such as ubiquinone and vitamin E 
quinone. NQOI is thought to be responsible for generating the vitamin E 
hydroquinone, which is considered to have stronger antioxidant properties than 
vitamin E (Ross and Siegel, 2004). On the other hand, the function of NQO2 is 
less well understood and there are different opinions and evidence in relation to 
its function. The selective expression of NQO2 in certain tissues suggests a 
tissue-specific action. NQO2 knockout mice are less susceptible to toxic doses 
of menadione when compared to the wild type. However, they are more 
susceptible to the carcinogenic effect of polycyclic aromatic hydrocarbons 
(Vella et al., 2005). NQO2 is also thought to carry the MT3 binding site for 
melatonin and is inhibited by melatonin (Calamini et al., 2008). NQO2 
polymorphism has been linked to Parkinson's disease as well as schizophrenia 
(Harada et al., 2001, Harada et al., 2003). The ability of NQO2 to reduce 
coenzyme QO suggests that coenzyme Q10 might be a substrate of NQO2 and 
that NQO2 might play a role in the respiratory chain, by maintaining high 
levels of reduced coenzyme Q10 in the cells (Boutin et al., 2005). Both NQO1 
and NQO2 are thought to play a role in the reduction of vitamin K to its 
hydroquinone derivative. Oral anti-coagulants were found to be potent 
inhibitors of NQOI but not of NQO2, hence it is thought that NQO2 is a 
dicoumarol-insensitive vitamin K reductase (Chen et al., 2000). 
1.2.10 Medical Applications of NQOs 
Antimalarial drugs such as chloroquine, primaquine and quinacrine are potent 
inhibitors of NQO2 and thus inhibit its activity in RBCs. This leads to the 
accumulation of quinones and consequently oxidative stress, caused by the 
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formation of semiquinone and their auto-oxidation producing reactive oxygen 
species. The absence of NQO1 in the RBCs increases their susceptibility to the 
oxidative stress caused by the inhibition of NQO2 (Kwiek et al., 2004). 
Quinone oxidoreductases may also be used to reduce anticancer prodrugs such 
as CB 1954 and mitomycin C to their active metabolites, which is discussed in 
more detail in section 1.5.2. 
1.3 Bacterial Nitroreductases 
Polynitroaromatic compounds are usually synthetic compounds that are toxic 
and mutagenic to several forms of living organisms. Consequently, some 
bacterial species have developed the ability to metabolise polynitroaromatic 
compounds by reducing the nitro groups (Esteve-Nunez et al., 2001, Spain, 
1995). Bacterial nitroreductases are divided into two groups, depending on 
their response to the presence of oxygen, and the number of electrons they 
utilise during the reduction process. Oxygen sensitive (type II) bacterial 
nitroreductases utilise the transfer of one electron to the nitro group to produce 
the nitro anion radical, which is then reoxidized in the presence of oxygen to 
regenerate the aromatic nitrocompound (Esteve-Nunez et al., 2001). Oxygen 
insensitive (type I) bacterial nitroreductases are FMN dependant flavoenzymes 
that transfer two electrons from the cofactor to reduce the aromatic nitro group 
via the nitroso or/and the hydroxylamine derivative into the amino derivative; 
in some cases the hydroxylamine may be the final product of the reduction 
(Figure 1.12) (Dolores Roldan et al., 2008, Esteve-Nunez et al., 2001). 
Bacterial nitroreductases are able to bioactivate anticancer prodrugs and thus 
are of clinical interest. 
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Figure 1.12 Stepwise reduction of nitroaromatic compounds to the amino derivative. 
1.4 Cancer 
Cancer can be broadly defined as "a collection of diseases characterized by 
unregulated cell growth leading to the invasion of surrounding tissues and 
metastasis to other parts of the body (King and Robins, 2006). " The causes of 
cancer are not known, but there is a correlation between the incidence rates of 
certain types of cancers and environmental factors such as urban air pollution, 
and lifestyle choices such as smoking, excessive alcohol intake and fatty diets 
(Goordarz Danaei, 2005). 
1.4.1 The Development of Cancer 
All cancers are monoclonal in origin, i. e. arise from the proliferation of one 
abnormal cell. There are different models describing the sequence of events in 
the development of cancer, which depend on the source of the data used in the 
model development, which may range from animal experiments through to cell 
and molecular biology, and to clinical studies (Figure 1.13) (King and Robins, 
2006). 
1.4.2 Hypoxia in Tumours 
Tumours can be divided into three histologically distinct regions. The first is 
the anoxic region which is composed of dead necrotic cells; the second is the 
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avascular hypoxic region which is characterized by hypoxic cells. The third 
region is known as the vascularised axoic region 
Model 1: Animal experiments 
Carcinogensis 
Differentiated 
cells 
Model 2: Cell biology 
Normal 0 Immortal cell 10 Cancer 
Model 3: Molecular biology 
Normal 
Model 4: Clinical data 
Normal 
DNA changes 
Precancer No Cancer 
Dedifferentiated 
cells 
Metastasis 
Hyperplasia Carcinoma insitu 
Excess normal 
cell. 
localized 
- Invasive I_1 
cancer 
Surrounding 
tissue 
Metastatic 
cancer 
Remote 
tissues 
Figure 1.13 Cancer development models, adapted from (King and Robins, 2006) 
There are several mechanisms by which the hypoxic areas are formed in 
tumours. The growth of cancer cells requires the development of a blood vessel 
supply which occurs by a process known as angiogensis. The resultant blood 
vessels are highly irregular with leaky walls and sluggish flow. This results in 
perfusion-related (acute) hypoxia due to the inadequate supply of oxygen and 
nutrients. Diffusion-related (chronic) hypoxia is caused by the growth of the 
tumour leading to the inadequate supply of oxygen to cells distant from blood 
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vessels supplying nutrients and oxygen. Finally, anaemic hypoxia is caused by 
the decreased capacity of the blood to transport oxygen. Hypoxic regions of 
tumours are more resistant to treatment using ionizing radiation, as well as to 
most anticancer drugs. The resistance of the hypoxic areas to anticancer drugs 
is not intrinsic and does not reflect on the inability of the drug to attack these 
areas but rather the drugs inability to reach them. It may also be caused by the 
drugs being ineffective towards slowly dividing cells, as seen in hypoxic 
regions of solid tumours (Brown, 2000, Martin Brown and Giaccia, 1998, 
Vaupel and Harrison, 2004). 
1.5 Cancer Treatment 
Solid tumours are usually first removed by surgery, which is then followed by 
chemotherapy and/or radiotherapy to destroy any remnants of the tumour. 
Chemotherapeutic agents are generally non specific towards cancerous cells 
and hence have a variety of side effects, usually towards fast dividing cells 
such as the stomach and bone marrow. Moreover some chemotherapeutic drugs 
may have specific toxicity towards vital organs such as the liver and kidney 
(King and Robins, 2006). 
1.5.1 Anticancer Targeted Prodrug Therapy 
Prodrugs are inactive molecules that are converted in vivo into their active 
forms. Anticancer targeted prodrugs can selectively target tumours by several 
mechanisms. One such mechanism is the activation of the prodrug by 
exogenous enzymes delivered to the tumour cells by either Anti-body-directed 
enzyme prodrug therapy (ADEPT) or gene directed enzyme prodrug therapy 
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(GDEPT). The prodrug may also be selectively activated by endogenous 
enzymes overexpressed in cancerous cells. The selective activation of 
anticancer targeted prodrugs in cancer cells lead to higher therapeutic 
effectiveness and a lower incidence of side effects compared to conventional 
drugs. 
1.5.1.1 ADEPT 
In this approach, the drug activating enzyme is conjugated with an antibody 
that specifically binds to an antigen expressed onto the surface of tumour cells. 
Once the prodrug is administered, it is activated by the conjugated enzyme at 
the tumour site. The efficiency of this technique is enhanced by the use of 
small drug molecules generated from the activation of the prodrug which are 
able to diffuse into tumour cells that do not express the specific antigen 
(Figure 1.14) (Knox and Connors, 1995, Singh et al., 2008). 
1.5.1.2 GDEPT 
In gene directed enzyme prodrug therapy, a gene encoding the activating 
enzyme is delivered inside the tumour cell using vectors. The choice of the 
vector used to deliver the gene into the cells is the most challenging step in 
GDEPT. Viral vectors are the most effective method for gene delivery, as 
utilized by virus-directed enzyme prodrug therapy (VDEPT), despite the fact 
that they may cause a severe immunogenic response. Other possible vectors 
used for gene delivery include bacterial, natural and synthetic vectors. The 
expressed enzyme should not be present in normal cells to ensure the 
selectivity of the treatment. The enzyme is then expressed by transfected 
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tumour cellst and the prodrug is activated. The prodrug must be stable and 
sufficiently lipophilic to be able to diffuse into the untransfected cells of the 
tumour. As with ADEPT, the diffusion of the activated drug to neighbouring 
untransfected cells increases the efficiency of the treatment (Figure 1.15) 
(Singh et al., 2008, Hedley et al., 2007). 
Enzyme 
Prodru 
a ministrati n 
Active drug 
Prodrug 
Cell Death 
Figure 1.14 Representation of ADEPT. Adapted from (Singh et al., 2008). 
1.5.2 Bioreductive Anticancer Drugs 
Bioreductive anticancer drugs are prodrugs that are reduced to their active 
derivative using enzymes, where the active reduced product then leads to cell 
death. The bioreduction of the drug may occur by exogenous enzymes 
delivered to the tumour cells or endogenous enzymes expressed at higher 
concentrations in cancer cells. The bioreduction of the drug may also occur by 
* Cells containing the delivered gene and expressing the enzyme of interest. 
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endogenous enzymes active only under hypoxic conditions thus minimizing the 
side effects towards normal non-hypoxic cells (Chen and Hu, 2009). Since 
only a proportion of the tumour is hypoxic, drugs activated under hypoxic 
conditions may not be effective against the whole of the tumour. However, the 
activated drug may diffuse out of the hypoxic cells killing the neighbouring 
non hypoxic population. This phenomena is known as the `bystander effect' 
(Denny, 2001). 
Prodrug 
Figure 1.15 Representation of GDEPT. Adapted from (Singh et al., 2008). 
There are four main classes of anticancer prodrugs that are designed for 
bioreductive activation; quinones, nitroaromatics, N-oxides and metal 
complexes (Chen and Hu, 2009). Both quinones and nitroaromatics can be 
reduced in vivo to their active form by quinone oxidoreductases such as NQO1 
and NQO2, which are over expressed in certain cancer tumours. Bacterial 
nitroreductases are able to reduce nitroaromatics to their active metabolite, and 
may be delivered to cancer cells using either GDEPT or VDEPT techniques. 
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1.5.2.1 Quinones 
Mitomycin C (MMC) is an example of a quinone anticancer prodrug that is 
currently being clinically used. It is reduced by both NQOI and NQO2 to the 
hydroquinone derivative, which is then attacked by two nucleophilic centres in 
the DNA, to form DNA cross links (Figure 1.16) (Chen and Hu, 2009, Colucci 
et al., 2008, McGuinness et al., 1991, Lin et al., 1980). Other examples of 
bioreductive drugs activated by both NQO1 and NQO2 include indolequinones 
such as E09 and diaziridinyl benzoquinones such as AZQ (Figure 1.17). The 
reduction of diaziridinyl benzoquinone to its hydroquinone derivative activates 
the aziridinyl groups. The aziridinyl groups are then attacked by nucleophiles, 
such as the N7 of the guanine base of DNA, resulting in ring opening and the 
formation of DNA adducts (Mossoba et al., 1985a, Skibo and Xing, 1998). 
+2e 
OHS 
, 
DNA 
OH 
1 
I') 
NH 
OH 
I, 
OH 
ÖCONH2 
OH 
Figure 1.16 Reduction of MMC and formation of DNA cross links 
NH 
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(a) (b) 
Figure 1.17 Structures of (a) E09 and (b) AZQ 
An alternative use for the quinone moiety is the release of the active drug 
molecule upon its bioreduction in the cancer cells (Figure 1.18). This 
technique can be applied to indolequinones, naphthoquinones and 
benzoquinones (Chen and Hu, 2009, Jaffar et al., 1998). E09 has been 
proposed as such a delivery system, where upon its reduction the active 
metabolite of E09 and another anticancer drug are both produced (Chen and 
Hu, 2009). Furthermore, the chemical association of some drugs with a 
quinone moiety has produced promising results by increasing bioavailability 
and/or decreasing the incidence of side effects. The chemical association of 5- 
fluorodeoxyuridine (FUDR) with indolequinone resulted in increased 
selectivity and cytotoxicity towards hypoxic cells. The increase in cytotoxicity 
is thought to be caused by the electrophilic iminium cation resulting from the 
release of the drug (Tanabe et al., 2005). Camptothecin is a potent DNA 
topoisomerase inhibitor however it has unfavourable properties such as poor 
water solubility and stability, in addition to its poor selectivity. Its chemical 
association with indolequinone was found to increase its selectivity towards 
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hypoxic cells, in addition to increasing its water solubility and stability (Zhang 
et al., 2005). 
Drug OHug 
ýý 
Me 
I MeO Me + Drug 
Figure 1.18 Release of active drug upon reduction of indolequinone derivative. 
1.5.2.2 Nitroaromatics 
Flavoenzymes reduce nitroaromatic compounds through a stepwise reaction to 
the amino derivative via the nitroso and hydroxylamine derivatives 
(Figure 1.12). In most cases, the hydroxylamine is the final product of the 
reduction and is the active metabolite. The reduction of the nitro group, a 
strong electron withdrawing group, to a hydroxylamine, an electron donating 
group, changes the electronic environment of the aromatic ring. This 
subsequently can lead to the activation of a latent alkyalting species attached to 
the aromatic ring, as seen with CB 1954. As with quinones, nitroaromatic 
compounds can also be used as delivery systems to release the active drug 
upon reduction. 
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1.5.2.2.1 Bioreduction of CB 1954 
CB 1954 (Figure 1.19) is a nitroaromatic prodrug reduced by both bacterial 
nitroreductases and quinone oxidoreductases to the hydroxylamine derivative. 
The reduction of the nitro group activates the aziridinyl group allowing 
nucleophilic attack on the aziridine ring by DNA. The 4-hydroxylamine 
metabolite then reacts with thioesters such as acetyl-CoA to probably generate 
4-(N-acetoxy)-5-azriridin-1-yl)-2-nitrobenzamide. The resultant product then 
attacks the DNA forming DNA cross links (Knox et al., 1988). Escherichia 
coli and Enterobacter cloacae nitroreductases are able to reduce both nitro 
groups with similar efficiency resulting in the production of equimolar amounts 
of the 2- and 4- hydroxylamine metabolites, which may be further reduced to 
produce the 2- and 4- amine derivatives (Knox et al., 1992). Although NQO1 
and NQO2 are have been classified as quinone reductases, they are also able to 
catalyze reduction of some nitroaromatic compounds, such as CB 1954. Unlike 
bacterial nitroreductases, quinone oxidoreductases only reduce the 4-nitro 
group, generating the 4-hydroxylamine derivative (Figure 1.19) (Knox et al., 
1992, Skelly et al., 2001). It has been established that rat NQO1 and human 
NQO2 are more effective in reducing CB 1954 than human NQO 1 and mouse 
NQO1, despite the high degree of homology shared between them. The 
difference between the catalytic ability of the enzymes is attributed to residue 
104, which in rat NQO1 and human NQO2 is a tyrosine and in human and 
mouse NQO1 is a glutamine (Figure 1.5) (Chen et al., 1997, Skelly et al., 
2001, Knox and Chen, 2004). There have been contradicting discussions on the 
cytotoxicty of the reduction products. It is thought that the 4-hydroxylamine 
derivative is more cytotoxic as it is able to form DNA cross links. On the other 
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hand, recent studies have suggested that the 2-amine derivative may also play a 
role in the cytotoxic effect of CB 1954, due to its superior ability to diffuse into 
the neighbouring cells. This is due its higher stability and more lipophilic 
nature compared to the hydroxylamine derivative (Helsby et al., 2004). 
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Figure 1.19 Structure and bioactivation of CB1954 by quinone oxidoreductases. 
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There is an increasing interest in NQO2 and other enzymes that are able to 
reduce aromatic nitro groups such as bacterial nitroreductases. This may be 
attributed to their role in targeted anticancer therapy by activating bioreductive 
anticancer drugs, such as quinones and nitroaromatics. The importance of 
highly conserved aromatic residues in the catalytic site of bacterial 
nitroreductases has been well documented. On the other hand, no study has 
been undertaken to determine whether the presence of aromatic residues in the 
catalytic site is of importance in all the flavoenzymes capable of reducing 
aromatic nitro groups. This knowledge could aid in a better understanding of 
the mechanism of action of the previously mentioned enzymes. Furthermore, 
this may aid in identifying other novel enzymes that are capable of reducing 
aromatic nitro groups and subsequently may be of importance in targeted 
prodrug therapy. 
There are several 3D structures in the Brookhaven database of reduced 
flavoproteins including bacterial nitroreductases showing significant changes 
in the conformation of the reduced flavoproteins as well as the position of 
surrounding amino acids. However, the structure of the reduced NQO2 has not 
yet been determined. The determination of the reduced structure may aid in a 
better understanding of the mechanism of electron transfer in NQO2 as well as 
determining if any significant changes occur in the binding pocket upon 
reduction of the flavin cofactor. 
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1.6 Aims of the Thesis 
The project aims on utilizing X-ray crystallography, fluorescence spectroscopy 
and bioinformatics to increase the understanding of the mechanism of action of 
and identifying the presence of conserved residues between flavoenzymes 
reducing aromatic nitro groups. The specific aims of the project are listed 
below: 
" The use of bioinformatics computational tools and homology modelling 
to identify key conserved aromatic residues in the catalytic site of 
flavoproteins reducing aromatic nitro groups. 
" 
The determination of the kinetic profile of NQO2 with novel substrates 
using fluorescence spectroscopy. 
9 The crystallization of NQO2 and reduction of NQO2 crystals. 
" Structure determination of reduced NQO2 using X-ray crystallography. 
" Analysis of reduced 3D structure of NQO2 to gain more insight into the 
mechanism of action of NQO2 and probable route of electron transfer 
between the reduced flavin cofactor and substrate. 
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2.1 Introduction 
The determination of the 3D structures of proteins helps in gaining valuable 
knowledge about the biological roles and mechanisms of action of proteins. 
Moreover, the determination of the structure of a protein ligand complex may 
aid in identifying key binding sites and interactions between the protein and the 
ligand. Furthermore, it aids in the identification of any changes in the protein 
structure upon ligand binding. This information is used in structure-based drug 
design, where the aim is to design more specific and potent drugs. A number of 
techniques can be used to determine the 3D structure of biological 
macromolecules, which include nuclear magnetic resonance spectroscopy 
(NMR), small angle X-ray scattering (SAXS), and X-ray crystallography. 
X-ray crystallography utilises the distinct patterns produced by the diffraction 
of X-ray beams by the crystalline form of proteins. X-ray crystallography 
involves several steps; the first is the protein expression and purification. This 
is followed by the crystallization of the protein. The production of a crystal of 
suitable size and quality is usually a limiting step in the utilization of this 
technique and is a process of trial and error. Once a crystal of suitable quality is 
obtained, it is then mounted onto a rotating goniometer in the path of the X- 
rays. The diffracted beams are then detected by an X-ray detector and the 
resulting images are processed using specialized software to determine the 
protein structure (Figure 2.1). 
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Figure 2.1 Schematic representation of the processes involved 
in structure determination using X-ray crystallography. 
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2.2 Protein Crystallization 
A crystal can be defined as an orderly three dimensional arrangement of 
identical or different molecules, forming identical building blocks held together 
by non-covalent interactions. 
In a saturated solution, the solid phase and free molecules in solution exist in 
equilibrium, where an increase in the solid phase will be accompanied by 
equivalent dissolution. Therefore a solution needs to be in a supersaturated 
state to be able to support crystal formation and growth. The supersaturated 
zone is divided into two separate zones; the nucleation zone and the metastable 
zone (Figure 2.2). In the nucleation zone, spontaneous nucleation and rapid 
crystal growth occur. The metastable zone does not support the formation of 
new nuclei and the rate of crystal growth is slower than in the nucleation zone. 
An ideal crystal will be one that is initiated in the nucleation zone just beyond 
the metastable zone. As the nuclei form, the concentration of protein in 
solution decreases, and the solution then moves from the nucleation zone to the 
metastable zone. Once in the metastable zone, no new nuclei are formed and 
crystal growth is slower and more controlled. 
Crystallization from highly saturated solutions, as in the nucleation zone, 
usually results in the formation of numerous small crystals that are not of 
suitable size for X-ray diffraction. Moreover, the rapid growth of the crystals 
usually results in defective crystals containing impurities (McPherson, 2009). 
The crystal will then cease to grow once the protein concentration has dropped 
back to the soluble region. In some cases, the crystal may cease to grow even 
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when the protein concentration has still not reached the solubility limit. This is 
thought to be due to the accumulation of impurities or denatured protein onto 
the crystal surface preventing the further growth of the crystal (Durbin and 
Feher, 1996). 
Precipitant concentration 
Figure 2.2 Phase diagram for crystallization, showing 
precipitation zone, supersaturation zone and soluble zone. 
2.2.1 Protein crystallization techniques 
The most widely utilized technique in protein crystallization is vapour 
diffusion. This technique depends on the removal of water from a microdrop, 
containing a mixture of protein solution and reservoir solution, to a larger more 
concentrated reservoir solution containing the precipitant. There are two 
different procedures that rely on the vapour diffusion technique; sitting drop 
and hanging drop. In the sitting drop technique, the microdrop is placed on a 
plastic post in the middle of the reservoir solution. The well is then sealed 
using transparent tape (Figure 2.3 (a)). In the hanging drop technique, the 
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microdrop hangs upside down on a microscope cover slip on top of the 
reservoir solution. The well is sealed using silicon vacuum grease between the 
coverslip and the crystallization plate (Figure 2.3 (b)) (McPherson, 2009, 
Rhodes, 2000). 
Microdrop 
4w 
Reservoir 
Sitting drop 
(a) 
Hanging drop 
(b) 
Figure 2.3 Schematic representations of sitting and hanging drop 
vapour diffusion methods. 
2.2.2. Cryocrystallography 
Collecting diffraction data at or near lOOK decreases the amount of radiation 
damage to which the crystal is subjected to. This is due to the decrease in the 
diffusion rate of the free radicals produced by the X-ray radiation, which 
decreases the distance they are able to travel in the crystal and thus the amount 
of damage they cause. This prolongs the crystal lifetime and allows the 
collection of higher quality datasets and in some cases may allow the collection 
of higher resolution datasets. Due to the high water content of macromolecular 
crystals, they must be placed in a protective `cryo-protectant' solution before 
freezing. This is to prevent the formation of ice which is problematic in 
macromolecular crystallography as it interferes with the diffraction of the X- 
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rays and disrupts the crystal order (Garman, 1999, Garman, 2003, Drenth, 
2007, Hope, 1988). There are many types of cryoprotectant solutions; these 
include small organic molecules such as polyethylene glycol, xylitol and 
glycerol. These act by disrupting the order of water molecules and thus 
preventing the formation of ice (Garman, 1999, Garman, 2003, Drenth, 2007). 
Highly concentrated solutions of salts such as sodium malonate and sodium 
formate can also be used as cryoprotectants. The involvement of numerous 
water molecules in the hydration of the salt ions, prevents the formation of ice 
(Rubinson et al., 2000). Another technique to prevent ice formation involves 
dipping the crystal in oil such as paraffin oil or Paratone-N® prior to freezing. 
Different types of cryoprotectant solutions may also be used in combination 
(Kwong and Liu, 1999). 
2.2.3 Nature of the Crystal 
A crystal can be defined by four parameters; the asymmetric unit, the space 
group, the unit cell and the crystal lattice. The unit cell is the smallest possible 
volume that when repeated is representative of the whole crystal and acts as the 
building block of the crystal. It is defined using six values, the lengths of the 
edges a, b and c and the angles between them a, ß and y. Alternatively, the 
unit cell may be defined using three vectors ii, b and Z, which are coincident 
with the unit cell edges and are of the same length. The unit cell is usually 
composed of several asymmetric units, which can be defined as the largest 
volume of atoms that do not posses any symmetry. In the case of proteins, this 
may be one protein molecule, or if the protein possesses self symmetry, then it 
may be a fraction of the molecule. The arrangement of the asymmetric units 
38 
Chapter Two 
- 
Introduction to Crystallography 
within the unit cell defines the space group to which the unit cell belongs. The 
unit cells are then repeated in a regular manner to form the crystal 
(Figure 2.4). A lattice is defined as a regular infinite arrangement of similar 
points. If every molecule in the unit cell is represented by a point, the crystal 
lattice is generated. There are fourteen different 3D lattices, known as Bravais 
lattices (McPherson, 2009, Massa, 2004, Ladd and Palmer, 2003). 
(b) 
(a) 
(d) 
' C-) 
Figure 2.4 Schematic representation of crystal parameters showing (a) asymmetric unit, 
(b) the spatial relationship between different asymmetric units, (c) unit cell 
and (d) crystal. Adapted from (McPherson, 2009) 
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2.2.3.1 Lattice planes and Miller indices 
Lattice planes are families of related planes that intersect the crystal lattice at 
regular intervals. The planes are defined by three values known as Miller 
indices (hkl), corresponding to the number of times they intersect ä, b and c 
respectively (Figure 2.5) (Massa, 2004, McPherson, 2009). 
(010) planes 
ý ksuna) 
:ý 
I`. 
b 
I- 
-- 
R 
X 
4. 
I 
I... 
(100) planes ý/7 (solid) 
'I 
"- 
(210) planes 
(dashed) 
Figure 2.5 Lattice planes and their designated Miller Indices 
in a 2D section of a crystal lattice. 
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2.2.4 X-ray Diffraction by Crystals 
2.2.4.1 Bragg's Law 
Diffraction of X-rays occurs due to the interaction of the X-ray photons with 
electrons. The excited electrons then emit X-rays in random directions at the 
same wavelength as the incident beam, as they return to the ground state. Due 
to the repetitive nature of crystals, the diffracted X-rays from different planes 
of the crystal may interfere with each other. The scattered X-rays may be out of 
phase and thus interfere with each other destructively cancelling one another. 
In some cases, the scattered X-rays may be in phase resulting in constructive 
interference, amplifying their intensity. According to Bragg's law, 
equation (2.1), constructive interference occurs only when the distance 
travelled by the X-ray beams scattered from parallel planes is an integer of the 
wavelength of the incident X-ray beams (Figure 2.6) (Bragg and Bragg, 1913, 
Blow, 2002). 
n2 = 2d sin 0 (2.1) 
Where d is the distance between planes, 9 is the angle of incidence of the 
beam, A is the wavelength of the incident beam and n is an integer. 
Figure 2.6 Constructive interference as defined by Bragg's law, where d is the distance 
between planes and 0 is the angle of incidence of the beam. 
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2.2.4.2 Reciprocal lattice and Ewald's Sphere 
The reciprocal lattice is constructed using the end points of vectors 
representing each family of planes. The vector for each family is perpendicular 
to the set of planes and has a length of 1/dhkj. The dimensions of the reciprocal 
unit cell are defined using a*, b* and c*. The reciprocal lattice is based on 
1/dhkl and thus the real and reciprocal unit cells dimensions are inversely 
related. Therefore for a large unit cell, the reciprocal unit cell is small and vice 
versa. It is important to note that the reciprocal lattice rotates in the same 
manner as the crystal (Drenth, 2007, McPherson, 2009, Authier, 1981). 
The reciprocal lattice aids in determining the best orientation of a crystal, with 
respect to the incident beam, that satisfies Bragg's law and thus generating 
strong reflections. This is achieved via the construction of a sphere passing 
through 0, the origin of the reciprocal lattice, with the diffracting crystal at its 
centre, C. This is known as Ewald's sphere (Ewald, 1921). Ewald's sphere 
demonstrates that when a reciprocal lattice point passes through the sphere, the 
associated family of planes satisfy Bragg's law and thus a diffracted ray is 
produced (Figure 2.7). As the crystal is rotated, different reciprocal lattice 
points come in contact with the sphere, each diffracting the beam along the line 
connecting the individual lattice point and the centre of the sphere, thus 
forming a diffraction pattern. Any reciprocal lattice point that is not within a 
distance of 2/?. of the origin of the sphere can not come in contact with it and 
thus can not generate any reflections. Consequently, the number of reflections 
is dependant on the dimensions of the unit cell as well as the wavelength of the 
X-ray beam. The use of shorter wavelength radiation increases the diameter of 
the sphere and thus allows for the inclusion of more lattice points and therefore 
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the generation of more reflections. In addition, due to the inverse relationship 
between the dimensions of the real unit cell and the reciprocal unit cell, large 
real unit cells have smaller more densely populated reciprocal unit cells. This is 
accompanied by an increase in the number of reflections (McPherson, 2009, 
Rhodes, 2000). 
RecýprOCa, 
\a, tý%ce 
Figure 2.7 Construction of Ewald's sphere, where BC represents the incident beam 
and CP represents the diffracted beam and 0 is the origin on the 
reciprocal lattices. Adapted from (Dauter, 1999). 
2.3 Data collection 
During data collection the crystals are mounted onto goniometers which allow 
the correct orientation of the crystal in the path of the X-ray beam. Throughout 
data collection, the mounted crystal can be rotated to allow different angles of 
the crystal to be exposed to the X-ray beam. The angle of rotation of the crystal 
is known as the oscillation angle. 
2.3.1 Data Collection Strategy 
Crystals are generally not perfectly packed and can thus be represented by a 
collection of small mosaic blocks, which can be considered as optically 
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independent each affecting the path of the X-ray beam in a slightly different 
manner. This is especially true for protein molecules which are flexible and 
held together by weak forces. As a result of the slight irregularities in the 
arrangement of the building blocks, the diffracted beam takes the form of a 
cone rather than a straight line (Figure 2.8). This results in larger elliptical 
spots, spread over several diffraction images. Thus each reflection must be 
measured over a narrow range of oscillation angles rather than one single 
defined angle. The amount of data collected from each oscillation is limited by 
the degree of overlapping between adjacent spots. Due to the symmetry of the 
crystals, a substantial amount of reflections are equivalent and thus are 
redundant. The optimum strategy for data collection involves the smallest 
rotation of the crystal that is able to record all unique reflections. This can be 
determined by considering the space group of the crystal. This decreases the 
amount of radiation damage a crystal is subjected to due to the decrease in X- 
ray exposure time (Rhodes, 2000). 
2.4 Data Processing 
2.4.1 Indexing and Integration of Images 
Initial data processing can be divided into three stages; indexing, cell 
refinement and integration. These can be carried out by a variety of data 
processing programme suites such as MOSFLM (Leslie, 1992), XDS 
(Kabsch, 2010) and HKL2000 (Otwinowski and Minor, 1997). Indexing is the 
process by which the unit cell dimensions and the crystal orientation are 
determined. This gives an indication of the most likely Laue group of the 
crystal. This is then followed by the refining of the previously determined 
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parameters. These parameters include the cell parameters; such as unit cell 
dimensions, crystal orientation and mosaicity, as well as the detector and beam 
parameters. Once the correct unit cell parameters have been established, the 
images can be integrated. This involves predicting the position and calculating 
the intensity of the spots in the collected images, according to the determined 
Laue group. For accurate integration, a good estimation of background 
intensity values must be calculated (Leslie, 2006, Kabsch, 2010). 
ý_ i ýý ýJLJ 
(a) 
ý 
ý 
(b) 
i 
(c) 
Figure 2.8 Schematic representation of varying degrees of crystal packing and the 
associated effect on the shape of the diffracted X-ray beams. (a) Shows a typical crystal, 
(b) shows perfect arranged crystals resulting in sharp diffraction spots and (c) shows 
highly irregular crystals resulting in elliptical diffraction spots. 
Adapted from (Schneider, 2007). 
2.4.2 Scaling and Merging of Reflections 
The spot intensities are affected by different experimental factors such as 
radiation damage and changes in the intensity of the incident beam. Therefore, 
the measured intensities from different images are not all on the same scale. 
Consequently, estimated corrections are applied to the intensities to bring them 
all on to the same scale. This improves the consistency of the data within a 
dataset. Scaling also gives an estimate of the data quality and identifies parts of 
the collected data that are in poor agreement with the remainder of the data. 
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After the intensities are corrected, the intensities are then merged so that an 
average intensity is calculated for each hkl reflection (Evans, 2006, Rhodes, 
2000, Kabsch, 2010). 
2.4.2.1 Assessing Data Quality 
There are a number of criteria that can be used to assess the quality of the data 
and can aid in determining whether parts of the data collected should be 
discarded. These criteria include completeness, presence or absence of 
twinning, Rmerge, signal to noise ratio (mean 1/al) and B-factors. 
Rmerge is the measure of agreement between multiple observations of the 
intensity of unique reflections in the same dataset, and is defined in 
equation (2.2). 
Rmerge ýýi _J 
Fhkl- 
j -F hkl 
1: Fhkl 
hkl 
(2.2) 
Where Fhki_J is the jth measurement of Fhkl and F hkl is the average value of all 
measurements of Fhkl (McPherson, 2009). 
The value of R, 11erge increases if the crystal is damaged by X-ray exposure and 
by any errors that arise during the data collection or integration processes. The 
use of Rmerge as the sole indicator for data quality is not reliable, as its value 
increases with the increase in data redundancy (Evans, 2006, Weiss, 2001, 
Weiss and Hilgenfeld, 1997). Completeness is another data quality indicator 
and is defined as the fraction of unique reflections that have been measured of 
l 
46 
Chapter Two 
- 
Introduction to Crystallography 
those that could be observed in theory. The nominal resolution limits chosen at 
the data processing stage to maximise the quality data should take into account 
the values of Rmerge, mean 1/ol and completeness (Kleywegt, 2000). The 
examination of the values of both B-factors and Rmerge of each image provides 
valuable information about radiation damage and the occurrence of errors 
during the data collection and integration processes. This then allows for the 
exclusion of images or groups of images that are significantly worse than 
others. 
2.4.3 The Structure Factors and the Phase Problem 
The diffraction images provide atomic positions in reciprocal space which can 
be assigned by miller indices (hkl) and the intensity of each reflection which is 
proportional to the square of the amplitude of the structure factor Fhkl. The 
structure factor is the sum of the diffractive contribution of all atoms in the unit 
cell to the intensity of a single reflection. The structure factor can be described 
by equation (2.3) 
n 
_ 
2ni(hxj +kyj +lzj) Fhkl- 2] fje 
j=1 (2.3) 
Where n is the number of atoms in the unit cell and f; is the scattering power of 
atom j with co-ordinates xj, yj and zj in the unit cell. 
The electron density in a unit cell can be calculated by performing a Fourier 
transformation on all the structure factors to give the Fourier transform in 
equation (2.4), 
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, 
o(X, Y, Z)= ýýýý 
ýFhkl ý-2; ri(hx+ky+lz)+ia(hkl ) 
I 
(2.4) 
Where p(x, y, z) is the electron density at position (x y z), V is the volume of the 
unit cell, Fhkr is the structure factor for each diffraction spot and a(hkl) is the 
phase angle for the diffracted waves. 
As mentioned before the amplitude of the structure factors is proportional to 
the intensity of the recorded spots, but the measurement of the phase angles is 
not possible experimentally. This is known as the phase problem and can be 
overcome by several methods such as; molecular replacement, isomorphous 
replacement, anomalous scattering and the heavy atom method (Rhodes, 2000, 
McPherson, 2009). 
2.4.3.1 Molecular Replacement 
Molecular replacement was developed in 1962 by Rossmann and Blow 
(Rossmann and Blow, 1962), but its use has become more common as the 
number of available 3D structures has increased. It is thought that about 70 per 
cent of the phases of newly deposited structures are determined using 
molecular replacement (Evans and McCoy, 2008). Molecular replacement 
utilizes the phases of a known molecular model to provide an initial estimate 
for a new structure. This involves two steps; rotation and translation of the 
model. This is repeated until the predicted diffraction pattern of the model best 
matches the observed reflections. The phases of the model protein are then 
used with the experimentally determined structure factor amplitudes to produce 
an initial electron density map. Recently developed molecular replacement 
software utilise the maximum likelihood probability approach, which takes into 
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account consistent errors in the data. It is thought that the choice of model is 
the most important step in molecular replacement. A high sequence identity 
between the model and protein under study usually indicates high structural 
similarities, which increases the probability of success of the molecular 
replacement step (Evans and McCoy, 2008). 
2.4.4 Electron Density Maps 
There are several different types of electron density maps used to relate the 
calculated model and the diffraction data and determine the degree of 
agreement between the built model and the experimental data. The two most 
commonly used are the difference maps and the composite maps. Traditionally 
composite maps are contoured at la while difference maps are contoured at 
3a§ (Tronrud, 2010). 
2.4.5 Refinement of the Model 
Refinement is defined as the changing of the model parameters, in order to best 
explain the experimental observations. The model parameters include atomic 
positions defined by the x, y and z co-ordinates, B-factors and occupancy. 
B-factors describe the uncertainty of the atom position within the collected data 
due to either the vibration of the atom or defects in the collected data. The 
experimental observations include unit cell parameters, structure factor 
amplitudes and standardized stereochemistry. The number of model parameters 
to be refined is much larger than the number of experimental observations; this 
causes the refinement process to be problematic. Therefore stereochemical 
§ Sigma values relate to the probability of finding an electron within the volume enclosed by 
the electron density map, where la and 3a correspond to 99% and 68% respectively. 
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restraints such as bond lengths and angles are included in order to increase the 
number of observations. 
Rigid body refinement is often the first step in the refinement process. The 
protein is treated as a rigid body, and thus only the overall position and 
orientation in the unit cell of the protein are refined. This is then usually 
followed by restrained refinement where each atom is refined separately but 
restraints are placed on the geometry of the molecule, in order to find the best 
solution, where the difference between the observed and calculated structure 
factors are minimal, with idealized geometry (Tronrud, 2004, Drenth, 2007). 
2.4.5.1 Refinement Indicators 
To decrease the incidence of errors in the model, the refinement process is 
monitored using a quality indicator known as Rfacror, which is defined in 
equation (2.5). It measures the difference between the calculated structure 
factors and the observed structure factors. A desirable value for Rfactor is 
between 0.18 and 0.25 according to the resolution and data quality. 
Rfactor =E hkl 
II Fobs I- I'caidI I 
E Fobs (2. sý hk1 II 
Where Fob, is the observed structure factor and Fcalc is the calculated structure 
factor 
Rfactor can be biased towards the model and thus another quality indicator 
known as Rfree, which is less prone to overfitting, was introduced (Brunger, 
1992). A percentage of unique reflections, usually between 5 to 10 per cent are 
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set aside and not included in the refinement process. This fraction of data is 
then used in calculating Rfree according to equation (2.6). The monitoring of 
Rfree as well as Rfactor helps in preventing the over fitting of the data and model 
bias (Kleywegt, 2000). 
Rfree 
Z lI1obsIHFcalc ll 
hkl(free) 
I 
hkl (free) 
I Fobs I (2.6) 
Where Fobs is the observed structure factor for the free unrefined data and Fcalc 
is the calculated structure factor for the free unrefined data 
2.4.6 Model Quality 
The peptide back bone of the protein can be defined by two dihedral angles 
and '1f (Figure 2.9), which are greatly restricted due to steric repulsion by the 
side chains of the amino acids. Glycine can adopt a larger range of b and IF 
values as it lacks a side chain. The Ramachandran diagram (Ramachandran et 
al., 1963), ab '1` scatter plot, defines areas of favourable c and `Y values and 
is an important indicator of the quality of the protein model. Residues outside 
the favourable regions should be closely examined and their geometry justified 
by the presence of strong electron density (Rhodes, 2000, Kleywegt, 2000). 
Moreover, further aspects of the stereochemistry and geometry of the model 
should also be examined. The bond lengths and angles should be compared to a 
library of `ideal' values, and any deviations should be noted. 
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Figure 2.9 Backbone of protein, showing c andW angles. 
Hydrophobic, electrostatic and hydrogen bonding interactions are the main 
stabilizing forces in the protein structures. Consequently, hydrophobic residues 
tend to interact with each other, charged residues tend to form salt bridges and 
hydrophilic residues prefer to either interact with one another or with the bulk 
of the solvent. Violations of these rules, such as the presence of a charged 
residue in a hydrophobic binding pocket, tend to point towards errors in the 
model. Likewise, the position of added water molecules should be thoroughly 
checked to establish that they can form hydrogen bonds with neighbouring 
water molecules or protein atoms (Kleywegt, 2000). 
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Sequence analysis and Structural Studies of 
Nitroaromatic Reducing Enzymes 
3.1 Introduction 
Reducing enzymes play a crucial role in the bioactivation of chemotherapeutic 
agents such as mitosenes, diaziridinylbenzoquinones and CB 1954, in addition 
to reducing nitroaromatic and nitro heterocyclic aromatic compounds. The 
reduction of nitroaromatic and nitro heterocyclic aromatic compounds 
produces the hydroxylamine derivative which then reacts with thioesters such 
as acetyl CoA (Skelly et al., 2001). The thioester derivative can attack 
bio-molecules such as, proteins and DNA. In the case of 
diaziridinylbenzoquinones, the quinone moiety is reduced to the dihydroxyl 
benzene derivative hence activating the aziridine group, making it susceptible 
to nucleophilic attack by the N7 of the guanine base of the DNA (Mossoba et 
al., 1985b, Rauth et al., 1998, Skibo and Xing, 1998). CB 1954 has the unique 
ability to act as a difunctional-alkylating agent, due to the reduction of the nitro 
group, in addition to the activation of the aziridine group forming interstrand 
DNA cross links (Figure 1.16,1.17 and 1.19) (Fu, 1990, Knox et al., 2000, 
Roldan et at., 2008, Skelly et al., 2001, Skibo and Xing, 1998). 
Bacterial nitroreductases are able to reduce nitro compounds to the hydroxyl 
amine derivative. As previously mentioned in chapter one, they are divided 
into two groups, oxygen insensitive and oxygen sensitive. Oxygen insensitive 
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(type I) bacterial nitroreductases are further divided into two groups, group A 
and group B, according to the percentage sequence identity they share and their 
phylogenetic origin. Members of both groups share several structural 
characteristics, where they are dimeric globular proteins with a characteristic 
a+ß fold and a conserved binding pocket (Roldan et al., 2008). In addition to 
bacterial nitroreductases, some mammalian enzymes such as 
NAD(P)H: quinone oxidoreductase (NQO1) (Boland et al., 1991) and N- 
ribosyl dihydronicotinamide (NRH): quinone oxidoreductase II (NQO2) 
(Bianchet et al., 2004) are also able to reduce nitroaromatic compounds to their 
hydroxylamine derivatives. 
Several previously published studies on bacterial nitroreductases showed the 
conservation of aromatic residues in the binding pocket in bacterial 
nitroreductases. It is suggested that the aromatic residues present in the binding 
pocket, play an important role in the interactions of the protein with the 
substrate, the cosubstrate, and the flavin cofactor (Koike et al., 1998, Parkinson 
et al., 2000). It was also suggested that phenylalanine residues present in the 
binding pocket may play an active role in either the transfer of electrons 
between flavin cofactor and substrate or by stabilizing the intermediate enol 
form of the cofactor (Koike et al., 1998). All previously published studies on 
the presence of conserved residues specifically considered bacterial 
nitroreductases, and did not include any other aromatic nitro group reducing 
enzymes. 
The aim of this work is to use sequence and structural alignments to determine 
the occurrence of similarities in the active sites of enzymes that are capable of 
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reducing nitroaromatic compounds to the hydroxylamine derivative as an 
intermediate or final product. Several criteria were placed for the enzymes used 
in this study, in addition to the ability of the enzyme to reduce nitroaromatic 
compounds to their hydroxylamine derivative, the mechanism of action of the 
enzyme was also considered. Only flavoproteins, utilizing flavin cofactors and 
are capable of two electron transfers were considered in this study. 
The determination of the conservation of residues was done by examining the 
primary, secondary and tertiary structures to be compared using sequence and 
3D structural alignments, in order to detect the conservation of residues in the 
binding pocket, specifically aromatic residues. Sequence and structural 
alignments are very useful tools in aiding the identification of conserved 
regions and the detection of any specific residue patterns in enzymes. Sequence 
alignment may aid in the identification of the function of proteins, by the 
identification of closely related proteins. In addition, the comparison of areas 
of local similarities in protein 3D structures has been used to identify 
functional sites, and assigning probable function for newly discovered proteins 
(Jones and Thornton, 2004, Watson et al., 2005). 
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3.2 Methods and Materials 
3.2.1 Summary of Methods Used 
T 
Extract active site 
from structures 
(3.2.4) 
Select enzymes 
(3.2.2) 
Download structures 
and/ or sequences 
(3.2.3) 
T 
Align all sequences 
(3.2.5) 
Homology modelling 
for sequences 
(3.2.8) 
"+ 
Overlay active sites 
(3.2.6) 
Group 
identifi- 
cation 
Overlay of 3D 
structures from 
database and model 
(3.2.9.1) 
Sequence alignment of 
groups 
(3.2.9.2) 
T 
Secondary structure 
alignment 
(3.2.9.3) 
(3.2.10) 
Identification of 
conserved residues 
> 
I 
Template examination 
(3.2.8.2) 
Group 
identifi- 
cation 
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3.2.2 Identification of Enzymes 
A review of published scientific literature was performed using the ISI web of 
knowledge to identify enzymes that reduce nitro aromatic compounds to their 
hydroxylamine derivatives, using the criteria previously mentioned. Glycerol 
trinitrate reductase (GTN) and 2-cyclohexen-l-one are members of the old 
yellow enzyme (OYE) family, from which several members are able to reduce 
nitro aromatic compounds to the hydroxylamine derivative. Therefore they 
were also included with the selected enzymes due to the similar mechanism of 
action. 
3.2.3 Strategy for Obtaining Sequences and 3D Structural Data 
To obtain sequence and 3D structural data for the enzymes of choice, the 
following strategy was adopted. The RSCB protein databank was searched for 
3D structures of the identified proteins. When found they were downloaded 
with the associated sequence in FASTA format. The first choice was always to 
download the wild-type protein of the same species identified in the relevant 
literature and with no substrate in the binding pocket. If no 3D structure was 
available, the European Bioinformatics Institute website was then used to 
search the databases and download the appropriate sequences in FASTA 
format. As with the structure search, the first choice was to download the 
sequence associated with the species previously identified in the literature. 
3.2.4 Extraction of Active Site Residues from 3D Structures 
In order to compare the relative position of the amino acid residues in the 
active site of the different proteins, it was necessary to identify and extract the 
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residues forming the active site, and separate them from the remaining 
residues. The active site of the proteins, for which a 3D structure was available, 
was defined using PyMOL (Delano, 2008). An object containing all the 
residues within 8A of the FAD or FMN cofactor was created; all water 
molecules, and substrate if present, were then deleted. The resultant structure 
was then saved as a pdb file. 
3.2.5 Sequence Alignment 
To identify the presence of conserved regions in the sequences of the 26 
chosen proteins, sequence alignment were carried out using, ClustalW2 (Larkin 
et al., 2007) and T-Coffee (Notredame et al., 2000). Both were accessed 
through the European Bioinformatics website. The BLOSUM 62 matrix 
scoring function was used for all alignments. It is a global alignment algorithm, 
which attempts to align every residue in the sequence. It is based on the 
likelihood of substitution for a residue by another residue. If the residues are 
identical, a high score is given, while if the residue is substituted by a similar 
residue, then a lower positive score is given. If the substituted residues are 
significantly different, then a negative score is given to the alignment. The 
scores are then added together to give the overall alignment score between the 
two proteins (Altschul, 1991). For T-Coffee alignments, the default settings 
were used, while for Clustal W2, several different parameters were tested, as 
defined in section 3.2.5.1. 
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3.2.5.1 Alignment parameters used in alignments with Clustal W2 
Clustal W2 has different parameter combinations available, depending on how 
the penalties are dealt with in the alignment algorithm, thus allowing the 
optimization of the alignment results. Several different combinations of these 
parameters were used to try to align the sequences of the all 26 identified 
proteins, as defined in Table 3.1 
Alignment GAPOPEN GAPEXTN GAPDIST 
Alignment 1 
(Default parameters) 10 0.2 4 
Alignment 2 25 0.2 4 
Alignment 3 25 1 6 
Alignment 4 5 0.05 2 
Table 3.1 Different parameter combinations used for Clustal W2 alignments where 
GAPOPEN is the penalty added to the alignment score when a new gap Is added to the 
alignment, while GAPEXTN is the penalty added to the alignment score for each residue 
added to a pre-existing gap. The GAPDIST is the penalty added to avoid gaps being 
closely spaced to each other. 
3.2.6 The 3D Structural Alignment of the Active Site Residues 
Sybyl 8.0 (International) was used to superimpose the active site structures of 
the chosen proteins, previously created using PyMOL and to compare the 
positions and types of amino acids in the different active sites. The flavin 
cofactors in the active site models were overlaid, by selecting the same atoms 
in the cofactor molecules in the active sites. 
The flavin cofactors in the active sites were overlaid by selecting N 10, N5, N3 
and C8 atoms in the isoalloxazine ring of the cofactor (Figure 1.1). The 
structures were then aligned using Sybyl, by the "fit atoms" command in the 
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"align compounds" menu. On occasion, where the equivalent atoms in the 
different cofactor molecules did not superimpose, the structural alignment was 
then repeated using additional atoms from both the ring and tail portion of the 
cofactor. 
From the visual inspection of the overlaid 3D structures of the active sites, it 
was established that the proteins fall into several different groups showing 
clear similarities in the residue positioning around the flavin cofactor. The 
proteins, to which no visual similarities were identified, were reconsidered at a 
later stage. 
3.2.7 Sequence Alignment for Enzymes within Different Structural Groups 
For the groups previously identified in section 3.2.6, two sequence alignments 
were done on the proteins within each group separately using the default 
settings of T-Coffee and Clustal W2. 
3.2.7.1 Calculation of percentage identity and similarity between sequences of 
group members 
For each group, both the identity and similarity between the group members 
was determined using the Emboss Pairwise Alignment Algorithm (Rice et al., 
2000), using the BLOSUM 62 matrix. This was done to ensure the removal of 
any enzymes that are identical or share more than 75 per cent similarity where 
large regions of structural similarities would be expected. Enzymes that 
showed less than 25 per cent similarity to other group members were also 
excluded, as alignments between sequences with low percentage identities are 
of low quality (Pei, 2008). 
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3.2.8 Homology Modelling 
3D homology models were created for the sequences for which there were no 
3D structures available in the RSCB protein databank; this was to aid in the 
identification of the structural group to which the enzyme belonged to. 
Homology modelling is dependent on finding a suitable template protein, with 
a 3D structure, that is homologous to the required target protein. The structure 
of the required model is then predicted based upon its similarity with the 
template protein. 
This was done using two separate software packages; SWISS-MODEL (Arnold 
et al., 2006) and ModWeb (Eswar et al., 2003). SWISS-MODEL was accessed 
via the ExPASy Proteomics web server (Basel); where model building was 
done in the fully automated mode. ModWeb was also accessed via its web 
server (Eswar Narayanan), the models created were scored using the 
normalised DOPE scoring method (Shen and Sali, 2006) and the best scoring 
model was selected for output. In addition to the final 3D model, both software 
packages gave information about the template which was used to create the 3D 
model. 
3.2.8.1 Choice of model 
Each of the software packages used produced one model per protein; these 
were compared, to decide which model would be used for future studies and to 
determine whether the models produced for the same protein have significant 
structural differences. The two models for the same protein were aligned using 
rigid body alignment, based on the sequence identity. This was done using 
Sybyl 8.0, using the "align structures by homology" command, utilizing only 
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the backbone atoms of the protein for the alignment. This is done by firstly 
aligning the sequences of the proteins, and then the backbone atoms of the 
matching residues are then superimposed. The root mean square deviation 
(RMSD) is then calculated using the least square fit method. The resulting 
overlaid structures were then visually examined for differences between the 
structures. 
3.2.8.2 Template examination and group identification 
The homology models produced by the modelling software did not contain the 
cofactor molecule in the structure. Thus extracting the active site residues for 
structural alignment and subsequent group identification was not possible using 
the previously used method. 
On occasion, some of the template proteins, which were used to build the 3D 
model, were other proteins used in this study and were identified as members 
of an identified group. This information is then used to identify the potential 
group to which the model may belong to. For protein sequences to which no 
group was identified, the models built were then aligned using Sybyl 8.0, as 
previously described in section 3.2.8.1, to all the groups to determine the group 
they belong to. 
3.2.8.3 Percentage identity and similarity calculation for modelled proteins 
Once the group to which the modelled protein belongs was identified, the 
percentage identity and similarity of the speculated group members and the 
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other group members was determined in the same manner described in section 
3.2.7.1 
3.2.8.4 Validation of group identification 
The pdb structures from the RSCB protein databank and those produced by the 
modelling software were overlaid using Sybyl 8.0 as described in section 
3.2.8.1, with the other members of the group identified using the template 
information. This was done to validate the information gained from the 
templates and to ascertain that all the group members have similar structural 
characteristics. 
3.2.9 Structural and Sequence Alignment for Proteins Groups 
3.2.9.1 Structural alignment 
The binding pockets of the previously overlaid proteins in section 3.2.8.4 were 
visually examined to check that the cofactor molecules and surrounding 
residues were aligned correctly and identify the conservation of residues. 
3.2.9.2 Sequence alignment 
After the identification of all group members, two sequence alignments using 
the default parameters of T-Coffee and Clustal W2 were done using the 
sequences of all the group members. 
3.2.9.3 Secondary sequence alignment 
Another sequence alignment was also carried out using PROMALS (Pei and 
Grishin, 2007), where the software predicts secondary structures of sequences 
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and uses this information to aid in the sequence alignments. The PROMALS 
software was accessed via its web server (Pei), where the default parameters 
were used. 
3.2.10 Identification of Conserved Residues 
The identification of the conserved residues within the group members was 
done in two steps. First, the active sites of the overlaid structures from section 
3.2.9.1 were visually examined and conserved residues in the area surrounding 
the flavin cofactor were identified. Afterwards, the sequence and secondary 
structure alignments from sections 3.2.9.2 and 3.2.9.3 were then examined, to 
determine whether the identified residues are also conserved in the alignments. 
3.3 Results 
3.3.1 Obtaining the Sequences and 3D Structural Data 
Table 3.2 and Table 3.3 show a list of the names and accession codes of the 26 
proteins identified in the literature search, in addition to the pdb code if 
present. All the 3D structures were obtained from X-ray crystallographic 
experiments with resolutions ranging from 1 to 2.4 A. Furthermore, the table 
lists the identified species to which the obtained sequence or 3D structure 
belongs and the activity of the enzyme. 
3.3.2 Active Site Residue Extraction from 3D Structures 
The extraction of the active site was successful for all the enzymes to which a 
3D structure was available with the exception of NfnB. When attempts were 
made to define the active site of NfnB, it was found that the crystal structure 
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did not contain any flavin cofactor, although NfnB is reported to utilise a flavin 
cofactor to reduce nitroaromatic compounds. In addition, it is also reported to 
share high sequence homology with other known bacterial nitroreductases such 
as E. coli and E. cloacae nitroreductases that utilize FMN (Watanabe et al., 
1998). NfnB was found to share a high sequence identity with both NEC and 
NfsB, 92.6 and 93.5 per cent respectively, suggesting structural similarity. 
Therefore, it can be discarded from subsequent procedures, and represented by 
the previously mentioned enzymes. 
Accession 
Protein Organism Activity 
code 
Cyclohexan-I- Pseudomonas Old yellow enzyme family (Williams et Q9Z3T1 
one reductase syringae al., 2004) 
Rhizobium Old yellow enzyme family (Williams et GIN 031246 
radiobacter at, 2004) 
Pseudomonas Reduction of nitrobenzene (Nadeau et NbzA Q6DLR9 
pseudoalcaligenes al., 2000, Somerville et al., 1995) 
Clostridium Reduction of nitroaromatic NitA Q97L47 
acetobutylicum compounds (Kutty and Bennett, 2005) 
Clostridium Reduction of nitroaromatic NO Q97DC3 
acetobutylicum compounds (Kutty and Bennett, 2005) 
Pseudomonas Reduction of TNT (Caballero et al., PnrA Q7B4Y3 
putida 2005a, Caballero et al., 2005b) 
Pseudomonas Reduction of TNT (Caballero et al., PnrB Q8KRI2 
putida 2005a, Caballero et al., 2005b) 
Enterobacter Oxygen insensitve bacterial 
rnr Q9EXU3 
cloacae nitroreductases (Koder et al., 2001) 
Reduction of TNT (Pak et al., 2000, Pseudomonas 
XenB Q4KH19 Ramos et al., 2005, Williams and Bruce, fluorescens 
2002) 
Activation of CB 1954 (Barak et al., YieF POAGE6 Escherichia coli 2006) 
Bacillus Activation of CB 1954 (Anlezark et al., 
ywrO Q65EJ8 
licheniformis 2002) 
Table 3.2 Final list of enzymes, accession code and associated species. 
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Accession Pdb 
Protein Organism Activity 
code code 
Aliivibrio Oxygen insensitive bacterial 
FRase I P46072 1 VFR 
fischeri nitroreductase (Zenno et al., 1994) 
Oxygen insensitive bacterial 
FRP Q56691 I BKJ Vibrio harveyi nitroreductases (Lei et al., 1994, 
Roldan et al., 2008) 
Helicobacter Reduction of metronidazole 
FrxA Q60049 2HOU 
pylori (Kwon et al., 2000) 
Morphinone Pseudomonas Reduction of TNT (Ramos et al., Q51990 IGWJ 
reductase putida 2005, Williams et al., 2004) 
Enterobacter Reduction of nitrofurazone NEC Q01234 ]NEC 
cloacae (Bryant and Deluca, 1991) 
Burkholderia Reduction of TNT (Ramos et al., 
NemA Q63LY5 3GKA 
pseudomallei 2005) 
Oxygen insensitive bacterial 
Sallmonella 
NfnB P15888 3HZN nitroreductases (Watanabe t al., 
typhimurium 
1998) 
Escherichia Oxygen insensitive bacterial 
NfsA P17117 1F5V 
coli nitroreductases (Zenno et at., 1996) 
Oxygen insensitive bacterial 
Escherichia nitroreductases and NfsB P38489 1 YLR 
coli reduction of CB 1954 (Knox et at., 
1992) 
Thermus Oxygen insensitive bacterial 
NOX Q60049 1 NOX 
thermophilus nitroreductases (Park et al., 1992) 
Active against CB 1954 (Boland et NQO1 P16083 1D4A Homo sapien 
al., 1991) 
Active against CB 1954 (Bianchet NQO2 P15559 1 QR2 Homo sapien 
et al., 2004) 
Saccharomyces Reduction of TNT (Ramos et al., 
OYE Q02899 1OYA 
pastorianus 2005) 
Enterobacter Reduction of TNT (Ramos et al., 
PETN P71278 2ABA 
cloacae 2005, Williams and Bruce, 2002) 
Reduction of TNT (Blehert et al., Pseudomonas 
XenA Q88NF7 2H8X 1999, Pak et at., 2000, Ramos et at., 
putida 2005, Williams and Bruce, 2002) 
Table 3.3 Final list of enzymes, accession and pdb codes 
and associated species 
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3.3.3 Sequence Alignment for All Enzymes 
Several different sequence alignments for all the sequences, listed in 
Table 3.2 and Table 3.3 were done. The default parameters of T-Coffee were 
used as well as several different parameter combinations for Clustal W2. The 
alignments did not show any apparent conserved regions between all the 
enzymes, rather some conservation of residues could be seen in sub-groups of 
the enzymes. 
3.3.4 The 3D Structural Alignments of Active Site Residues 
When Sybyl 8.0 was used to overlay all the active sites defined by PyMOL, it 
was observed that not all the active sites superimpose, and that they do not 
share the same orientation of residues within the active site, where the position 
of amino acids is different relative to the flavin cofactor. 
Upon closer visual examination of the overlaid active sites, it was noticed that 
two distinct groups of proteins were identified, where members of the 
individual groups shared similar orientation of the flavin cofactor and 
arrangement of amino acids in the active site. Group I consisted of Morphinone 
reductase, NemA, OYE, PETN and XenA while group II consisted of FrxA, 
NEC, FRase I, NOX and NfsB. Furthermore, Frp and NfsA seemed share 
similar orientation of residues around the flavin cofactor, but did not share any 
similarity with any of the other proteins. Similarly, NQOI and NQO2 did not 
belong to any of the identified groups, but showed structural similarities to 
each other. 
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3.3.4.1 Group I active site structural alignment 
The overlaid active sites of group I showed that the members of this group 
have two conserved amino acids, a histidine residue and a tyrosine residue 
(Figure 3.1). The positions of the different conserved residues in the protein 
sequences are listed in Table 3.4. The position of the conserved tyrosine 
residue in all sequences ranges between 344 and 375 with the exception of 
XenA, where it is at position 27. The positions of the conserved histidine 
residues in all the sequences are very close, ranging from 178 to 191. The 
active sites of the enzymes showed similar structural characteristics. The 
binding pocket is wide and is easily accessible to the solvent and is on the 
si face** of the flavin. 
Figure 3.1 Aligned active sites of members of group I, Morphinone reductase (red), 
NemA (blue), OYE (yellow), XenA (Green) and PETN (magenta). The conserved tyrosine 
residues are represented by bold sticks on the left hand side of the figure while the 
conserved histidine residues are represented by sticks on the right hand side of the figure. 
Figure created using USCF Chimera (Pettersen et al., 2004). 
.. The si face of the Flavin is viewed when the pyrimidine ring is on the right and the ribotidyl 
chain is pointing upwards, the re face of the flavin is viewed when the pyrimidine ring is on the 
left. 
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Morphinone reductase NemA OYE XenA PETN 
Conserved residue I His-186 His-181 His-191 His-178 His-181 
Conserved residue 2 Tyr-356 Tyr-344 Tyr-375 Tyr-27 Tyr-351 
Table 3.4 Conserved residues of group I 
3.3.4.2 Group II active site structural alignment 
The overlaid active sites of members of group II showed one conserved 
residue, a tyrosine (Figure 3.2). Table 3.5 shows the position of the conserved 
residues in the protein sequences, which ranged from position 137 to 144. 
Unlike group I members, the binding pocket of group II members is on the re 
face of the flavin cofactor. The active site is not buried within the enzyme 
structure and the flavin cofactor is on the protein surface, at the interface 
between two identical chains. 
Figure 3.2 Aligned active sites of group II, NfsB (red), FrxA (blue), NOX (yellow), NEC 
(green) and FRase I (magenta). The conserved tyrosine residues are represented by 
bold sticks on the right hand side of the figure. 
Figure was created using USCF Chimera (Pettersen et al., 2004). 
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NfsB FrxA NOX NEC FRase I 
Conserved residue Tyr-144 Tyr-143 Tyr-137 Tyr-143 Tyr-144 
Table 3.5 Conserved residues of group II. 
3.3.5 Sequence Alignment for Enzymes within Identified Groups 
3.3.5.1 Calculation of identity and similarity within identified groups 
The percentage identity and similarity between group members were compared 
in a pair wise manner, to each other. The calculated percentage identities and 
similarities are shown in Table 3.6 andTable 3.7 for group I and II members 
respectively. The members of group I were found to have percentage 
similarities ranging between 64.0 and 38.2 per cent, which is within the 
previously decided acceptable range for comparison, Table 3.6. 
NemA OYE XenA PETN 
Morphinone 60.4% 51.2% 42.0% 64% 
reductase (49.5r/() (35.1%) (51.2%) (50%) 
46.9% 40 % 59.2% NemA ( 33ý, 1 (28.7%) (45.5%) 
I 38.2% 46.4% OYI ý, ý. h"; ) (33.6%) 
41.5%0 Xený (26.0%) 
Table 3.6 Percentage similarity bct\%cen group I members, the percentage 
identity is shown between parentheses. 
On the other hand, two members of group II were found to share a high 
percentage of similarity, Table 3.7, where NEC shared 92.6 per cent with 
NfsB. Due to the high similarity found between the previously mentioned 
proteins, a decision was taken that only NEC would be used for future 
comparative purposes, as a representative of both proteins. The remaining 
70 
Chapter Three 
- 
Nitroaramatic reducing enzymes 
members of the group shared a percentage similarity ranging from 50.2 per 
cent to 38.5 per cent, which is within the previously decided acceptable range. 
NEC FRaseI NfsB NOX 
45% 46.2% 45.9% 38.5% 
FrxA 
(21.8%) (25.4%) (24.2%) (21.4%) 
50.2% 92.2% 41.6% 
NEC (37.4%) (87.6%) (26.6%) 
49.8% 42.1% 
FRase l
(33.5%) (27.2%) 
38.6% 
NfsB 
(25.2%) 
Table 3.7 Percentage similarity between group 11 members, the percentage 
identity is shown between parentheses. 
NfsA and Frp, which were thought to be members of the third group, were 
found to share 65 per cent identity and 51.7 per cent similarity. 
3.3.5.2 Sequence alignment of group 1 
The alignments of the members of group I using the default settings of both 
T-Coffee and Clustal W2 showed that the conserved residues in the 3D active 
site structures were aligned in the sequence alignments, with the exception of 
Tyr-27 in XenA. The Tyr-27 residue of XenA, was found to be in the same 
region of the active site with regards to the flavin cofactor as the other 
conserved tyrosine residues previously mentioned in Table 3.4 (Figure 3.1), 
but was not aligned in the sequence alignments. The conserved histidine and 
tyrosine residues are highlighted in yellow in the sequence alignments done 
using both T-Coffee and Clustal W2 (Figure 3.3 and Figure 3.4). The full 
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sequence alignments using Clustal W2 and T-Coffee can be found in 
appendices A3.1 and A3.2 respectively. 
OYE LTKDEIKQYIKEYVQAAKNSIAAGADGVEIHSANGYLLNQFLDPHSNTkTDEYGGSIEN 
PETN LELDEIPGIVNDFRQAVANAREAGFDLVELHSAHGYLLHQFLSPSSNQRTDQYGGSVEN 
XenA MTLDDIARVKQDFVDAARRARDAGFEWIELHFAHGYLGQSFFSEHSNKRTDAYGGSFDN 
NemA LELDEIPGVVAAFRRGAENARAAGFDGVEVHGANGYLLDQFLQDSANRRTDAYGGSIEN 
Morphin LETDGIPGIVEDYRQAAQRAKRAGFDMVEVHAANACLPNQFLATGTNRRTDQYGGSIEN 
-one ::. 
OYE DKRTLIGYGRFFISNPDLVDRLEKGLPLNKYDRDTFYQMSAHGYIDYPTYEEALKLGWD 
PETN GLIDAVAFGRDYIANPDLVARLQKKAELNPQRPESFYGGGAEGYTDYPS---------- 
XenA NQLDLVSVGRAHLADPHWAY---------------- FAAKELGVEKASWTLPAPY-AHW 
NemA GQADAVAWGKLFIANPDLPRRFKLNAPLNEPNAATFYAQGEVGYTDYPALES------- 
Morphin NTADAVAFGRPFIANPDLPE"rFI-LGAALNEPDPSTFYGGAEVGYTDYPFLDNGH---D; 
- 
one 
Figure 3.3 Sequence alignment of group I members using T-Coffee 
OYE AEQEAKAr: rANNPQHSL'IKDEIKQYIriEYVQAAi': NSIAAGADGVEIHSAN 195 
PETN 
-ENGNAIRVDTTTPRALELDEIPGIVNDFRQAVANAREAGFDLVELHSAH 184 
XenA IAFG---AHLPKVPREMTLDDIARVKQDFVDAARRARDAGFEWIELHFAH 179 
NemA 
------ 
PQRPYVTPRALELDEIPGVVAAFRRGAENARAAGFDGVEVHGAN 184 
Morphinone FEDGTAGLHPTSTPi? ALEiDGIPGIVEDY QAAQ-A? J, AGFDMVEVHAAN 189 
OYE GYGRFFISNPDLVDRLEr: C3LPLN,; YD: DTFYQMSAHGYIDYPTYEEALý; L 395 
PETN AFGRDYIANPDLVARLQKKAELNPQRPESFYGGGAEGYTDYPSL------ 346 
XenA SVGRAHLADPHWAYFAAKELGVEKAS----- WTLPAPYAHWLE------- 358 
NemA AWGKLFIANPDLPRRFKLNAPLNEPNAATFYAQGEVGYTDYPALESAA-- 361 
Morphinone AFGRPFIANPDLPEI=F-LGAALNEPDPSTFYGGAEVGYTDYPFLDNGHD: 
' 375 
Figure 3.4 Sequence alignment of group I members using Clustal W2. 
Small and Red hydrophobic 
Blue Acidic 
Magenta Basic 
Hydroxyl + 
Green amine + basic 
Residues identical in all aligned 
sequences 
Conserved substitution in all aligned 
sequences 
Semi-conserved substation in all 
aligned sequences 
Table 3.8 Consensus symbols and colours used in Clustal W2 and T-Coffee alignments. 
3.3.5.3 Sequence alignment of group II 
The sequence alignments using T-Coffee and Clustal W2 of group II members 
(Figure 3.5 andFigure 3.6) showed that the conserved tyrosine residues 
highlighted in yellow, were aligned in both sequence alignments. The full 
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sequence alignments using Clustal W2 and T-Coffee can be found in 
appendices A3.4 and A3.5 respectively. 
NEC PEAKAANHKGRTYF--ADMHRVDLKDDDQWMAKQVYLNVGNFLLGVGAMGLDAVPIEGF 
NOX AQKQAIQ-R---AF--AAMG---QEARKAWASGQSYILLGYLLLLLEAYGLGSVPMLGF 
FRasel EQKEAAF-ASFK-F--VELNCDENGEHKAWTKPQAYLALGNALHTLARLNIDSTTMEGI 
FrxA SPFAQII-K---NFQENDMý'LNSE:? SLFDWASKQTYIQMANMMMAAAMLGIDSCPIEGY 
Figure 3.5 Sequence alignment of group II members using T-Coffee 
NEC QVYLNVGNFLLGVGAMGLDAVPIEGFDAAILDEEFGLr: Er(GFTSLVVVPV 190 
NOX QSYILLGYLLLLLEAYGLGSVPMLGFDPERVRAILGLPSR-AAIPALVAL 183 
FRasel QAYLALGNALHTLAPLNIDSTTMEGIDPELLSEIFADELKGYECHVALAI 191 
FrxA QTYIQMANMMMAAAMLGIDSCPIEGYDQEKVEAYLEEKGYLNTAEFGVSV 190 
Figure 3.6 Sequence alignment of group 11 members using Clustal W2. 
3.3.6 Homology Modelling 
SWISS-MODEL and ModWeb modelling servers were used to create 3D 
structures for the sequences for whom no structures were found in the 
Brookhaven database. Table 3.9 shows the templates from which the models 
were produced by both software, SWISS-MODEL and ModWeb, in addition to 
the percentage identity the template shares with the modelled protein. A 
sequence identity above 30 per cent shared between the modelled protein and 
the template is the generally accepted limit. The low sequence identity 
decreases the accuracy of the model building process, and produces models 
with low quality (Elofsson, 2002, Tramontano, 1998). The models that were 
built for the protein YieF were based on templates that share a sequence 
identity below 30 per cent with YieF. Hence a decision was made to use these 
models with caution. The percentage identity shared between the mr and the 
template proteins was calculated to be 89 per cent. The remaining sequence 
identities shared between the templates and the modelled proteins ranged from 
69.0 to 31.2 per cent. 
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Protein 
ModWeb template 
code 
SWISS-MODEL 
template code 
2-Cyclohexan- l 
-one 
reductase 
3GKA (51 %) 3GKA (49%) 
GTN 3GKA (50%) 2ABA (46%) 
Nbza 3GR3 (36%) 3GR3 (35%) 
NitB 3E10 (34%) 3E10 (31.2%) 
PnrA 3F2V (43%) 2BKJ (35%) 
PnrB 3HZN (54%) 1DS7 (51.6%) 
mr 3HZN (89%) 1KQB (96%) 
XenB 3GKA (69%) 3GKA (69%) 
YieF 2Q62 (19%) 2Q62 (20.5%) 
ywrO 3FV5 (43%) No result produced 
Table 3.9 List of templates used to create models and their percentage identity, 
stated in between parenthesis, to the modelled protein 
3.3.6.1 Template examination and group identification 
Upon examination of the template pdbs used for building homology models, it 
was found that some of the template proteins were enzymes that have been 
selected and have already been assigned to a specific group. 
NemA (pdb code: 3GKA) was used as the template protein for building the 
models of several proteins, 2-Cyclohexan-l-one reductases, XenB and GTN. 
The model of GTN built by SWISS-MODEL was based on PETN 
(pdb code: 2ABA). Both NemA and PEIN were previously identified to 
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belong to group I, and thus it is thought that the previously mentioned proteins; 
2-Cyclohexan-l-one reductases, XenB and GTN, also belong to the same 
group and may share the same structural characteristics. Therefore 
2-Cyclohexan-l-one reductases, XenB and GTN were allocated to group I. 
The models built for mr and PnrB using WebMod were both based on NfnB 
(pdb code: 3HZN); this suggests that mr and PnrB might be structurally related 
to NfnB. NfnB is reported to be structurally related to members of group II, 
thus it was thought that mr and PnrB may be members of group II. Frp 
(pdb code: 2BKJ) was used by SWISS-MODEL as a template to create the 
model for PnrA, suggesting that their active sites might align. Hence PnrA may 
belong to group III. The other templates used for building the remaining 
models did not provide any insight into the structural information allowing for 
their allocation to the predetermined group. 
3.3.6.2 Comparison of models produced by homology modelling 
Alignment of both models for each protein using Sybyl 8.0 showed that both 
software packages produced similar models, even when different templates 
were used. Table 3.10 shows the RMSD values between the models produced 
from both modelling servers. 
The models chosen were those produced by the SWISS-MODEL, except for 
the protein ywrO, where the model produced by WebMod was used since no 
model was produced for ywrO by SWISS-MODEL. 
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Enzyme Cyclohexone reductase GTN NbzA NitB 
RMSD (ý) 0.286 0.768 0.406 0.351 
Enzyme PnrA PnrB rnr XenB 
RMSD (ý) 1.06 0.538 0.491 0.283 
Table 3.10 RMSD values showing the difference between the 2 homology 
models for each protein (All atoms have been considered in the calculations). 
3.3.6.3 Percentage identity and similarity calculation between modelled and 
previously identified group I members 
The new members of group I showed sequence similarity ranging from 
69.3 per cent to 40.3 per cent, which is within the previously decided 
acceptable limit (Table 3.11). The percentage similarity and identity shared 
between the previously identified group I members is stated in Table 3.6. 
Cyclohexone 
GTN XenB 
reductase 
Morphinone 53.9 % 58.8 % 61.9 % 
reductase (44.5 %) (45.3 %) (49.3 %) 
62.1% 60.8% 69.3% 
NemA 
(48.0 %) (48.2 %) (58.5 %) 
46.9% 47.9% 48.9% 
OYE 
(32.3 %) (34.5 %) (34.3 %) 
57.3% 62.0 % 42.1% 
PETN (43.0 %) (47.0 %) (27.2 %) 
44.7% 40.3% 63.2% 
XenA 
(28.0 %) (26.4 %) (49.5 %) 
Table 3.11 Percentage similarities between previously 
identified and new members of group I, the percentage 
identity is shown between parentheses. 
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3.3.6.4 Percentage identity and similarity calculation between modelled and 
previously identified group II members 
The calculated percentage identity and similarity between the modelled 
proteins and the previously defined group II members are stated in Table 3.12. 
The pairwise alignment showed that mr is almost identical to NEC, sharing 
98 per cent similarity, and thus will be excluded from further examination. On 
the other hand, PnrB shared a percentage similarity within the decided limit 
with the other members of group II. The percentage similarity and identity 
shared between the previously identified group II members is stated in 
Table 3.7 
mr PnrB 
FrxA 47.5% (23.8%) 46%(26.6%) 
NEC 98.3% (96.3%) 70% (51.6%) 
FRasel 32.9% (51.1%) 51.4% (34.1%) 
NOX 41.2% (26.7%) 45.8% (28.2%) 
Table 3.12 Percentage similarities between previously 
identified and new members of group II, the percentage 
identity is shown between parentheses. 
3.3.7 Structural and Sequence Alignment for Group I Proteins 
3.3.7.1. Structural alignment 
The full protein structures of both the experimentally determined structures and 
the models were aligned using the "homology" in Sybyl 8.0. The alignment of 
GTN, 2-Cyclohexan-l-one reductase and XenB to the other protein members 
of group I showed that the two conserved residues the histidine and tyrosine of 
were also conserved in the newly added protein models (Figure 3.7). 
77 
Chapter Three 
- 
Nitroaroinatic reducing enzymes 
Table 3.13 shows the position of the conserved residues in the sequences of the 
newly added proteins. The position of the conserved residues in the previously 
identified members of group I is stated in Table 3.4. 
Figure 3.7 Active site of group I members, morphinone reductase (red), XenA (green), 
NemA (blue), OYE (yellow), PETN (magenta), GTN (orange), XenB (cyan) and 
2-Cyclohexan-1-one reductase (white). The conserved tyrosine residues are represented 
by bold sticks on the left hand side of the figure while the conserved histidine residues are 
represented by sticks on the right hand side of the figure. 
Figure was created using USCF Chimera (Pettersen et al., 2004). 
Protein 2-Cyclohexan-l-one reductase GTN XenB 
Conserved residue I His-173 His-178 His-173 
Conserved residue 2 Tyr-343 Tyr-356 Tyr-343 
Table 3.13 Conserved residues in modelled group I proteins. 
3.3.7.2 Sequence alignment 
The sequence alignments of all group I members showed that the residues 
conserved in the structural alignment, are also conserved in the sequence 
alignments, with the exception of Tyr-27 in XenA, as has been previously 
noted. The Tyr-27 residue in XenA is aligned with the other residues 
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structurally, but not in the sequence alignments. Figure 3.8 and Figure 3.9 
show the sequence alignments using both T-Coffee and Clustal W2 
respectively, the conserved tyrosine and histidine residues are highlighted in 
yellow. Full sequence alignments using Clustal W2 and T-Coffee can be found 
in appendices A3.1 and A3.2 respectively. 
OYE TJDEI'r: QYIY. EYVQAA'r: NSIAAGADGVEIHSANGYLLNQFLDPHSNTrtTDEYGGSI 
PETN ELDEIPGIVNDFRQAVANAREAGFDLVELHSAHGYLLHQFLSPSSNQRTDQYGGSV 
XenA TLDDIARVKQDFVDAARRARDAGFEWIELHFAHGYLGQSFFSEHSNKRTDAYGGSF 
NemA ELDEIPGVVAAFRRGAENARAAGFDGVEVHGANGYLLDQFLQDSANRRTDAYGGSI 
GTN TIDDIGLILEDYRSGARAALEAGFDGVEIHAANGYLIEQFLKSSTNQRTDDYGGSI 
XenB ETAEIADIVDAYRVGAENAKAAGFDGVEIHGANGYLLDQFLQSSTNQRTDQYGGSL 
Cyclo. SADEIPRLLNDYEHAAKNAMAAGFDGVQIHAANGYLIDQFLRDNSNVRGDAYGGSI 
Morphin- ETDGIPGIVEDYäQAAQRAKRAGFDMVEVHAANACLPNQFLATGTN:? --TDQYGGSI 
one 
.:.. 
OYE i, EEVr: D:, 'i-TLIGYGi, FFISNPDLVDPLE. ýGLPLN!! YD:? DTFYQMSAHGYIDYPTYE 
PETN LIG-KGLIDAVAFGRDYIANPDLVARLQKKAELNPQRPESFYGGGAEGYTDYPS-- 
XenA ALQ-ANQLDLVSVGRAHLADPHWAYFAAKELGVEKAS---WTLPAP--YA---H-- 
NemA ALD-AGQADAVAWGKLFIANPDLPRRFKLNAPLNEPNAATFYAQGEVGYTDYPALE 
GTN AVE-SGKVDAVAFGKAFIANPDLVRRLKNDAPLNAPNQPTFYGGGAEGYTDYPAL- 
XenB WLA-AGKADAVAFGVPFIANPDLPARLKADAPLNEAHPETFYGKGPVGYIDYPT-- 
Cyclo ALA-TGEADAITFGRPFLANPDLPHRFAERLPLNKDVMETWYSQGPEGYVDYPTAD 
Morphin RLD-DNTADAVAFGRPFIANPDLPEPFRLGAALNEPDPSTFYGGAEVGYTDYPFLD 
one 
. ... .. 
Figure 3.8 Sequence alignment of group I using T-Coffee 
OYE rANtiPQHSLT DE Ir QYIýEYVQAAr"tiSIAAGADý; VEIHSA: ti 195 
PETN 
-ENGNAIRVDTTTPRALELDEIPGIVNDFRQAVANAREAGFDLVELHSAH 184 
XenA 
---IAFGAHLPKVPREMTLDDIARVKQDFVDAARRARDAGFEWIELHFAH 179 
NemA 
------PQRPYVTPRALELDEIPGVVAAFRRGAENARAAGFDGVEVHGAN 184 
GTN 
-DDGTGAFAETSEPRALTIDDIGLILEDYRSGARAALEAGFDGVEIHAAN 181 
XenB 
------PLADFPTPRALETAEIADIVDAYRVGAENAKAAGFDGVEIHGAN 176 
CyClo. 
------GKQDYDEARPLSADEIPRLLNDYEHAAKNAMAAGFDGVQIHAAN 176 
Morphinone FEDGTAGLHPTSTPRALETDGIPGIVEDYRQAAQRAKRAGFDMVEVHAAN 189 
OYE KýTLIGYGRFFISNPDLVDRLEKGLPLNKYDRDTFYQMSAHGYIDYPTYE 390 
PETN LIDAVAFGRDYIANPDLVARLQKKAELNPQRPESFYGGGAEGYTDYPSL- 346 
XenA QLDLVSVGRAHLADPHWAYFAAKELGVEKAS 
----- 
WTLPAPYAHWLE-- 358 
NemA QADAVAWGKLFIANPDLPRRFKLNAPLNEPNAATFYAQGEVGYTDYPALE 358 
GTN "r; VDAVAFGKAFIANPDLVRRLKNDAPLNAPNQPTFYGGGAEGYTDYPALA 370 
XenB KADAVAFGVPFIANPDLPARLKADAPLNEAHPETFYGKGPVGYIDYPTL- 349 
Cyclo EADAITFGRPFLANPDLPHRFAERLPLNKDVMETWYSQGPEGYVDYPTAD 358 
Morphinone TADAVAFGRPFIANPDLPERFRLGAALNEPDPSTFYGGAEVGYTDYPFLD 370 
Figure 3.9 Sequence alignment of group I using Clustal W2 
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3.3.7.3 Secondary Structure prediction and alignment 
The secondary structure prediction and sequence alignment using PROMALS 
showed that the conserved histidine residue in all proteins of group I is at the 
end of a predicted ß-sheet, while the conserved tyrosine residue, was not 
predicted to be in either an a-helix or ß-sheet (Figure 3.10). The conserved 
tyrosine and histidine residues are highlighted in yellow. The full secondary 
structure alignment is in appendix A3.3, showed that the secondary structures 
of the members of group I are highly conserved where the a-helices and (3- 
sheets are generally aligned in many areas. 
Conserv. 57 7 759 565 67 57 9977 77 9 96779 797 
ti rr PQRPYVTPRALELDEIPGVVAAFRRGAENARAAGFDGVEVHGANGYLLDQFLQ 193 
XenB PLADFPTPRALETAEIADIVDAYRVGAENAKAAGFDGVEIHGANGYLLDQFLQ 185 
i'yrio GKQDYDEARPLSADEIPRLLNDYEHAAKNAMAAGFDGVQIHAANGYLIDQFLR 185 
GTN AFAETSEPRALTIDDIGLILEDYRSGARAALEAGFDGVEIHAANGYLIEQFLK 190 
Morph GLHPTSTPRALETDGIPGIVEDYRQAAQRAKRAGFDMVEVHAANACLPNQFLA 198 
PETN IRVDTTTPRALELDEIPGIVNDFRQAVANAREAGFDLVELHSAHGYLLHQFLS 193 
OYA AKKANNPQHSLTKDEIKQYIKEYVQAAKNSIAAGADGVEIHSANGYLLNQFLD 204 
, nA GAHLPKVPREMTLDDIARVKQDFVDAARRARDAGFEWIELHFAHGYLGQSFFS 188 
Consensus: hhhhhhhhhhhhhhhhhhhh eeeee hhhhh 
Conserv. 95 5677977 75 6 77 667 5 77 999 5 
NemA GKLFIANPDLPRRFKLNAPLNEPNAATFYAQGEVGYTDYPALESAA------- 361 
XenB GVPFIANPDLPARLKADAPLNEAHPETFYGKGPVGYIDYPTL----------- 349 
Cyclo GRPFLANPDLPHRFAERLPLNKDVMETWYSQGPEGYVDYPTADQK-------- 360 
GTN GKAFIANPDLVRRLKNDAPLNAPNQPTFYGGGAEGYTDYPALAQ--------- 371 
Morph GRPFIANPDLPERFRLGAALNEPDPSTFYGGAEVGYTDYPFLDNGHDRLG--- 377 
PETN GRDYIANPDLVARLQKKAELNPQRPESFYGGGAEGYTDYPSL----------- 364 
OYA GRFFISNPDLVDRLEKGLPLNKYDRDTFYQMSAHGYIDYPTYEEALKLGWDKK 400 
XenA GRAHLADPHWAYFAAKELGVEK---ASWTLPAPYAHW---- LE---------- 358 
Consensus: hhhhh hhhhhh hhh 
Figure 3.10 Secondary structure alignment of group I using PROMALS. 
The helical regions are colour coded red in the sequence alignment, while the ß-sheets are 
colour coded blue. 
If the predicted helices or sheets are aligned in more than 50 per cent of the 
sequences, than they are denoted by h for the a-helices or e for the 13-sheets in 
the last line of the alignment. The magenta coloured sequences are used as 
reference sequences for closely related sequences present in the alignment, 
which are shown in black and are immediately below the reference sequence. 
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The number on top of the sequence alignment is the conservation index, which 
quantifies the conservation of residues at each aligned position. The 
conservation index is only shown if its value is above five (Pei and Grishin, 
2001). 
3.3.8 Structural and Sequence Alignment for Group II Proteins 
3.3.8.1 Sequence alignment 
Figure 3.11 shows the structural alignment of the members of group II and that 
the Tyr- 144 residue of PnrB is present in the same position as the other 
conserved tyrosine residues of the other group II members. The 3D structure of 
PnrB showed the same structural characteristics as the other group members, 
where the active site is found on the surface of the enzyme and the flavin 
cofactor is easily accessible to the solvent. 
Figure 3.11 Active site of members of group II, NOX (yellow), FRasel (magenta), 
NEC (green), FrxA (blue) and PnrB (red). The conserved tyrosine residues are 
represented by bold sticks on the right hand side of the figure. 
Figure created using USCF Chimera (Pettersen et al., 2004). 
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3.3.8.2 Structural alignment 
Subsequently, when the sequences of group II members were aligned using 
both T-Coffee and Clustal W2, the structurally conserved tyrosine residues 
were also found to be aligned in the sequence alignments (Figure 3.12 and 
Figure 3.13). The conserved tyrosine residues are highlighted in yellow. The 
full sequence alignments using Clustal W2 and T-Coffee can be found in 
appendices A3.4 and A3.5 respectively. 
NEC PEA'', AANHý: Gi<TYFADMH-VDL-: DDDQWMAý: QVYLNVGNFLLGVGAMGLDAVPIE-FDA 
NOX AQKQAIQ--RAFA--AM---GQEARKAWASGQSYILLGYLLLLLEAYGLGSVPMLGFDP 
FRasel EQKEAAFASF--KFVELNCDENGEHKAWTKPQAYLALGNALHTLARLNIDSTTMEGIDP 
FrxA TNSRFAQIIKNFQENDMKLNSERSLFDWASKQTYIQMANMMMAAAMLGIDSCPIEGYDQ 
PnrB EQARAGQNQSRRHYVNLHRFDQKDVQHWMEKQTYLALGTALLGAAAHGLDATPIEGFDS 
Figure 3.12 Sequence alignment of group 11 using T-Coffee 
NEC WLERVVDQEEADGilFNTPEAKAANHKGRTYFADMHRVDLKDDDQWMAHýQV 142 
NOX Y. LDEVIHPG----- VQGERREAQKQAIQRAFAAMG---QEARKAWASGQS 136 
FRasel DYDVVLSKAVADKRITEEQKEAAFASFK--FVELNCDENGEHKAWTKPQA 143 
FrxA SDYVKKVMHEVKKRDYDTNSRFAQIIKNFQENDMKLNSERSLFDWASKQT 142 
PnrB HLNAVLDQEAADGRFRDEQARAGQNQSRRHYVNLHRFDQKDVQHWMEKQT 143 
NEC YLNVGNFLLGVGAMGLDAVPIEGFDAAILDEEFG 
---- 
LKEKGFTSLVVV 188 
NOX YILLGYLLLLLEAYGLGSVPMLGFDPERVRAILG---- LPSR-AAIPALV 181 
FRasel YLALGNALHTLARLNIDSTTMEGIDPELLSEIFA---- DELKGYECHVAL 189 
FrxA YIQMANNMMAAAMLGIDSCPIEGYDQEKVEAYLEEKGYLNTAEFGVSVMA 192 
PnrB YLALGTALLGAAAHGLDATPIEGFDSKVLDAELG---- LRERGFTSVVIL 189 
Figure 3.13 Sequence alignment of group II using Clustal W2 
3.3.8.3 Secondary Structure prediction and alignment: 
The conserved tyrosine residue in group II members is aligned in the centre of 
an a-helix in all the members of group II (Figure 3.14). The secondary 
structure alignment revealed that all the members of group II have similar 
secondary structure, where most of the a-helices or 13-sheets were found to be 
aligned. The full alignment is shown in appendix A3.6 
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Conserv 99 95 66 6565 6569 9555 
PnrU DVQHWMEKQTYLALGTALLGAAAHGLDATPIEGFDSKVLDAELGLR 
---- 
ERGFT 184 
NEC DDDQWMAKQVYLNVGNFLLGVGAMGLDAVPIEGFDAAILDEEFGLK---- EKGFT 183 
FRasel EHKAWTKPQAYLALGNALHTLARLNIDSTTMEGIDPELLSEIFADE 
---- 
LKGYE 184 
FrxA SLFDWASKQTYIQMANMMMAAAMLGIDSCPIEGYDQEKVEAYLEEKGYLNTAEFG 186 
1111-1A: ARKAWASGQSYILLGYLLLLLEAYGLGSVPMLGFDPERVRAILGL ----- PSRAA 175 
Consensus hhhhhhhhhhhhhhhhhhhhhhh eeee hhhhhhh ee 
Figure 3.14 Secondary structure alignment of group II using PROMALS. 
The helical regions are colour coded red in the sequence alignment, while the ß-sheets are 
colour coded blue. 
3.3.9 Structural and Sequence Alignment for Group III Proteins 
3.3.9.1 Identification of group III members 
The structural alignment of Nbza, NitA, NitB, Frp, NfsA and PnrA showed that 
they shared similar structural characteristics. The binding pocket of the 
proteins is on the re face of the flavin cofactor. The active site is considerably 
wide and well protected from the solvent. Therefore, they were considered to 
be members of group III. In addition, an aromatic residue was found to be 
present in the same position relative to the flavin cofactor (Figure 3.15). The 
type of residue was not conserved and is varied between histidine (Frp, NfsA 
and PnrA) tyrosine (NitA) and phenyl alanine (Nbza and Nit B). The position 
of the aromatic residues in protein sequence is listed in Table 3.14. 
Frp NfsA pnrA Nbza NitA NitB 
Conserved residue Tyr-69 His-69 His-68 Phe-122 Tyr-68 Phe-67 
Table 3.14 Conserved aromatic residues in group III. 
3.3.9.2 Percentage identity and similarity between group III members 
The percentage identity and similarity of group III members were calculated in 
a pair wise manner (Table 3.15). The percentage similarity between the group 
III members ranged between 65.0 and 25.5 per cent, which is within the 
previously decided acceptable range. 
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Figure 3.15 Active site of members of group III, PnrA (red), Frp (green), 
NfsA ( blue), Nbza (magenta), NitA (cyan) and NitB (white). The aromatic residues 
are represented by bold sticks on the left hand side of the figure. 
Figure was created using USCF Chimera (Pettersen et al., 2004). 
Frp NfsA Nbza NitA NitB 
50.9% 50% 25.5% 45.3% 28.8 % 
PnrA 
(32.9%) (30.4%) (15.9%) (30.1%) (16.3%) 
65% 28.2% 50.2% 34.0 % 
Frp 
(51.7%) (18.2%) (32.7%) (19.2%) 
27.1% 51.2% 31.5% 
NfsA 
(18.0%) (34.7%) (16.5%) 
29.3% 35.5% 
Nbz<< 
(15.8%) (16.0%) 
34.0% 
NitA 
(20.1%) 
Table 3.15 Percentage similarity between group III members, 
the percentage identity is shown between parentheses. 
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3.3.9.3 Sequence alignment 
When the sequences of group III were aligned using the default settings of T- 
Coffee and Clustal W2, it was found that the structurally overlapping residues 
did not align in either of the sequence alignments (Figure 3.16 andFigure 3. 
17). The aromatic residues that are structurally aligned are highlighted in 
yellow. Moreover, several attempts were made to align the sequences using 
different parameters in Clustal W2 (Table 3.1). As with the previous 
alignments the structurally conserved residues did not align in any of the 
alignments. The full sequence alignments using the default parameters of 
Clustal W2 and T-Coffee can be found in appendices A3.7 and A3.8 
respectively. 
NitA 
------------------------VGNQEYVAKAPVFLVFVMDFYRTYLAGEKTGLKQVI 
NitB 
------------------------MGSQ-FLKGAPLVIVVVEN----------------- 
NfsA 
------------------------ 
TGGQKHVAQAAEFWVFCADFNRHLQICP----- DAQ 
Frp 
------------------------AGNQAYVESAAEFLVFCIDYQRHATINP-----DVQ 
Nbza NSFRGQLGDALGIPRSDITLRRRDVERQFRFFDAPVGLIFTMD----------------- 
pnrA 
------------------------SGNQRHVEQAPLFLVWLVDWSRLRRLARTLQAPTAG 
Figure 3.16 Sequence alignment of group III using T-Coffee 
NitA DEIVKSAQAMPNSINGQQTSVIVVR--DKKKREKLAELVGNQEYVAKAPV 75 
NitB DTLLKAALLAPTSMGKRSWEFIAVT--NKNLISELSTARKMGSQFLKGAP 72 
NfsA EAIINSARATSSSSFLQCSSIIRIT--DKALREELVTLTGGQKHVAQAAE 75 
Frp QTIIQAGLAASSSSMLQVVSIVRVT--DSEKRNELAQFAGNQAYVESAAE 75 
pnrA SWAIAAAQSASTSSNLQAWSVLAVR--DRERLARLARLSGNQRHVEQAPL 98 
Nbza KDILSAAKYAPSSSNTQPWRCYVITGEARERITTAAVEAYRAAPEGLPPE 80 
Figure 3.17 Sequence alignment of group III using Clustal W2 
3.3.9.4 Secondary Structure prediction and alignment 
As with the other sequence alignments, the structurally conserved residues did 
not properly align (Figure 3.18); however the aligned sequences showed 
similar predicted secondary structural features. This is demonstrated by the 
alignment of the a-helices and ß-sheets. (Full alignment can be found in 
appendix A3.9). 
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Conserv 6666 
Nbza ITVEA-YRAAPEGLPPEYPFFPQPLHEPYATRFNSFRGQLGDALGIPRSDITLR 117 
NitB TARKMGSQFLKGAPLVIVVVENPE------------------------------ 80 
NfsA TLTGG-QKHVAQAAEFWVFCADFNRHLQICPDAQLG------------------ 94 
Frp QFAGN-QAYVESAAEFLVFCIDYQRHATINPDVQA------ D------------ 94 
c7r4 RLSGN-QRHVEQAPLFLVWLVDWSRLRRLARTLQAP-TAGID------------ 122 
^; -rA. ELVGN-QEYVAKAPVFLVFVMDFYRTYLAGEKTGLK-QVIHE------------ 99 
Consensus hhhhh hhhhhh eeeeee hhhhhhhhhhh hhhhh 
Figure 3.18 Secondary structure alignment of group III using PROMALS. 
The helical regions are colour coded red in the sequence alignment, while the ß-sheets are 
colour coded blue. 
3.3.10 Structural and Sequence Alignment for Group IV Proteins 
3.3.10.1 Structural alignment 
When attempts were made to align NQO 1, NQO2, YieF and ywrO to the other 
groups, it was found that they do not align with any of the known groups. On 
the other hand, the four of them aligned to each other suggesting that they 
might be all members of a fourth group. Unlike the previous groups, the 
group IV members shared a lower degree of overall structural similarities. 
NQO2, YieF and ywrO lacked the tail region present in NOQ1. In addition, the 
3D structure of ywrO is also lacking another region when compared to NQO1, 
NQO2 and YieF (Figure 3.19). On the other hand, the active site of the four 
enzymes is quite similar. 
It was found that there is an aromatic residue present in the same region 
relative to the flavin cofactor in all four protein structures (Figure 3.20). The 
type of residue is not conserved, in NQO1 and NQO2, it is a phenylalanine, 
while in YieF and ywrO it is a tyrosine. Although the residues show different 
orientations, this might be due to errors in the modelling of the ywrO and YieF 
proteins, caused by the low identity shared with the template used for the 
model building. The position of the aromatic residue in the different protein 
sequences is listed in Table 3.16. 
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Figure 3.19 Overlaid cartoon representations of the structures of group IV members, 
NQO1 is shown in grey, NQO2 is shown in yellow, ywrO is shown in red and 
YieF is shown in blue. Figure created using USCF Chimera (Pettersen et at., 2004). 
Figure 3.20 Active site of group IV members, NQOI(red), NQO2(blue), ywrO (green) 
and YieF (magenta). The conserved tyrosine residues are represented by bold sticks. 
Figure was created using USCF Chimera (Pettersen et al., 2004). 
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NQOI NQO2 YieF ywrO 
Conserved residue Phe-106 Phe-105 Tyr-81 Tyr-68 
Table 3.16 Conserved residues in group IV 
The percentage similarity and identity for members of group IV were 
calculated, and the percentage similarity ranged between 24.6 and 50.4 percent, 
which are within the acceptable range (Table 3.17). 
NQO2 YieF ywrO 
NQOI 50.4% (38.5%) 24.6% (13.9%) 31.8% (18.2%) 
NQO2 34.5 % (18.4%) 36.7% (22.9%) 
YieF 31.7 % (20.6%) 
Table 3.17 Percentage similarity between members of group IV, 
the percentage identity is shown between parentheses. 
3.3.10.2 Sequence alignment: 
The sequence alignments of group IV members using both T-Coffee and 
Clustal W2 showed the alignment of the overlapping phenylalanine and the 
tyrosine residues (Figure 3.21 and Figure 3.22). The aromatic residues of 
interest are highlighted in yellow. The full sequence alignments using Clustal 
W2 and T-Coffee can be found in appendices A3.10 and A3.11 respectively. 
NQO1 TGr: L4'DPANFQYPAESVLAYý: EGHLSPDIVAEQKýLEAADLVIFQFPLQWFGVPAILr' 
NQO2 TGTLSNPEVFNYGVETHEA-KQRSLASDITDEQKKVREADLVIFQFPLYWFSVPAILK 
YieF 
------------ 
PLYDADVQQEEGFPATVEALAEQIRQADGVVIVTPEYNYSVPGGLK 
ywrO 
---------- 
EYP---------- DEAIDVEýýEQ,: LCEEHD: "IVFQFPLYWYSSPPLLH 
Figure 3.21 Sequence alignment of group IV using T-Coffee 
NQO1 IFQFPLQWFGVPAIL:, 'GWFERVFIGEFAYTYAAMYD, 'GPF'S: 
-, 
AVLSI"I' 147 
NQO2 IFQFPLYWFSVPAILKGWMDRVLCQGFAFDIPGFYDSGLLQGKLALLSVT 149 
YieF VIVTPEYNYSVPGGLKNAID------ WLSRLPD---- QPLAGKPVLIQTS 116 
ywrO VFQFPLYWYSSPPLLKKWLDHVLLYGWAYGTNG 
---- 
TALRGKEFMVAVS 106 
Figure 3.22 Sequence alignment of group IV using Clustal W2 
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3.3.10.3 Secondary Structure predication and alignment 
As with groups I and II, the structural sequence alignment showed that the 
secondary structures of the group members showed highly aligned helices and 
sheets. In addition, the residues of interest, tyrosine and phenylalanine were 
also conserved (Figure 3.23). The aromatic residues of interest are highlighted 
in yellow. (Full alignment is found in appendix A3.12) 
Conserv. 555 59 5555595555559 99 555 
ywri_- EKEQKLCEEHDRIVFQFPLYWYSSPPLLKKWLDHVLLYGWAYGTN---- GTA 95 
N002 TDEQKKVREADLVIFQFPLYWFSVPAILKGWMDRVLCQGFAFDIPGFYDSGL 139 
NC VAEQKKLEAADLVIFQFPLQWFGVPAILKGWFERVFIGEFAYTYAAMYDKGP 136 
irF EALAEQIRQADGVVIVTPEYNYSVPGGLKNAIDWLSRLP---------- DQP 105 
consensus hhhhhhhhh eeeee hhhhhhhhhhhh 
Figure 3.23 Secondary structure alignment of group IV using PROMALS 
3.4 Discussion and Conclusion 
Two different techniques were used to study the sequence and structural 
similarities between the enzymes. First a structural alignment of the active sites 
was undertaken and the residues surrounding the flavin cofactor were 
examined. This was followed by sequence alignments using Clustal W2 and T- 
Coffee, as well as PROMALS which utilizes secondary structure prediction. 
The sequence alignments using PROMALS showed the same results as the 
alignments using Clustal W2 and T-Coffee. Therefore increasing the 
confidence of the results, as the use of secondary structure prediction in protein 
sequence alignment increases the accuracy of the result especially for distantly 
related proteins with less than 20 per cent sequence identity (Pei, 2008). In 
addition to increasing the confidence in the results, PROMALS illustrated the 
fact that all the members of each group share similar secondary structures. 
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The studied enzymes were found to fall into four distinct groups. Group I 
consisted of morphinone reductase, XenA, XenB, OYE, NemA, PETN, GTN 
and 2-Cyclohexan- l 
-one reductase. These enzymes have two conserved 
aromatic residues in their binding pocket, a histidine residue within an average 
distance of 3.3 A from the 02 of the flavin isoalloxazine ring. In addition, a 
tyrosine residue is also conserved within 4.8 A of C7 of the isoalloxazine ring 
of the flavin cofactor. Group I sequence alignments showed the alignment of 
the histidine residues in all the sequences. On the other hand, the Tyr-27 
residue in XenA did not align with the remaining tyrosine residues in any of 
the sequence alignments. This is thought to be due to their positions in the 
protein sequence. The Tyrosine residue of XenA is at position 27, while the 
tyrosine residues of the other group members are at positions ranging from 343 
to 375. The large gap in the position of the residues of interest in the sequences 
makes it impossible for the tyrosine residue of XenA to align with the other 
residues in sequence alignments. 
OYE is one of the most intensively studied flavoenzymes and thus the amino 
acid residues in the active site involved in substrate binding and mechanism of 
action have been well characterized. Both His-191 and Tyr-375 residues in 
OYE are thought to play a role in the orientation of the substrate in the active 
site, via hydrogen bonding. The mutation of the histidine residue decreases the 
binding affinity of substituted phenol substrates to OYE. Tyr-196 is thought to 
be involved in the mechanism of action of OYE, where it provides one of the 
hydride ions to be transferred to the substrate. This tyrosine residue was found 
to be conserved in all the examined enzymes with the exception of morphinone 
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reductase, where it is replaced by a cysteine residue. Gln-114 and Asn-194 are 
involved in hydrogen bonds with the flavin cofactor and are thought to affect 
its orientation. While the Gln-l 14 was found to be conserved in the sequence 
alignments of group I the Asn-194 was not and is replaced by a histidine 
residue in some of the enzymes (Figure 3.24) (Brown et al., 1998, Fox and 
Karplus, 1994, Brown et al., 2002, Kohli and Massey, 1998). 
ýrý, 
41"Y. 
do'k 
Figure 3.24 Active site of group I members, morphinone reductase (red), XenA (green), 
NemA (blue), OYE (yellow), PETN (magenta) GTN (orange), XenB (cyan) and 
2-cyclohexan-l-one reductase (white). The conserved Gin residues are represented as 
sticks in the bottom left hand side of the figure, while the Tyr 196 and Asn 194 of old 
yellow enzyme and corresponding aligned residues are represented as sticks on the top of 
the figure. Figure created using USCF Chimera (Pettersen et al., 2004). 
Group II was found to consist of NOX, Nec, FRasel, FrxA and PnrB which 
have a tyrosine conserved residues in proximity to C7 of the flavin cofactor. 
The average distance between the C7 and OH group of tyrosine amino acid is 
6.9 A. Sequence alignments of group II members showed the alignment of all 
the conserved tyrosine residues. The conserved tyrosine residues in group I and 
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group II are both in the same region, the hydroxyl groups of the tyrosine 
residues in both groups are within an average distance 3.2 A of each other. 
Group III members were found to be NfsA, Frp, PnrA, Nbza, Nit A and Nit B. 
They have different types of aromatic residues, histidine, phenylalanine and 
tyrosine in the same position, within 3.5 A of 04 of the cofactor. The sequence 
alignment of group III members did not result in the alignment of the 
structurally conserved residues despite the fact that the positions of the residues 
in the sequences are very close. Group II and III members are classified to 
belong to group B and A bacterial nitroreductases respectively according to 
their phylogentic origin. Members of the same group are known to share high 
sequence and structural similarities (Koike et al., 1998, Parkinson et al., 2000, 
Dolores Roldan et al., 2008). The role of the identified conserved amino acids 
is not yet known, and has not been discussed in the literature. The residues 
involved in the binding of the flavin cofactor to the bacterial nitroreductases 
are well studied and they do not include the previously mentioned conserved 
residues. Thus it is thought that they might play a role in the correct orientation 
of the substrate or in the mechanism of electron transport. 
Group IV members are ywrO, YieF, NQO1 and NQO2, which have either a 
phenylalanine or tyrosine, conserved 6.4 A from 02 of the isoalloxazine ring of 
the flavin. The homology models of YieF produced by both ModWeb and 
SWISS-MODEL were based on templates sharing a sequence identity of 
approximately 20 per cent with YieF. The use of low templates sharing a 
sequence identity less than 30 per cent with the required protein produces 
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unreliable models (Dalton and Jackson, 2007, Tramontano, 1998). The 
sequence alignments for group IV showed the conserved residues in all four 
enzymes perfectly aligned. Consequently the results obtained from the 
sequence alignment of group IV increased the confidence in the results 
obtained from the structural alignments. The postulated mechanism of action of 
NQO1 involves two aromatic residues Tyr-155 and His-161. The tyrosine 
residue is conserved in all members of the group with the exception of YieF, 
where it is replaced by an arginine residue, while the histidine residue is not at 
all conserved between any of the group members (Deller et al., 2008). Residue 
104 is known to play an important role in the reduction of nitro groups by 
NQO1 and NQO2. In human NQO1 this residue is glutamine while in NQO2 
and rat NQO1 it is a tyrosine. The presence of the tyrosine residue in that 
position is thought to increase the efficiency of the enzyme towards the 
reduction of the CB 1954 (Chen et al., 1997, Skelly et al., 2001, Knox and 
Chen, 2004). This residue is conserved in all group members except for the 
previously mentioned exception of human NQO1 (Figure 3.25). 
The positions of the conserved residues in the different groups are different 
with respect to the FAD molecule. Although both the conserved histidine 
residue of group I members and the conserved aromatic residue of group IV 
members are within close proximity to 02 of the flavin cofactor, they are on 
opposite sides of the flavin cofactor. On the other hand, the conserved tyrosine 
residues of group I and II are in close proximity to C7 of the flavin cofactor. 
The conserved residues in group III are within close proximity to 04 of the 
flavin (Figure 3.26). 
93 
Chapter Three 
- 
Nitroaromatic reducing enzymes 
Figure 3.25 Active site of group IV members, NQOI (red), NQO2 (blue), 
ywrO ( green) and YieF (magenta). The Glu 104 of NQO1 and aligned tyrosine residues 
are represented as sticks on the left hand side of the figure. While Tyr 155 of NQO1 
and aligned tyrosine r residues are represented as sticks on the right hand side of the 
figure. Figure created using USCF Chimera (Pettersen et al., 2004). 
Figure 3.26 The different orientations of the conserved residues in 
the aligned active sites around the flavin cofactor, where group I is represented by 
OYE (yellow), group 11 is represented by FRasel (magenta), group III is represented by 
Frp (green) and group IV is represented by NQO2 (red). Figured created using USCF 
Chimera (Pettersen et al., 2004). 
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All groups showed the presence of aromatic residues in the area surrounding 
the binding pocket suggests that they are of some importance. The aromatic 
residue may either play a role in the electron transportation or may help in the 
binding and correct orientation of the substrate or/and cosubstrate in the 
binding pocket. The difference in the type of conserved aromatic residue may 
account for the differences in the reduction potential of different enzymes or 
substrate affinity of the different enzymes (Knox and Chen, 2004). 
The identification of trends in the structure and sequences of flavoenzymes 
may aid in the better understanding of the mechanisms of action by which the 
anticancer prodrugs such as CB 1954 are reduced. This may lead to the 
designing of more efficient drugs. Moreover, the identification of trends of 
conservation in residues may help in the identification of novel enzymes that 
are better able to reduce such drugs which may then be used as part of the 
GDEPT and ADEPT approaches. 
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4.1 Introduction 
4.1.1 Enzyme Reactions 
In simple enzyme reactions the substrate combines with the enzyme forming an 
enzyme-substrate complex. An enzyme-product complex is then formed which 
disassociates to the release of the free product and enzyme. In certain cases, the 
reaction is more complex and may involve other components such as 
cosubstrates, cofactors, inhibitors and activators. The rates of reaction are 
designated by k, which are marked by positive numbers for the forward 
reactions and negative numbers for the backward reaction (Bisswanger, 2008). 
E+S K' 'ES K2 'EP K3 E+P ý K2 ý K-3 
The progress of the reaction can be monitored in two different ways, either by 
measuring the rate of appearance of the product or the rate of disappearance of 
the substrate or cosubstrate. A typical progress curve for enzyme catalyzed 
reactions can be divided into three distinct phases (Figure 4.1): 
1. Pre-steady state: 
This is the phase with the fastest rate, but is not considered during 
experiments due to its extremely short duration, (micro to milliseconds) 
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and very low intensity. This phase can not be detected under normal 
conditions. 
2. Steady state: 
During this phase the reaction intermediates are at equilibrium and are 
thus at constant concentrations. This is a linear region of the curve and 
therefore the reaction rate can be directly calculated from the slope of 
the diagram. 
3. Substrate depletion: 
During this phase the rate of reaction is continuously decreasing due to 
substrate depletion (Bisswanger, 2004). 
Figure 4.1 Progress curve of an enzyme reaction. 
Adapted from (Bisswanger, 2004) 
4.1.2 Enzyme Kinetic Constants 
Enzyme catalyzed reactions can be described by the Michealis-Menten 
equation (4.1) within the steady state range of the reaction (Bisswanger, 2004); 
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v= 
V 
max[S] 
(4.1) [S]+Km 
Where, 
v Reaction rate 
V,,, 
nx 
Maximum rate of reaction 
[S] Concentration of substrate 
K,,, Michealis constant 
The Michealis constant, K,,,, is indirectly proportional to the affinity of the 
enzyme for the substrate and is specific to the enzyme/substrate combination. 
The Lineweaver-Burke equation (4.2) is the double reciprocal of the Michealis- 
Menten equation and results in a linear relationship between 1/[S] and IN. The 
Lineweaver-Burke plot is prone to errors due to the absence of points at high 
substrate concentrations resulting in large extrapolations to determine the 
intercepts. 
1 Km 
+ 
. 
2) V Vmax Vmax[S] (4 
The Hanes-Woolf equation (4.3) is another representation of the Michealis- 
Menten plot, which overcomes the errors caused by the uneven distribution of 
the data. 
[S] 
. 
Km 
1+ 
vV max 
,V 
max 
(4.3) 
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Vmax T K 
.......................................... 
- 
V 
msx121< ................ 
Km 
(a) 
1/v 
-1/Km 
(b) 
1/ Vmax 
(s]/v l 
Slope= 1/Vmax 
KmIVmax 
-Km 
Is 
1/(s 
is] 
(c) 
Figure 4.2 (a) Classical representation of Michealis-Menten equation (b) Lineweaver- 
Burke plot, the y-axis intercept is 1/V,,,,, while the x-axis intercept is 
-1/K, 
 (c) Hanes-Woolf plot, the y-axis intercept is K,,, /Vm, 
, 
the x-axis intercept is 
-K,,, 
while the slope is UV,,,,. 
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4.1.3 Potential NQO2 Substrates 
4.1.3.1 Novel substrate, GC201 
GC201 (Figure 1.19) was designed to be a substrate for NQO2 and was kindly 
provided by Professor Christopher Moody, School of Chemistry 
- 
University of 
Nottingham. It is a potential NQO2 substrate, where NQO2 is thought to 
reduce the quinone derivative into the dihydroxyl derivative (Figure 4.3). 
OH 0 
H3CO 
-. 
ý 
H3CO 
OH 
Figure 4.3 Reduction of GC201 
4.1.3.2 Coenzyme QO, Coenzyme Q1 and Coenzyme Q2 
Coenzyme QO is a natural known substrate for NQO2 and thus it is speculated 
that other members of the coenzyme Q family (Figure 4.4) may also be 
substrates for NQO2 (Boutin et al., 2005). 
H3CO 
H3CO 
0 (a) 
CH3 
H3CO 
H3CO 
(c) 
Figure 4.4 Structures of (a) coenzyme QO, (b) coenzyme Ql and (c) coenzyme Q2 
H3CO 
H3CO 
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4.1.4 Experimental Methods for Determining Michealis-Menten Constants 
There are several reported experimental methods based on different techniques 
used to determine the reaction kinetics constants for NQO2 with different 
substrates. These techniques included HPLC (Boutin et al., 2005), UV/visible 
spectroscopy (Calamini et al., 2008, Kwiek et al., 2004, Zhao et al., 1997) and 
fluorescence spectroscopy (Boutin et al., 2008, Fu et al., 2005, Mailliet et al., 
2005, Boutin et al., 2005). The previously reported method based on the 
measurement of fluorescence was used here to explore the kinetics of reactions 
between NQO2 and a variety of substrates. This method was chosen over other 
reported methods as it is more sensitive than methods based on UV/visible 
spectroscopy. It is also less time consuming than HPLC, and provides the 
opportunity to monitor the reaction during real time compared to samples taken 
at regular time intervals from the reaction mixture. 
The decrease of the fluorescence of an artificial cosubstrate, 
N-benzyldihydronicotinamide (NBDH) (Figure 4.5), upon its consumption by 
NQO2 was monitored during the reaction. For each molecule of NBDH 
consumed, there is one molecule of substrate consumed, due to the one to one 
stoichiometry of the reaction. 
NH2 
Figure 4.5 Structure of NBDH 
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Since the fluorescence of a substance is directly proportional to its 
concentration, equation (4.4) within a linear range. Thus, the decrease of the 
fluorescence is directly proportional to the decrease in the concentration of the 
cosubstrate, which is in turn equivalent to the consumption of the substrate 
(Sharma and Schulman, 1999). 
If 
= 
2.3(DfIocCl (4.4) 
Where, 
1f Intensity of emitted light 
Of Quantum yield of fluorescence 
to Intensity of incident light 
E Molar absorbativity 
C Molar concentration 
l Pathlength 
4.2 Experimental Methods and Materials 
All chemicals were purchased from Sigma-Aldrich unless otherwise stated. 
The fluorescence and UV/visible spectroscopy work was carried out using 
Perkin Elmer LS-55 fluorescence spectrophotometer. The fluorescence 
cuvettes used were purchased from Hellma, catalogue number: 114F-QS. The 
graphs were created using GraFit version 7 (Leatherbarrow, 2009), which was 
also used for linear regression analysis. The composition of the solutions used 
can be found in Appendix A2. 
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4.2.1 Cloning of NQO2 
The cloning of the NQO2 gene in TOP10 E. coli bacteria was kindly done by 
Dr. John Heap, Institute of Infection, Immunity and Inflammation 
- 
The 
University of Nottingham. The expression vector used was pMTL1015, which 
was then transformed into TOP 10 E. coli bacterial cells. The expressed NQO2 
from the clone has a six residue histidine tail, His-Tag. 
4.2.2 Expression and Harvesting of NQO2 
Before the bacterial cells were grown the working bench surface was sterilized 
using ethanol. In addition, all glassware and pipette tips used were sterilized by 
autoclaving. 
A few bacterial cells from a glycerol stock were used to inoculate five ml of 
2xTY media containing five µl tetracycline solution, (five mg ml"' in ethanol), 
this was grown overnight at 37°C and 180 rpm. The overnight culture was then 
used to inoculate 50 ml of 2xYT media containing 50 µl tetracycline solution, 
(5 mg ml"' in ethanol). This was allowed to grow at 37°C and 180 rpm until the 
optical density (OD), at 595 nm, reached one. Subsequently it was then 
transferred to 500 ml of 2xTY media containing 500 µl of tetracycline solution 
(5 mg ml-' in ethanol), which was allowed to grow overnight at 37°C and 180 
rpm. The inserted plasmid confers tetracycline resistance to the bacterial cells, 
and thus the antibiotic was used to prevent contamination by other bacterial 
species. 
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After the bacteria were allowed to grow overnight, the media was then 
centrifuged at 4500 rpm for 30 minutes to form a pellet of the E. coli cells. The 
supernatant was then discarded and the pellet was resuspended in 20 ml of lysis 
buffer. The suspension was then sonicated at an amplitude of ten microns to 
break down the E. coli cells, according to the following scheme; 10 seconds on, 
10 seconds off, 10 seconds on, 10 seconds off, 10 seconds on, 10 seconds off. 
This was repeated three times with a 30 second break between repetitions. The 
suspension was kept on ice during the sonication to prevent the denaturation of 
the protein by heat and the action of proteolytic enzymes. The suspension was 
then centrifuged at 15000 rpm for 45 minutes. The supernatant was carefully 
collected, avoiding the solid pellet formed at the bottom and centrifuged again 
at 15000 rpm for one hour. The supernatant was then filtered through a 0.22 
µm Minisart TM syringe filter (Sartorius), to remove any particulate matter 
remaining. The resulting yellow solution contained NQO2 in addition to other 
bacterial enzymes. 
The protein content of the filtrate was determined by measuring the absorbance 
of the protein solution at 288 nm. The extinction coefficient of NQO2 was 
calculated, using Protein Calculator v3.3 (Putman), to be 1.71(mg/ml)"' cm'' 
and 44380 M"' cm'. 
4.2.3 Purification of NQO2 
The presence of the His-tag allows the use of nickel-nitrilotriacteic acid 
(Ni-NTA) Superflow resin (Novagen), to purify the protein from other proteins 
produced by the bacterial culture. A gradient elution with increasing 
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concentrations of imidazole was used to separate NQO2 from the other 
bacterial proteins. Six to eight ml of Ni-NTA Superflow resin suspension in 
30 per cent ethanol at a 1: 1 ratio, were placed in a Bio-Rad purifying column. 
The ethanol was allowed to run through, and the remaining resin was washed 
with 2X5 ml of distilled water to remove all traces of ethanol. 
The solution, containing NQO2 in addition to other contaminating proteins, 
was then added to the column, in addition to imidazole to a final concentration 
of 10 mM, to reduce non-specific binding. This was then left to equilibrate for 
one hour by slow rotation, at 4 °C. The flow through (FT), which is the 
solution in which the protein solution equilibrates with the resin, was allowed 
to run through. The protein was then eluted using increasing concentration of 
imidazole solution, from 10 mM to 250 mM, according to the protocol in 
Table 4.1. 
Elution fraction 1 2 3 3' 
Imidazole concentration (mM) 10 50 200 200 
Volume of solution (ml) 12 12 10 10 
Table 4.1 Elution protocol of NQO2 from Ni-NTA resin 
4.2.4 Assessment of Protein Purity 
The purity of the eluted fractions was tested using reducing sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE), where the protein 
samples are boiled in the presence of a reducing agent to break disulphide 
linkages and thus denaturing the protein structure. 
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4.2.4.1 Preparation of gel 
The gels were prepared using the Bio-Rad mini gel casting system. The 
concentration of the polyacrylamide stacking gel used was 5% and that of the 
resolving gel was 12.5 %. The resolving gel was first prepared according to the 
protocol in Table 4.2, and then poured between the glass plates assembled in 
the Bio-Rad casting stand to a height of 3 cm from the top of the plates. The 
gel surface was covered with isopropanol, to remove any air bubbles present 
and to smooth the gel surface, and the gel was allowed to set for 30 to 45 
minutes. The isopropanol was then drained off, and any excess dried with a 
tissue. The stacking gel was then prepared according to Table 4.2, and added 
on top of the resolving gel. The appropriate well comb was then carefully 
inserted into the solution, avoiding the formation of air bubbles, and the gel 
was allowed to set for 30 to 45 minutes. 
Resolving gel Stacking gel 
Distilled water 4.7 ml 5.15 ml 
10 % SDS 150 µ1 75 µl 
1.5 M Tris-HC1 pH 8.8 3.75 ml 0.94 ml 
Acrylamide/Bis-acrylamide 30 % 
(Severn Biotech LTD) 6.25 ml 1.75 ml 
10 % w/v Ammonium persulphate 150 µl 75 µl 
TEMED 7.5 µl 5.5 µl 
Table 4.2 Preparation of resolving and stacking gels of SDS-PAGE 
The gel was then placed in the electrophoresis apparatus, and the reservoirs 
were filled with SDS-PAGE running buffer. 
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4.2.4.2 Preparation of samples and running of the gel 
10 µl of the protein samples were mixed with 5 gl of 3x loading buffer and 
then heated to 95° C for five minutes. The samples were then centrifuged at 
2000 rpm for one second, to gather the droplets together. 
The treated samples and the protein molecular weight marker, either Precision 
plus protein marker (Bio-Rad) or Protein perfect markers (Merck) were then 
loaded into the wells of the gel, according to the order in Table 4.3. The gel 
was then run at a constant voltage of 200 V for 50 minutes. The gel was then 
stained for 30 minutes using Coomassie staining solution, and then destained 
using Coomassie destaining solution for one hour. 
Lane 1 2 3 4 5 6 
Elution protein fraction, corresponding to Protein marker FT 1 2 3 3' 
Imidazole concentration (mM) 10 50 200 200 
Table 4.3 Samples in gel lanes 
4.2.5 Concentrating and Storage of NQO2 
The pure eluted fractions were mixed together and concentrated using vivaspin 
concentrator tubes from Vivascience (molecular weight cut of. 10,000). The 
tubes were centrifuged at a speed of 4500 rpm and 2x 25 ml of 50 mM Tris- 
HCl pH 8 were added to remove any traces of imidazole remaining from the 
elution protocol. The protein solution was then spun to a concentration of 
0.4 mM. The concentration of the enzyme solution was calculated as 
previously mentioned in section 4.2.2. The enzyme solution was stored in 
50 mM Tris-HC1 pH 8, at 4 °C for future use. 
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4.2.6 Optimizing Enzyme Kinetics Protocol 
4.2.6.1 UV visible absorbance scans 
A preliminary UV/visible spectrophotometric scan was carried out on 100 µM 
NBDH (TCI-Europe) in 10 mM octyl-ß-D-glucopyranoside in 50 mM Tris- 
HCl at pH 8.5 to determine the ! max to be used in the fluorescence studies as 
the excitation wavelength. 
4.2.6.2 Fluorescence emission and excitation spectrums 
An emission spectrum for NBDH was obtained at Xmax = 361 nm as the 
excitation wavelength, to determine the wavelength at which the highest 
emission occurred. In addition, an excitation spectrum was also obtained, using 
an emission wavelength of 462 nm, to check the excitation wavelength of this 
compound. The NBDH solution used was at 100 µM in 10 mM octyl-ß-D- 
glucopyranoside in 50 mM Tris-HC1 at pH 8.5. 
4.2.6.3 Effect of air exposure on the fluorescence of NBDH 
To asses whether NBDH is oxidized upon air exposure, the fluorescence of 
NBDH in a cuvette was measured over a period of time. The emission of 
100 gM NBDH at 462 nm, using 361 nm as the excitation wavelength was 
measured at zero time, and then after one, four and six hours. The initial stock 
of 10 mM NBDH was dissolved in dimethylsulphoxide (DMSO), and the 
subsequent dilution to 100 gM was carried out in 10 mM octyl-ß-D- 
glucopyranoside in 50 mM Tris-HCI at pH 8.5. 
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4.2.6.4 Fluorescence emission controls for other reaction components 
To ensure that none of the other components of the reaction interfere with the 
fluorescence of the cosubstrate, the fluorescence emission spectrum of 1 mM 
of menadione, coenzyme Q0, coenzyme Q1 and coenzyme Q2 were measured 
at the excitation wavelength of 361 nm. In addition, the emission spectrum of 
200 µM of NQO2, at the excitation wavelength of 361 nm was also measured. 
The substrates were dissolved in DMSO and the appropriate dilutions were 
then carried out in 10 mM octyl-ß-D-glucopyranoside in 50 mM Tris-HC1 at 
pH 8.5. The stock solution of NQO2 was in the storage buffer, 50 mM Tris- 
HC1 pH 8 and was diluted to the appropriate concentration in 10 mM octyl-ß- 
D-glucopyranoside in 50 mM Tris-HC1 at pH 8.5. 
4.2.7 Calibration Curve Relating Concentration of NBDH to its 
Fluorescence 
The relationship between NBDH concentration and its fluorescence at 462 nm, 
when excited at 361 nm was explored by measuring the emissions of several 
concentrations of NBDH ranging between 10 to 350 µM. For each 
concentration, three measurements were taken, where each measurement was 
an accumulation of five scans that were averaged. The NBDH solutions were 
kept on ice, in closed eppendorf tubes throughout the experiment to decrease 
the effect of air oxidation. The average fluorescence for each concentration was 
then plotted against its concentration. 
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4.2.8 Optimization of Published Reaction Conditions 
The substrate used for the optimization of the reaction conditions was 
menadione, as it is a known substrate for NQO2 and the kinetics of the reaction 
are well documented (Boutin et al., 2005, Zhao et al., 1997). 
The NBDH solution was divided into several 0.5 ml aliquots, which were kept 
sealed and in ice; the aliquot being used was replaced every hour with a fresh 
one, to minimize the effect of air oxidation. In an eppendorf tube containing 
the reaction medium, 10 mM octyl-ß-D-glucopyranoside in 50 mM Tris-HCI at 
pH 8.5, the required volume of the substrate and cosubstrate were added to the 
reaction medium and were allowed to equilibrate for two minutes, at room 
temperature. The enzyme in 50 mM Tris-HCI pH 8 was then added to the 
mixture and the eppendorf was the shaken to mix the reaction components. The 
mixing time was the same for all the eppendorfs, to ensure the consistency of 
the method used. The reaction mixture was then immediately transferred into a 
fluorescence cuvette and the decrease in fluorescence emission at 462 nm, 
using an excitation wavelength of 361 nm, was measured at one second 
intervals. The rate of decrease in the concentration of NBDH was then 
calculated from the decrease in fluorescence, using the linear equation obtained 
from the linear range of the calibration curve. The maximal rate of decrease in 
the concentration of the cosubstrate for each reaction was then plotted against 
the corresponding concentration of substrate producing a Michealis-Menten 
plot, allowing the calculation of K,,,. 
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4.2.8.1 Enzyme concentration optimization 
Several enzyme concentrations ranging from 2.5 µM to 37.5 pM were tested in 
order to determine the range at which the rate of the reaction and enzyme 
concentration are related by a linear equation. This range was determined by 
plotting the results during the experiment, and determining the necessary 
concentration range by examining the resultant curve. The optimal time the 
reaction took to reach completion was also a factor in deciding the 
concentration of enzyme to be used in the kinetic experiment. The required 
duration of the reaction was between 15 to 30 minutes, as reactions taking less 
than 15 minutes would not allow enough time for monitoring the initial rate of 
reaction. On the other hand, reactions taking more than 30 minutes would be 
too lengthy to allow all the required reactions to be completed in one day. The 
concentration of NBDH used was 100 µM, which is in the upper linear range 
of the calibration curve. While the concentration of menadione used was 
700 µM, which is the highest concentration possible for analysis of menadione, 
due its aqueous solubility. For each enzyme concentration, triplicate 
measurements were preformed. 
4.2.8.2 Temperature choice 
The choice of temperature was determined by carrying out two sets of 
reactions, one at 25 °C and the other at 37 T. The concentrations of the 
enzyme and NBDH were kept constant at 10 µM and 100 µM, respectively. 
The menadione concentration range was between 10 pM to 150 µM, which was 
adopted from the published method, where the used range was between 5 pM 
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and 100 µM (Boutin et al., 2005). For each menadione concentration, triplicate 
measurements were carried out. 
4.2.8.3 Reproducibility testing 
Using the optimum conditions, (Table 4.4) the rate experiment using 
menadione as the substrate was repeated twice, in order to ensure that the 
results were reproducible and the calculated values of Km were comparable to 
those published in the literature (Boutin et at., 2005, Zhao et al., 1997). The 
range of concentration used for menadione was again between 10 pM and 
150 µM. 
Reaction medium 
10mM octyl-ß-D-glucopyranoside, 
50mM Tris-HC1 at pH 8.5 
Total cuvette volume I ml 
Enzyme concentration 10 µM 
Cosubstrate concentration 100 gM 
Excitation wavelength 361 nm 
Slit opening 5 mm 
Emission wavelength 462 nm 
Slit opening 5 mm 
Temperature 37 °C 
Table 4.4 Optimum reaction conditions chosen. 
4.2.9 K. Determination for Novel Substrates 
4.2.9.1 Determination of linear relationship between enzyme concentration and 
reaction rate 
For coenzyme Q0, coenzyme Q1 and coenzyme Q2 the enzyme concentration 
used in the kinetic experiment was chosen by determining the linear 
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concentration at which the enzyme operates for each substrate using the 
method described in section 4.2.8.1. The enzyme concentration range tested for 
coenzyme QO was from 2.5 gM to 10 gM, while that tested for coenzyme Q1 
and coenzyme Q2 was from 20 gM to 150 gM. The range used was determined 
by plotting the results during the experiment and determining the required 
range by examining the resultant curve. For GC201, the testing of the optimum 
enzyme concentration was not possible due to the limited quantity available of 
the substrate; therefore the same optimum concentration for menadione was 
used. The cosubstrate concentration used was kept constant at 100 iM. The 
concentrations of coenzyme QO, coenzyme Q1, coenzyme Q2 and menadione 
were 150,70,350 and 150 gM respectively. 
4.2.9.2 Kn determination 
The Michealis-Menten plot for each substrate was determined using the same 
method and conditions described in Table 4.4 except for the concentration of 
enzyme. The enzyme concentration was changed according to the linear range 
relating the enzyme concentration and the reaction rate, for the specific 
substrate. For GC201 and coenzyme Q0, the enzyme concentration used was 
10 µM, while for both coenzyme Ql and coenzyme Q2, the enzyme 
concentration used was 100 µM. 
In addition to the different concentration of the enzyme used for each substrate, 
the substrate concentration range used to determine the K. was also different. 
For coenzyme Q0, the substrate concentration ranged from 20 gM to 400 µM, 
while for coenzyme Q1 the range used was between 20 µM to 140 µM. For 
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coenzyme Q2 the range used was from 30 p. M to 1.05mM and the tested range 
for GC201 was from 25 µM to 1.2 mM. The range of substrate concentration 
used was determined by plotting Michealis-Menten plot of the results during 
the experiment and determining the required range by examining the resultant 
curve. Due to the decrease in the rate of reaction at higher concentrations of the 
substrates, direct determination of the K,,, values from the Michealis-Menten 
plot using non-linear regression was not possible. Thus the Lineweaver-Burke 
diagram was plotted for each substrate, and was used to calculate the K, n values 
using linear regression. 
4.2.9.3 Substrate-cosubstrate reaction controls 
To verify that the decrease in fluorescence of the cosubstrate is not due to a 
reaction between the cosubstrate and substrate, but rather due to the action of 
the enzyme on both the substrate and cosubstrate. Reaction controls were done 
for all the different concentrations of substrate used in determining the K. for 
coenzyme Q0, coenzyme Ql and coenzyme Q2. For GC201, only a few 
concentrations, 25 µM, 400 µM, 700 itM and 1200 µM were chosen due to the 
limited availability of the substrate. This was preformed by adding the required 
volumes of the substrate and the cosubstrate to an eppendorf tube containing 
the reaction medium, 10mM octyl-ß-D-glucopyranoside in 50mM Tris-HC1 at 
pH 8.5. The eppendorf was then shaken and its contents were immediately 
transferred to the cuvette and the fluorescence of the mixture was monitored 
for three minutes. 
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5.1 Protein Preparation 
5.1.1 Assessing Protein Purity Using SDS-PAGE 
SDS-PAGE confirmed that the elution protocol, previously described in section 
4.2.3, can be used to successfully to purify NQO2 from other contaminating 
proteins produced by the E. coli culture. The identity of the enzyme was 
confirmed from its molecular weight, by comparison to the known molecular 
weights of the protein marker bands. Figure 5.1 shows an example of the gel 
used to asses the purity of NQO2 after its purification. Lane one shows the 
protein marker, the flow-through (FT) is shown in lanes two and three, 
followed by the elution fractions in increasing imidazole concentrations in 
lanes four to seven. The fractions eluted using 200 mM imidazole, lanes six 
and seven, showed a solitary band of protein, identified as NQO2 with the His- 
tag attached, with a total molecular weight of 27.4 kDa. The absence of other 
bands, confirms that there were no contaminating proteins eluted with NQO2. 
5.2 Optimizing Enzyme Kinetics Protocol 
5.2.1 UV Visible Spectrum of NBDH 
The UV/visible spectrum of NBDH showed two peaks where strong 
absorbance occurs, one at 220 nm and the other at 361 nm (Figure 5.2). 
Absorbance at 220 nm is not specific, as most aromatic compounds absorb 
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around that wavelength and is thus subject to interference. Therefore the peak 
at 361 nm was chosen as the excitation wavelength for the fluorescence assay. 
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Figure 5.1 SDS-PAGE showing protein marker, flow-through (FT) and elution samples 
at increasing imidazole concentrations. Molecular weights of marker bands are in kDa. 
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Figure 5.2 UV/visible absorbance spectrum of NBDH 
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5.2.2 Fluorescence Emission Spectrum of NBDH 
The emission spectrum of NBDH showed that the highest emission 
fluorescence intensity of NBDH, when excited at 361 nm, occurs at 462 nm 
(Figure 5.3). Consequently a wavelength of 462 nm was chosen to monitor the 
consumption of the cosubstrate during its reaction with NQO2. 
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Figure 5.3 Emission spectrum of NBDH using 361 nm as excitation wavelength 
5.2.3 Effect of Air Oxidation on the Fluorescence of NBDH 
The fluorescence of NBDH was found to decrease by four per cent in the first 
hour, followed by another four per cent decrease, in the following three hours. 
Between four and six hours, there was no significant decrease in the 
fluorescence of NBDH (Figure 5.4). Six hours was chosen as the duration of 
the experiment as it is far longer than any experiment would take. The usual 
reaction time ranged between 10 to 15 minutes, thus it was thought that such a 
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decrease in fluorescence, would not cause any significant interference in the 
reaction. To minimize any possible effect of air oxidation, the NBDH solution 
used in the assay was divided into several 0.5 ml allocates which were kept on 
ice and the opened allocate was replaced with a fresh one every hour. 
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Figure 5.4 Decrease in fluorescence of NBDH due to air oxidation over 6 hours. 
5.2.4 Fluorescence Emission Measurements for Other Reaction 
Components 
Except for NBDH, all the other components of the reaction did not show any 
significant fluorescence at 462 nm when excited at 361 nm (Figure 5.5). This 
indicated that their contribution to fluorescence at this wavelength is negligible 
and thus would not interfere with the monitoring of the fluorescence of NBDH 
during the reaction of NQO2 with the substrate. The concentrations used for 
the measurements of the fluorescence are much larger than those used during 
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the experimental procedure. The solutions were made up in 10 mM octyl-ß-D- 
glucopyranoside in 50 mM Tris-HCL at pH 8.5, and thus the effect of the 
buffer solution used in the experiment was also accounted for. 
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Figure 5.5 Fluorescence of 200 µM NQO2,1 mM coenzyme Q0,1 mM coenzyme Q 
1 mM coenzyme Q2 and 1 mM menadione relative to 100µM NBDH. 
5.2.5 Calibration Curve for NBDH 
The calibration curve relating the concentration of the NBDH to its 
fluorescence showed that up to 120 gM of NBDH, the relationship between the 
concentration of NBDH and its fluorescence is linear (Figure 5.7). The 
relationship between the concentration of NBDH and its fluorescence can be 
determined using the following linear equation, 
y=5.762x+71.05 (5.1) 
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The linear relationship between the concentration and fluorescence of NBDH is 
slightly improved if the concentration of NBDH considered is decreased from 
120 pM to 85 pM. This is demonstrated by a small increase in the regression 
coefficient (R`) from 0.994 to 0.9975. The concentrations of NBDH used in the 
kinetic experiment started at 100 pM and thus a decision was taken to use the 
linear relationship including the larger range of NBDH concentrations. 
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Figure 5.6 Calibration curve relating fluorescence of NBDH to its concentration, 
up to 120 µM. Insert shows calibration curve of concentrations of NBDH up to 85 µM. 
The absence of error bars from some points in the plotted graph is 
due to the small errors in the data. 
Upon the further increase in the concentration of NBDH, the relationship 
between the fluorescence and concentration is no longer linear, but reaches a 
maximum level and forms a plateau (Figure 5.7). Consequently there is no 
further increase in fluorescence by increasing the concentration of NBDH. 
R2 = 0.9975 ' /p 
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Figure 5.7 Calibration curve relating fluorescence of NBDH to its concentration, 
up to 350 µM. The absence of error bars from some points in 
the plotted graph is due to the small errors in the data. 
5.3 Protocol Development 
5.3.1 Choice of Enzyme Concentration 
Measurement of the effect of different enzyme concentrations on the rate of 
reaction of menadione with NQO2 showed that at enzyme concentrations 
ranging between 5 gM and 15 µM, there is a linear relationship between the 
enzyme concentration and reaction rate (Figure 5.8). While at both lower and 
higher enzyme concentrations, there is no noticeable effect caused by 
increasing the enzyme concentration. As the enzyme concentration of 10 µM 
was found to lie within the linear range of the graph, it was chosen to test the 
remaining conditions for menadione assay, such as the effect of the 
temperature and reproducibility of results. It also allows appropriate time for 
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the reaction, which is not too slow to reach completion and is not too fast to 
prevent accurate monitoring of the beginning of the reaction. 
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Figure 5.8 Effect of enzyme concentration on the rate of 
reaction of NQ02 with menadione 
5.3.2 Effect of temperature on reaction of menadione and K. 
When the two Michealis-Menten plots at different temperatures were overlaid, 
it was found that they share very similar profiles (Figure 5.9). With the 
exception of the temperature difference between the two experiments, all other 
remaining conditions such as enzyme and substrate concentrations were kept 
identical. The substrate concentration at which V,,, (,, (maximum velocity of the 
reaction) occurs is around 85 tM for both temperatures. The values of V,,.,., 
were found to be different, 0.175 tM sec-' and 0.39 µM sec- for 25 °C and 
37 °C respectively. The difference in the V,,,,,., values is caused by the increase 
in the reaction rate at the higher temperature. The value of K,,, calculated from 
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both curves is approximately 20 µM. The published K,,, values for the reaction 
of menadione and NQO2, using NBDH as a cosubstrate are 6.7 µM and 17 µM 
(Kwiek et al., 2004). 
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Figure 5.9 Michealis-Menten plots for the reaction between NQO2 and menadione 
at 25 °C and 37 T. The absence of error bars from some points in the 
plotted graph is due to the small errors in the data. 
5.3.3 Determining the Reproducibility of Results Using the Optimized 
Parameters 
The same experiment using the optimized tested parameters was repeated 
twice, to test the reproducibility of the results. Both repetitions showed almost 
identical profiles (Figure 5.10). The calculated K,,, values of 20 and 26 gM 
were considered to be similar, as previously published results using the same 
method showed similar errors (Boutin et al., 2005). On the other hand, the V,,,,,, 
values were calculated to be 0.53 gM sec-' and 0.36 gM sec-1. The large 
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difference in the V,,,,., values is thought to be caused by experimental and 
instrumental variations, caused by the experiments being carried out on 
different days. These variations though, did not affect the K,,, values of the 
experiment, thus it was decided that the chosen conditions were satisfactory 
and that the experimental results were reproducible. 
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Figure 5.10 Michealis-Menten plots for two kinetic experiments using menadione. 
The absence of error bars from some points in the plotted graph is due 
to the small errors in the data. 
5.4 Enzyme Kinetics for Substrates 
5.4.1 Substrate/cosubstrate Mixture Fluorescence Monitoring 
The decrease in the fluorescence of the mixture of cosubstrate/substrate 
mixture was measured to determine the effect of the different substrates on the 
fluorescence of the cosubstrate. The monitoring of the change in fluorescence 
of the cosubstrate/substrate mixtures showed no decrease in the fluorescence of 
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the NBDH upon its mixing with any of the tested substrates; menadione, 
coenzyme Q0, coenzyme Q1 and coenzyme Q2 (Figure 5.11). The 
concentrations used were the same as those used in determining the K,,, values. 
For GC201 only a few concentrations were tested due to the limited availability 
of the substrate. The absence of a large decrease in the fluorescence suggests 
that there is no reaction occurring between the cosubstrate and substrate. This 
is an important observation since it indicates that the observed decrease in the 
fluorescence during the enzymatic reaction is due to the reaction involving 
NQO2 and not between the substrate and cosubstrate. 
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Figure 5.11 Fluorescence decay over time of cosubstrate/substrate mixture 
solutions at the highest and lowest substrate concentrations tested. 
5.4.2 Relationship between enzyme and reaction rate 
The relationship between the concentration of NQO2 and the rates of reactions 
with coenzyme Q0, coenzyme Q1 and coenzyme Q2 were found to be linear 
for all substrates, within the concentration range tested (Figure 5.12). The 
concentration of NBDH used for all substrates was 100 gM while the 
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concentrations used for the substrates was differed according to the range of 
substrate concentration tested. 
The concentration of NQO2 that was chosen to determine the Kvalue for 
coenzyme QO was 10 µM, since this occurs in the centre of the tested range and 
was also used in the measurement of the K, of menadione. In addition, it was 
also used to asses and optimize the experimental conditions. The concentration 
used to determine the rate of reaction for both coenzyme Ql and 
coenzyme Q2 was 100 µM, since the lower enzyme concentration resulted in 
very slow reactions. 
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Figure 5.12 Effect of enzyme concentration on reaction rate. The absence of error bars 
from some points in the plotted graph is due to the small errors in the data. 
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5.4.3 K,,, determination for Substrates 
5.4.3.1 Coenzyme QO 
The Michealis-Menten plot shows a decrease in the rate of reaction at 
concentrations of coenzyme QO above 150 µM (Figure 5.13). This prevented 
the use of non-linear regression to determine the K,,, value directly from the 
Michealis-Menten plot. The Hanes-Woolf representation of the data was also 
plotted and it was found not to be linear, preventing its use in determing the 
K,,, and V,,,,,. (Figure 5.14). Therefore the Lineweaver-Burke plot was used to 
determine the kinetic constants. The K,,, was calculated to be 54.65 µM, and 
V,,,,,., was found to be 0.463 µM sec-1 (Figure 5.15). The points at which a 
decrease in the rate of reaction was observed in the Michealis-Menten plot 
were excluded from the calculations. 
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Figure 5.13 Michealis-Menten plot for the reaction of coenzyme QO with NQO2. 
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Figure 5.14 Hanes-Woolf plot for reaction of coenzyme QO with NQO2. The absence of 
error bars from some points in the plotted graph is due to the small errors in the data. 
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5.4.3.2 Coenzyme QI 
As with coenzyme Q0, the Michealis-Menten plot shows a decrease in the rate 
of reaction between NQO2 and coenzyme Q1 at concentrations of coenzyme 
Q1 above 55 µM (Figure 5.16). Therefore the K,,, and V,,,,,, values were 
calculated from the Lineweaver-Burke plot to be 97.98 µM and 1.556 µM sec-i 
respectively (Figure 5.17). As with coenzyme Q0, the points at which a 
decrease in the rate of reaction was observed in the Michealis-Menten plot 
were excluded from the calculations. 
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Figure 5.16 Michealis-Menten plot for reaction of coenzyme Q1 with NQO2. The absence 
of error bars from some points in the plotted graph is due to the small errors in the data. 
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Figure 5.17 Lineweaver-Burke plot of reaction between coenzyme Q1 and NQO2. 
The absence of error bars from some points in the plotted graph is due to the small 
errors in the data. The main graph shows concentrations of coenzyme Q1 
up to 55 µM, while the insert shows all data points collected. 
5.4.3.3 Coenzyme Q2 
The Michealis-Menten plot of the reaction between coenzyme Q2 and NQO2 
also showed a decrease in the rate of reaction at concentrations of 
coenzyme Q2 above 600 µM (Figure 5.18). K,,, and V...... were calculated from 
the Lineweaver-Burke plot to be 283.38 pM and 1.028 tM sec-1 respectively 
(Figure 5.19). As with coenzyme QO and coenzyme Q1, the points at which a 
decrease in the rate of reaction was observed were excluded from the 
calculations. 
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Figure 5.18 Michealis-Menten plot for reaction of coenzyme Q2 with NQ02. The absence 
of error bars from some points in the plotted graph is due to the small errors in the data. 
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Figure 5.19 Lineweaver-Burke plot of reaction coenzyme Q2 and NQO2. 
The absence of error bars from some points in the plotted graph is due to the 
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5.4.3.4 GC201 
The relationship between the enzyme concentration and the rate of reaction 
was not determined as the amount of substrate provided was limited. Thus the 
enzyme concentration that was used was the same as that used when measuring 
the K,,, for menadione, during the protocol development (section 5.3.3). 
Unlike the coenzyme Q series, the Michealis-Menten plot did not show a 
decrease in the rate of reaction at higher concentrations of the substrate. The 
increase in the concentration of the substrate resulted in a plateau, where the 
rate of the reaction remained relatively unchanged (Figure 5.20). This allowed 
the use of non-linear regression in the determination of the K,,, from the 
classical Michealis-Menten plot. The K,,, was found to be 168 µM, and the V,,,,,. z 
which was calculated to be 0.65 µM sec-1 
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Figure 5.20 Michealis-Menten plot for reaction of 6C201 with NQO2. 
The absence of error bars from some points in the plotted graph 
is due to the small errors in the data. 
132 
Chapter Five 
- 
Kinetic studies for NQO2 II 
5.5 Discussion and Conclusion 
GC201 was found to be a substrate for NQO2, as seen by the decrease in 
fluorescence of NBDH when mixed with both GC201 and NQO2. GC201 was 
designed to be a substrate for NQO2. The K,,, for GC201 was calculated to be 
168 µM. CB 1954 is a known anticancer prodrug that can be activated by 
several enzymes, including NQO2. It was found that there are two widely 
varied published K,,, values for CB 1954 from two different experimental 
techniques. The first was reported as 260 µM, where the method used N- 
ribosyl-1,4-dihydronioctinamide (NRH) as the cosubstrate and was dependant 
on using HPLC to monitor the consumption of CB 1954 (Wu et al., 1997). 
However, in another instance the Km for CB 1954 was reported to be 61 µM, 
where the method depended on measuring the decrease in the absorbance of an 
in-house cosubstrate upon its consumption in the reaction (Fu et al., 2005). 
The differences in the reported Km values are thought to be due to the different 
methods and the use of different cosubstrates for the reaction. The method used 
here is different from both methods and uses a different cosubstrate, and thus a 
direct comparison is not feasible. However, the calculated value of Km for 
GC201 is smaller than one of the values reported for CB 1954, suggesting that 
GC201 may be as a good a substrate for NQO2 as CB 1954. This is 
encouraging for further studies of GC201. 
The members of the coenzyme family tested were all found to be substrates for 
NQO2. Larger members of the coenzyme family are also thought to be 
substrates for NQO2, but that was not tested here. This is due to their 
insufficient solubility, in view of the fact that coenzyme Q2 required the 
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addition of extra DMSO to the media to ensure its complete dissolution. 
Therefore it was not possible to test whether this was the case and 
consequently determine the K, values. The calculated values of K,,, were 
inconclusive and require further investigation. This is due to the use of 
Lineweaver-Burke plots in their calculation. The Lineweaver-Burke plot 
results in the uneven distribution of data points due to the absence of data 
points at high substrate concentrations. Moreover, there is an exaggeration of 
errors casued by the use of the reciprocal of the reaction rate. This 
consequently results in errors in the calculation of V,,, and K,, values due to 
errors in the fitting of the line and the large extrapolation to calculate the 
intercepts. 
The calculated K. values for the coenzyme Q seris show a clear trend 
appearing in the ability of NQO2 to turnover the coenzyme Q series. A recent 
study involving NQO2 and the coenzyme Q seris showed a similar trend (Ferry 
et al. ). The increase in size of the side chain is associated with a decrease in the 
rate of turnover of the substrate by NQO2, demonstrated by the decreasing Km 
values. This may be related to the size of the active site and its ability to fit the 
substrate, where the bulkiness of the side group does not allow proper 
alignment of the substrate on top of the FAD molecule in the active site. 
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6.1 Introduction 
The mechanism of action of NQO2 is dependent on the reduction of the flavin 
cofactor by a cosubstrate before the subsequent transfer of electrons to the 
substrate. Thus during catalysis the substrate binds to the `reducedtt' form of 
the enzyme. To date all the published NQO2 structures are of the `oxidizedif ' 
form of the enzyme and the structure of the `reduced' form of the enzyme is 
not known. It is important to determine if the reduction process affects the 
binding pocket, by changing the geometry of the FAD or the position of amino 
acids. Moreover, it is also an essential aid in allowing the complete 
understanding of the mechanism of action of the enzyme. 
Several other flavoenzymes sharing the same mechanism of action with NQO2 
exhibit changes in the conformation of the flavin cofactor upon its reduction. 
The flavin cofactor of the Enterobacter cloacae nitroreductase, exhibits an 
increase in the bend of the flavin cofactor along the N5-N10 axis of the flavin 
isoalloxazine ring, known as a butterfly bend (Figure 6.1), by 9° upon its 
reduction from an initial bend of 16° in the oxidized form. Residues that 
interact with the isoalloxazine ring also shift to accommodate the bending of 
the ring; these include Lys-14, Asn-71 and Lys-74 which interact with the 
tt Reduced and oxidized forms: refer to the oxidation state of the flavin cofactor bound to the 
enzyme. 
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pyrimidine ring and N5 of the flavin. Ile-164, Tyr-144 and Leu-145 which 
interact with the dimethyl benzene moiety also show comparable movements 
(Haynes et al., 2002). Likewise, the crystal structure of thioredoxin reductase 
from Escherichia coli shows a much significant bend of 34° along the same 
axis (Lennon et al., 1999). Moreover, some flavoenzymes have shown 
positional changes of amino acids in the active site upon reduction of the flavin 
cofactor. For example, the reduction of monoamine oxidase (MAO) A causes 
drastic changes in the aromatic environment around the flavin cofactor 
(Hynson et al., 2004). 
C9 
C8 
C7 
ooý C6 
Figure 6.1 Side view of isoalloxazine ring, showing bend along N5-N10 axis. 
Hence an understanding of the changes that occur to the environment of the 
binding pocket upon the reduction of the FAD cofactor, such as the position of 
key residues in the binding pocket and any changes to the conformation of the 
isoalloxazine ring of the cofactor. This might provide useful information about 
the chemical mechanism of action of the enzyme during reductive catalysis. 
6.2 Methods and Materials 
All chemicals were purchased from Sigma-Aldrich unless otherwise stated. 
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6.2.1 Protein Production 
The NQO2 protein was expressed, harvested and purified as discussed in 
chapter four sections 4.2.2 and 4.2.3. The purity of the protein was assessed 
using SDS-PAGE, described in section 4.2.4. The protein solution was 
concentrated to several different concentrations ranging between 15 mg ml-' 
and 45mg ml-1. The concentration of the protein was calculated as described in 
chapter four, section 4.2.2. 
6.2.2 Protein Crystallization 
All solutions used in the crystallization protocol were filtered before use 
through a Ministart TM 0.2 gl syringe filter (Sartorius). The protein was then 
crystallized using the sitting drop vapour diffusion method in 24 well 
Cryschem TM plates (Hampton research). The reservoir solutions were added to 
the wells and mixed by stirring using a pipette tip. The protein solution was 
then placed in the centre of the sitting drop post, followed by an aliquot of the 
reservoir solution. The plates were then sealed using crystal clear sealing tape 
(Hampton research) and placed at 20°C in an incubator. The plates were then 
checked at regular intervals for the appearance of crystals. 
The conditions for crystallization of NQO2 were adapted from several 
previously published methods (Table 6.1). The precipitant used was 
ammonium sulphate in concentrations ranging from 1.2 to 2.0 M and the pH 
was adjusted using Na-HEPES (AbuKhader et al., 2005, Calamini et al., 2008, 
Foster et al., 1999, Fu et al., 2005). The published conditions were manually 
optimized to yield the best quality crystals. Several different parameters were 
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varied; the protein concentration was varied from 15 to 45 mg ml- I, t he 
concentration of ammonium sulphate was varied between 1.4 M and 2 M. The 
pH was also varied between pH 6.5 and 8. The effect of the drop size on 
crystallization was also investigated; this was done by changing the drop size 
between two gl and five µl. Finally, different ratios between the protein and 
reservoir solutions that were added to the crystallization drop were tested (1: 1, 
1: 2 and 2: 1). The final reservoir volume was kept constant at one ml. The 
concentrations of dithiothreitol (DTT) and FAD added to the reservoir solution 
were also kept constant at 1 mM and 12 µM respectively. 
Method Calamini Abu Khader Foster (Foster (Calamini et al., (AbuKhader et Fu (Fu et al., 
et al., 1999) 2008) al., 2005) 2005) Conditions 
Ammonium 1.4 M 1.3-1.7 M 1.66 M 1.2-2.0 M 
sulphate 
HEPES 100 mm 100mM 100 mm 100 mm 
pH 7.0 pH 6.0-7.0 pH 7.0 pH 7.0 
FAD 12 gM 12 gM 12 tM 10 gM 
DTT 1mM 1mM 1mM 
- 
1) Final protein 
Other Final protein concentration Final protein 
conditions concentration of concentration - 
of 7.5 mg/ml 16 mg/ml of 7.5 mg/ml 
2) 0.1 M NaCI 
Table 6.1 Crystallization conditions used in 
published method for the crystallization of NQO2. 
The quality of the crystals produced was judged using several criteria. The 
crystals were first visually inspected to ascertain the absence of visible cracks 
and visible twinning as they lead to interference in the diffraction pattern 
produced. In addition, the size of the crystals was also considered as an 
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important criterion since testing has proved that the increase in size of the 
crystal is accompanied by an increase in diffraction resolution. 
6.2.3 Crystal Reduction and Cryoprotectant Solution Optimization 
In order to minimize crystal damage caused by the soaking process and the 
transportation of the crystals between several soaking drops, the reduction of 
the NQO2 crystals was carried out in the cryoprotectant solution. 
Sodium dithionite was successfully used to reduce flavoenzymes in 
concentrations ranging from 20 mM to 100 mM (Gruber et al., 2009, Haynes et 
al., 2002, Lennon et al., 1999, Ludwig et al., 1997). Several different 
concentrations of sodium dithionite were tested, starting from 5 mM to 50 mM. 
A variety of cryoprotectant solutions were also tested, these included different 
concentrations of sodium malonate ranging from 0.8 M to 2 M, and sodium 
formate ranging from 2M to 3M in both 0.9 M and 1.8 M ammonium 
sulphate. In addition, sucrose solutions of concentrations up to 50 per cent were 
also tested. Successful cryoprotectant solutions should have a glassy 
appearance when placed in the nitrogen cryostream. In addition, the crystals 
should not be damaged by showing cracks when soaked in cryoprotectant. 
The combined solution of sodium dithionite and cryoprotectant solution was 
first degassed by bubbling helium gas through the solution. This was done to 
remove any traces of oxygen, which may hinder the complete reduction of the 
NQO2 crystals. The crystals were harvested from the crystallization tray using 
CryoLoops TM (Hampton research) ranging in size from 0.2 mm to 0.7 mm, 
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depending on the size of the crystal. The harvested crystals were then soaked in 
the combined solution for ten minutes in the crystallization sitting drop plates 
to limit oxygen exposure during the reduction process. The crystals were 
visually monitored for complete colour bleaching, indicating complete 
reduction, as well as the appearance of imperfections such as cracks or rough 
edges, indicating crystal damage. 
Crystals showing complete colour disappearance and no visual signs of damage 
were once again harvested using CryoLoops TM and quickly transferred to the 
goniometer into the nitrogen gas stream for in-house data collection or stored 
in liquid nitrogen for data collection at the synchrotrons. 
6.2.4 Data Collection 
Data was collected from the in-house X-ray source, equipped with a Rigaku 
R-AXIS IV++ detector using CuKa radiation from a Rigaku Micromax-007 
rotating anode and VariMax optics. Data was also collected from several trips 
to the Diamond Light Source and the European Synchrotron Radiation Facility 
(ESRF). The parameters used for data collection differed according to the setup 
used and the quality of the crystals. The number of frames was determined 
using initial test shoots and strategy optimization in iMosflm (Leslie, 1992). 
6.2.4.1 Dataset one 
This dataset was collected using the in-house X-ray source; the parameters 
used are listed in Table 6.2: 
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Oscillation I' 
Transmission 100 % 
Exposure time 5 minutes 
Number of collected frames 200 
Table 6.2 Parameters used for collection of dataset 1. 
6.2.4.2 Dataset two 
This dataset was collected at the ESRF; the parameters used for the dataset 
collection are listed in Table 6.3. 
Oscillation 10 
Transmission 100 % 
Exposure time 5 seconds 
Number of collected frames 200 
Beamline ID ID14/1 
Table 6.3 Parameters used for collection of dataset 2. 
6.2.4.3 Datasets three, four and f ve 
These datasets were collected at Diamond Light Source; the different 
parameters were used for each dataset are listed in Table 6.4. 
Dataset 3 Dataset 4 Dataset 5 
Oscillation (°) 1 1 1 
Transmission (%) 90 50 50 
Exposure time (seconds) 1 1 1 
Number of collected frames 200 120 240 
Beam ID 104 102 102 
Table 6.4 Parameters used for collection of datasets 3,4 and 5. 
Other datasets were collected but were discarded due to their relative low 
quality. 
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6.2.5 Data Processing 
6.2.5.1 Indexing and integration of images 
MOSFLM v 7.0.5 (Leslie, 1992) was used to index and integrate the images 
from the datasets collected. Preliminary unit cell parameters were determined 
using the first image collected. Subsequently, four images from two different 
segments 90° apart were then used to refine the unit cell and detector 
parameters. Once the accurate unit cell parameters were determined, all 
collected images were then integrated using the default parameters of 
MOSFLM. 
6.2.5.2 Scaling and merging of images 
Following the integration step in MOSFLM, SCALA (Evans, 1997) from the 
CCP4 programme suite (Bailey, 1994) was then used to scale and merge the 
hkl intensities. SCALA was also used to assess the quality of the data collected. 
The nominal resolution limit was chosen to satisfy all the criteria mentioned in 
Table 6.5. 
Parameter Acceptable value 
Rmerge : 540% 
Mean I/of >_ 3 
Completeness >_ 80% 
Table 6.5 Combined parameters for choice of 
nominal resolution limit. 
SCALA is also used to set up a random set of reflections, comprising of 
five per cent of the data, which will be later used in the calculation of Rfree 
during the refinement stage. 
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6.2.5.3 Molecular replacement 
Molecular replacement was done using Phaser (McCoy et al., 2007), through 
the CCP4 programme suite. Phaser utilizes a maximum likelihood algorithm to 
determine the orientation and the position of the given model that would result 
in the closet possible match to the given observed structure factors (Evans and 
McCoy, 2008). Phaser has two means to measure the success of the molecular 
replacement, the log-likelihood gain (LLG) and Z-scores. LLG is the difference 
between the likelihood of a model and the likelihood calculated from the 
Wilson plot. The likelihood refers to the probability of the data being 
measured. LLG gives an indication of how well different models resulting from 
molecular replacement step are in agreement with the data, and thus allows for 
the comparison of different output models for the same dataset. The Z-score is 
the number of standard deviations above the mean for a particular LLG score. 
The RF Z-score is related to the rotational function, while the TF Z-score is 
related to the translational function. The acceptable values of the Z-scores 
should be greater than five, and ideally should be greater than eight. 
The structure of the oxidized NOQ2 (pdb code: 1QR2) (Foster et al., 1999) 
from which the water molecules present in the structure have been removed 
was used as the model for the molecular replacement. This structure has no 
ligand present in the binding pocket which might cause changes in the position 
of amino acids in the binding pocket as well as the FAD molecules. 
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6.2.5.4 Refinement of model 
Refinement of the model produced by Phaser was done using REFMAC 5 
(Murshudov et al., 1997), through the CCP4 program suite. The acceptable 
values of Rfar, o, and Rfree depend on the resolution of the data undergoing 
refinement. The refinement procedure was done in several steps. The first step 
was a rigid body refinement which was followed by restrained body refinement 
step. Both Rfac, o, and Rf, ee were monitored during the refinement procedure. 
The number of cycles of refinement was chosen to give the lowest values of 
Rfactor and Rfree as well as the lowest difference between Rfactor and Rf, ee. This 
prevents the possibility of bias and over fitting of data as well as indicating the 
highest agreement between experimental data and produced model. The 
weighting term which controls the weight of the X-ray data versus the 
geometry of the protein was adjusted during the restrained body refinement so 
that the rms bond distance has a value between 0.01 and 0.02 A. 
COOT (Emsley and Cowtan, 2004) was used for the visual examination of the 
resulting model and associated maps. In addition, COOT was also used for 
manual model adjustment; the position of the atoms was checked to assure its 
agreement with the electron density maps. If the model and the electron density 
were not in agreement, attempts were made to fit different conformations of the 
amino acids into the electron density. Moreover, COOT was also used to 
manually add water molecules where required. 
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6.2.6 Identification of Unknown Electron Density in the Binding Pocket 
During the refinement procedure, an unidentifiable section of electron density 
was found in the binding pocket on top of the FAD molecule. The densities 
from several different datasets were compared. This was done by overlaying 
the different unidentified densities and comparing their shape using the 
`transform map command using LSQ' in COOT. The cryoprotectant solutions 
were considered at first as the source of the electron density. This hypothesis 
was disregarded as the electron densities in different crystals that have been 
soaked in different cryoprotectant solutions were very similar. 
6.2.6.1 Automated ligand identification 
The automated ligand identification function in Phenix (Adams et al. ) was then 
used in an attempt to identify the ligand occupying the electron density. This 
function tries to fit the most common 200 ligands in the protein database into 
the electron density and then analyzes the fitting of the ligands and provides a 
ranked list of the best fitting ligands. The ranking of the ligands is based upon 
the correlation between ligand and surrounding map. This is done through a 
graphical user interface and is fully automated. 
6.2.6.2 Refinement of probable molecules into the electron density 
Molecules involved in the protein harvesting, crystallization and reduction 
were considered as likely sources for the ligand occupying the unidentified 
electron density. Thus the probable molecules were manually added to the 
electron density to check if the have the right geometry and size for the 
unidentified electron density. 
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Dithiothreitol (DTT) is added to the crystallization mixture to ensure the 
reduction of the thiols in the crystallized protein. Upon its oxidation, DTT 
forms a six membered ring, (Cleland, 1964). All probable molecules, including 
the six membered ring oxidation product of DTT, were placed into the electron 
density in question, and then visually examined to see if the molecule was of 
the appropriate size and geometry. If the molecule was found to be of an 
appropriate size and geometry, the protein with the molecule added into the 
electron density, was then subjected to one round of restrained body 
refinement. The Rfac, o, and Rf ee were examined to see the impact of the 
molecule on the model quality; furthermore the resultant files were then once 
again visually examined to see the fit of the molecule into the electron density. 
The appearance of large areas of negative red peaks in the difference electron 
density map indicated that the molecule is bigger than that responsible for the 
unidentified electron density. On the other hand, the presence of large areas of 
green electron density after refinement indicates that the molecule is smaller 
than that responsible for the unidentified electron density. 
HS 
HOºý,, 
_ý 
HOº,,. S-1110H 
SýS 
_ý ýýýýnu vý  II lf-ý hv 
SH SH 
Figure 6.2 Oxidation of DTT 
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Molecule Source Structure 
Sodium used for crystal 
0' Sýý + 2Na Dithionite reduction 1 
ooj 
O O 
Ammonium present in ý + 
sulphate crystallization drop 
NH4 
OO 2- 
i 
O\' 0 S present n ý Na-HEPES 
crystallization drop 
N OH 
N HOB,, 
OH 
Dithiothreitol presentin SH 
crystallization drop 
HS 
OH 
HO 
present in 
Tris HO 
crystallization drop N112 
HO 
H 
added to the protein N Imidazole 
during purification N O 
Table 6.6 Structures of molecules with 
which the crystals have been in contact with. 
6.2.7 Model Validation 
COOT has several built in validation checks that were used to asses the quality 
of the model, such as geometry and rotamer analysis and density fit. Any errors 
that were discovered were manually adjusted in COOT before the final round 
of the refinement process. 
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Molprobity (Davis et al., 2007) was used to analyze the steric clashes between 
the different residues; this was done through the Molprobity web server. 
Molprobity also analyzes the geometry of the residues. Furthermore, 
PROCHECK (Laskowski et al., 1993) was also used to asses the 
stereochemical quality of the structure, and identify any areas of the structure 
that have geometries with large deviations from average values. PROCHECK 
produces a Ramachandran plot, in addition to a short summary file of the 
checks that were run by PROCHECK. 
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7.1 Protein Production 
NQO2 was expressed, harvested and purified as described in chapter four 
sections 4.2.2,4.2.3 and 4.2.4. The results of the SDS-PAGE used to asses the 
protein purity are described in chapter five, section 5.1.1. 
7.2 Protein Crystallization 
One of the variables explored during the protein crystallization trials was the 
protein concentration, as discussed in section 6.2.2. It was found that the use of 
7.5 mg ml-' NQO2 in the crystallization drop as have been previously 
published (AbuKhader et al., 2005, Foster et al., 1999) did not produce any 
crystals and it was necessary to increase the concentration of the protein to 
15 mg ml-1. The higher concentration of NQO2 was used by one other group in 
a published method, to produce NQO2 crystals of diffracting quality (Calamini 
et al., 2008). Trials using concentration of NQO2 higher than 15 mg ml'' 
resulted in the production of a large number of crystals that were too small to 
use to collect diffraction images. Another variable explored was the 
concentration of ammonium sulphate, which was used as the precipitant. It was 
found that concentrations ranging 1.6 M to 1.8 M produced crystals of 
appropriate quality to be used for X-ray diffraction. Lower concentrations of 
ammonium sulphate did not result in the production of NQO2 crystals. While 
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higher concentrations resulted in the precipitation of ammonium sulphate, 
rather than the crystallization of NQO2. It was also found that large deviations 
of pH from 7.2 caused the formation of distorted crystals. The change in drop 
size did not affect the process of crystal production or morphology. The final 
optimized conditions used for the production of NQO2 crystals are listed in 
Table 7.1 
Ammonium sulphate 1.6 
- 
1.8 M 
Na-HEPES 100 mm 
Sodium dithionite 1 mm 
FAD 12 µM 
pH 7.2 ± 0.2 
Table 7.1 Optimized conditions for NQO2 crystal production. 
All the NQO2 crystals grown showed a strong yellow colour; this is due to the 
crystallization of the oxidized FAD cofactor within the NQO2 crystals. Two 
different and distinct morphologies of NQO2 crystals were observed; one was 
a very flat plate-like with straight edges and usually grew attached to the 
bottom of the crystallization plate. Such crystals had a thickness ranging 
between 0.0025 mm and 0.005 mm (Figure 7.1, top row). On the other hand, 
the other crystal morphology showed a chunkier appearance, with tapered ends, 
with sizes that varied between 0.2 mm to 0.5 mm (Figure 7.1, bottom row). 
Both these crystal morphologies showed the ability to diffract X-rays. 
7.3 Crystal Reduction and the Choice of Cryoprotectant 
7.3.1 Crystal Reduction 
A wide range of concentrations of sodium dithionite were tested for their 
reducing potential. It was found that 25 mM was the optimum concentration of 
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sodium dithionite to reduce the NQO2 crystals. Higher concentrations of 
sodium dithionite caused the NQO2 crystals to crack before reduction 
occurred. On the other hand, lower concentrations of sodium dithionite did not 
reduce the crystals for sufficient time to allow the mounting of the crystals onto 
the goniometer or freezing in liquid nitrogen. The reduction process causes a 
change in colour of the crystal from bright yellow to colourless (Figure 7.2) 
'ooo/ 
711 
Figure 7.1 Photographs of NQO2 crystals obtained under varying conditions. 
The top row shows plate-like morphology, while the bottom row shows chunkier type 
morphology. 
Figure 7.2 Reduced NQ02 crystal mounted on goniometer. 
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7.3.2 Cryoprotection Solution Choice 
As previously mentioned in section 6.2.3 the crystal reduction was carried out 
in the cryoprotectant solution to minimize crystal damage. Therefore, 25 mM 
sodium dithionite were added to the cryoprotectant solutions during testing. 
The different cryoprotectant solutions used for the collection of datasets were 
1.2 M sodium malonate in 1.8 M ammonium sulphate, 2.8 M sodium formate 
in 1.8 M ammonium sulphate and 50 per cent sucrose. These solutions were 
chosen because they prevented the formation of ice crystals around the NQO2 
crystals and at the same time did not cause the crystals to crack. 
7.4 Data Processing 
7.4.1 Space Group and Cell Dimension Determination 
After indexing the images using MOSFLM, P212121 was the space group 
suggested for all the processed datasets, which is consistent with the space 
groups reported for most published structures of NQO2 (AbuKhader et al., 
2005, Calamini et al., 2008, Foster et al., 1999). During data processing, it was 
observed that there were two distinct unit cell dimensions (Table 7.2). Three 
crystals were found to have the unit cell dimensions listed in row one, while 
two crystals had the unit cell dimensions listed in row two. The different unit 
cells were not related to the different morphologies of the crystal. 
a b c a ß y 
Unit cell dimensions 1 
61.69 A 
(0.179 A) 
80.19 A 
(1.28 A) 
106.22 
(0.257 A) 90° 90° 90° 
Unit cell dimensions 2 
56.16 
(0.742 A) 83.30 (0.106 A) 106.49 (0.007 A) 90° 90° 90° 
Table 7.2 Average cell dimensions for the different cell units. 
The standard deviation for the length of the unit cell is between parentheses. 
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7.4.2 Data Processing Statistics for Different Datasets 
During the merging and scaling process carried out by SCALA, several data 
quality indicators were produced by the software. The data processing statistics 
for datasets one, two and three which were collected from crystals showing the 
chunkier morphology are listed in Table 7.3. The data processing statistics for 
the datasets four and five which were collected from crystals showing the 
plate-like morphology are listed in Table 7.4. Other datasets were also 
collected, but these were discarded upon the examination of the data processing 
statistics which suggested that they are of relative poorer quality. Particular 
interest was given to the resolution collected as well as to Ri71e, gei mean 1/of and 
percentage completeness values. 
Dataset one Dataset wo Dataset three 
Unit cell dimension 
a, b, c (A) 61.83,78.75, 106.00 
90,90,90 
55.63,83.22, 
106.49 
90,90,90 
56.68,83.37, 
106.48 
90,90,90 
Wavelength (A) 1.54 0.93 0.97 
Resolution range 
(A) 
19.64-1.73 
(1.83-1.73) 
44.19 
-1.65 
(1.74-1.65) 
53.24-1.6 
(1.69-1.6) 
R1T1e, ge(%) 8 (34.5) 7.8 (31.1) 5.6 (34.2) 
Number of 
observations 
393101 
(44345) 
495918 
(70897) 
261741 
(38237) 
Number of unique 
reflections 
51471 
(6839) 
63003 
(9088) 
61102 
(9120) 
Mean I/ai 18.4 (3.0) 18.7 (6.7) 14.8 (3.6) 
Completeness (%) 98.6 (91.7) 100 (100) 91.1 (94.4) 
Multiplicity 7.6 (6.5) 7.9 (7.8) 4.3 (4.2) 
Table 7.3 Data processing statistics for datasets collected from crystals showing chunkier 
morphology. (Values between parentheses are for higher resolution shell). 
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Dataset four Dataset five 
Unit cell dimension 
a, b, c (A) 
0, (°) 
61.76,80.61,106.50 
90,90,90 
61.49,81.20,106.15 
90,90,90 
Wavelength (A) 0.97 0.97 
Resolution range (A) 80.58-1.9 (1.9-2.0) 64.50-1.95 (1.95-2.06) 
Rmerýe (%) 10 (32.6) 8.2(40) 
Number of observations 173438 (24906) 180880 (26646) 
Number of unique 
reflections 
39233 (5541) 38249 (5694) 
Mean I/al 12.8 (4.2) 12.3 (3.8) 
Completeness (%) 92.5 (90.8) 97.5 (99.9) 
Multiplicity 4.4 (4.5) 4.7 (4.7) 
Table 7.4 Data processing statistics for datasets collected from crystals showing plate-like 
morphology. (Values between parentheses are for the higher resolution shell). 
7.5 Molecular Replacement 
The default setting for Phaser produced one solution for each dataset with high 
LLG and Z-score values (Table 7.5). This is a strong indication for the success 
of the molecular replacement step. The solutions found by Phaser for all the 
datasets had the same space group, P212121, which is similar to what was 
suggested by MOSFLM and SCALA. 
Dataset 1 Dataset 2 Dataset 3 Dataset 4 Dataset 5 
Space Group P212121 P212121 P212121 P212121 P212121 
Solvent content 48.20 % 50.53 % 49.26 % 51.83 % 51.82 % 
LLG 3669 3553 3405 3303 3581 
TF Z-score 47.1 47.2 51.4 54.3 60.0 
RF Z-score 29.1 31.7 34.1 31.8 34.0 
Table 7.5 Space group, solvent content, Z-scores and LLG values produced by Phaser. 
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7.6 Model Examination 
After one round of rigid body refinement followed by one round restrained 
body refinement, the resultant model and associated maps were thoroughly 
examined in COOT. The examination of the models and the maps for all the 
datasets in COOT showed no associated electron density for the two terminal 
residues Ala-1 and Gln-230, in both chains. Similarly, in all the datasets 
collected the electron density associated with residues Gly-57 to Glu-63 
inclusively, in chain B is weak. This is accompanied by high B-factors for this 
segment when compared to neighbouring residues (Table 7.6). This suggests 
that these residues may form a mobile loop, situated at the outer edge of the 
protein (Figure 7.3). However, for the remaining residues in both chains there 
is a good fit between the electron density and the model. 
Residue Gly-57 Thr-58 Leu-59 Ser-60 Asn-61 Pro-62 Glu-63 
B-factor 41.04 45.66 47.54 47.98 47.04 45.5 42.44 
Table 7.6 The Average B-factors of chain B residues 57 to 63 in all collected datasets. 
Upon the examination of the binding pocket it was found that the isoalloxazine 
ring of the flavin cofactor is flat and did not show any bend along the N5-N10 
axis (Figure 6.1). Moreover, a positive density in the difference map, 
Fobs 
-Fcaic, was present in both binding pockets in all the processed datasets. 
The electron density is flat and present on top of the FAD molecule. In datasets 
one to three the unidentified electron density is the same in both binding 
pockets. It lays parallel to the FAD molecule, on top of the central and 
pyrimidine rings (Figure 7.4). These datasets were collected from the NQO2 
crystals showing the chunkier morphology. In datasets four and five the 
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electron density showed a different pattern in the two binding pockets of the 
protein. In one of the binding pockets, the unidentified electron density is 
connected to the electron density of the N5 atom (Figure 1.1) of the 
isoalloxazine ring of the FAD molecule (Figure 7.5 andFigure 7.6). This 
occurs in the same binding pocket in both data sets. Meanwhile, in the other 
binding pocket the unidentified electron density is parallel to the FAD 
molecule with no interconnecting density, similar to what was observed in the 
binding pockets in datasets one, two and three. 
Figure 7.3 Cartoon representation of NQO2, mobile loop (residues Gly-57 to Glu-63 
inclusively) in both monomers is shown in red. Figure created using UCSF Chimera. 
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(a) 
(b) 
Figure 7.4 Active site of NQO2 showing the electron density maps of the unidentified 
electron density in the binding pocket of dataset two (resolution 1.65 k), where (a) shows 
the side view and (b) the top view. The difference map, Fobs 
-F,.,, (shown in blue), is 
contoured at 36 while the composite map, 2Fbs Fci. (shown in grey) is contoured at 1a. 
Red crosses represent water molecules. Figure was created using PyMOL. 
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Figure 7.5 Different orientations of electron density maps in the active site of dataset 4 
(resolution 1.9 A) showing interconnecting electron density. Difference map, 
Fob, 
-Feaic (blue) is contoured at 3a while the composite map, 2Fobs F, W, 
(grey) is contoured at la. Figure was created using PyMOL. 
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Figure 7.6 Electron density maps of the active site of dataset 5 (resolution 1.95 A) 
showing side view of interconnecting electron density. Difference map, Fobs 
-Fca, c (blue) is 
contoured at 2a while the composite map, 2Fbs Fcai. (grey) is contoured at la. Red 
crosses represent water molecules. Figure was created using PyMOL. 
7.7 Refinement and Ligand Identification 
7.7.1 Refinement Statistics After Manual Adjustments in COOT 
After refinement the resultant model and associated maps were thoroughly 
examined in COOT. Any errors found in the model during the visual 
examination were then manually fixed and the appropriate water molecules 
were added manually. This was then followed by another round of restrained 
body refinement. Table 7.7 show the final refinement statistics for datasets 
one, two and three collected from the NQO2 crystals having the chunkier 
morphology, while Table 7.8 shows the final refinement statistics for datasets 
four and five collected from the crystals having a plate-like morphology. 
7.7.2 Identification of Unknown Electron Density 
A possible interpretation for the unidentified electron density was thought to be 
the cryoprotectant solution. Different crystals soaked in sodium formate 
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(2.8 M), sodium malonate (1.2 M) and sucrose (50 per cent) were used to 
collect for datasets one, two and three respectively. They all showed the 
unidentified electron density present in the binding pocket (Figure 7.7 and 
Figure 7.8). When the electron densities of these different datasets were 
overlaid using COOT, it was found the unidentified electron densities were 
very similar in the three datasets (Figure 7.9). This suggests that they were 
caused by the same molecule, therefore the different cryoprotectants were ruled 
out as the ligand occupying the electron density on top of the FAD molecule 
Dataset I Dataset 2 Dataset 3 
Resolution (AL) 19.64-1.73 44.19-1.65 53.24-1.6 
R1acto, /Rfee 25.01/20.71 20.90/19.12 22.91/20.35 
No of water moelcules 140 183 179 
Average B-factors 
All atoms 25.490 12.230 19.839 
Protein 25.227 15.976 19.309 
Water 23.870 16.278 23.675 
Rms Deviations 
Bond length (A) 0.0159 0.0103 0.0115 
Bond Angles (°) 1.554 1.535 1.394 
Table 7.7 Refinement statistics for data sets of crystals having chunkier morphology. 
Dataset 4 Dataset 5 
Resolution (A) 80.58-1.9 64.50-1.95 
RfactolRfree 25.28/20.81 21.96/18.80 
No. of water molecules 166 152 
Average B-factors 
All atoms 20.365 21.740 
Protein 21.333 21.391 
Water 20.025 22.502 
Rms Deviations 
Bond length (A) 0.0175 0.0152 
Bond angles (°) 1.676 1.492 
Table 7.8 Refinement statistics for datasets of crystals having plate like morphology. 
160 
Chanter Seven 
-Structure of Reduced NQO2 II 
(a) 
(b) 
(c) 
Figure 7.7 Side view of unidentified electron density, where the difference map, Fob, 
-Fcaic 
(blue), is contoured at 3a while the composite map, 2Fons F,. Ic (grey) is contoured at 16. (a) Shows dataset 1, soaked in 2.8 M Na formate, (b) shows dataset 2, soaked in 
1.2 M Na malonate, while (c) shows dataset 3, soaked in 50 % sucrose. 
Figure was created using PyMOL. 
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(a) 
(b) 
(c) 
Figure 7.8 Top view of unidentified electron density, where the difference map, Fobs -Fcaic 
(blue), is contoured at 36 while the composite map, 2Fobs Fcaic (grey) is contoured at 16. 
(a) Shows dataset 1, soaked in 2.8 M Na formate, (b) shows dataset 2, soaked in 
1.2 M Na malonate, while (c) shows dataset 3, soaked in 50 % sucrose. 
Figure was created using PyMOL 
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(a) 
(b) 
Figure 7.9 Overlaid active site electron density difference maps of dataset one (green), 
dataset two (magenta) and dataset three (blue), where (a) shows the side view and (b) top 
view of the overlaid unidentified electron densities. Figure created using COOT. 
7.7.2.1 Automated ligand identification 
The automated ligand identification utility in Phenix was used in an attempt to 
identify the ligand occupying the unidentified electron density. The top two 
ligands suggested by the software were 4-hydroxycinnamic acid and palmitic 
acid (Figure 7.10). Both ligands had the same scores and thus shared the same 
probability to be the ligand. The structure of palmitic acid, a long aliphatic 
chain did not fit with the shape of the density and thus was excluded as a 
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possible ligand. On the other hand, 4-hydroxycinnamic acid has the right 
general structure shape, but it was ruled out as the probable ligand as there was 
no source of 4-hydroxycinnamic acid in the preparation and harvesting of 
NQO2 enzyme, the crystallization conditions or the preparation of the crystals 
for data collection. 
0 
OH 
HO 
(a) 
0 
OH 
(b) 
Figure 7.10 Structures of 4- hydroxycinnamic acid (a) 
and palmitic acid (b) 
7.7.2.2 Refinement of probable molecules into the electron density 
A number of molecules that were thought to be possible candidates as the 
unidentified ligand were refined into the electron density in the binding pocket. 
It was observed that when sulphur atoms were refined into the electron density, 
negative peaks appear both above and below the electron density suggesting 
that the sulphur atom is larger than the atoms of the ligand occupying the 
unidentified electron density peak. This observation therefore ruled out 
dithioreitol (Figure 7.11 (a)) and its reduction product (Figure 7.11 (b)), in 
addition to sodium dithionite (Figure 7.11 (c)), as the source of the 
unidentified electron density. Ammonium and sulphate ions, from ammonium 
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sulphate, and imidazole (Figure 7.11 (d)) were ruled out as the causing 
molecules for the electron density due to their small size relative to the electron 
density. Sodium HEPES was ruled out due to the presence of the long side 
chain which could not be accommodated into the electron density (Figure 7.11 
(e)). Tris was also ruled out due to its geometry, as the shape of the electron 
density suggested a ring shaped molecule (Figure 7.11 (f)). 
(a) 
(c) 
(e) 
(b) 
(d) 
(f) 
Figure 7.11 Different molecules refined into the unidentified electron density of dataset 2. 
(a) is dithioreitol, (b) is the dithioreitol reduction product, (c) is dithionite, 
(d) is imidazole, (e) is HEPES and (f) is Tris. The blue electron density is the difference 
map F b, -Fca,,, contoured at 3(y, while grey electron density is the 
composite map, 2Fbs-Fca, c, contoured at 1a. Figure created using PyMOL. 
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The Rfacfo, and Rf, Pe values did not show any significant changes when the 
different ligands were refined into the electron density. 
7.7.2.3 Analytical work 
Other analytical attempts were done to identify the ligand in the electron 
density; these included small molecule and protein mass spectrometry, as well 
as NMR. These results are not mentioned here as they did not provide any 
insight into the possible identity of the unknown ligand. 
7.8 Discussion 
7.8.1 Structural Differences Between Oxidized and Reduced NQO2 
The reduction of the NQO2 crystals was done by soaking of the crystals in a 
sodium dithionite solution until the crystal colour changes from bright yellow 
to colourless. The colour of the crystals was examined when the crystals were 
mounted onto the goniometer, prior to data collection. Furthermore, the colour 
of the crystals was examined once again after data collection. The colour of the 
crystals did not change once again from colourless to yellow. This suggests 
that the reduction process was successful and was not affected by either the 
storage of the crystals or their bombardment with X-rays during the collection 
of the data. 
The structure of the reduced NQO2 was compared to the published oxidized 
structure of NQO2 (pdb code: 1QR2). Special consideration was given to the 
residues of the active site around the FAD molecule, as well as to the geometry 
of the FAD. When the two whole structures were overlaid, the RMSD between 
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the two structures was calculated to be 0.388 A using all the atoms of the 
protein. This suggests that there are no large movements in the position of the 
chains upon its reduction (Figure 7.12). 
Figure 7.12 Overlaid cartoon representation of the structures of oxidized NQO2 
(pdb code: 1QR2, shown in yellow) and reduced NQO2 (shown in blue). 
Figure created using USCF chimera. 
The binding pockets of the two protein molecules were then thoroughly 
compared to determine if there are any changes in the position of the amino 
acids surrounding the active site. The geometry of the FAD isoalloxazine ring 
was also examined to determine if any conformational changes occurred upon 
its reduction. It was found that the reduction of the FAD molecule caused the 
flattening of the isoalloxazine ring along the N5-N10 axis (Figure 6.1). The 
angle was found to decrease by 6°, from 173° to 179° at N10 and by only 2° at 
N5, from 176° to 178 (Figure 7.13). The atomic numbering of the 
isoalloxazine ring of the flavin cofactor is illustrated in Figure 1.1. 
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Figure 7.13 Overlaid FAD molecules of the oxidized NQO2 (pdb code: 1QR2, grey) 
and reduced NQO2 (teal), showing the relative bending of the FAD in the 
oxidized structure compared to that of the reduced structure. 
Figure created using PyMOL. 
The flattening of the isoalloxazine ring is contrary to what was expected and 
reported in some of the other flavoproteins. Several published structures of the 
reduced flavoproteins showed an increase in the bend of the flavin cofactor 
when compared to their respective oxidized structure. Thioredoxin reductase 
shows an increase in the isoalloxazine bend by 34° upon the reduction of the 
cofactor (Lennon et al., 1999) (Figure 7.14). While old yellow enzyme shows 
an increase of the flavin bend by 13° (Fox and Karplus, 1994), and 
Enterobacter cloacae nitroreductase which shows an increase in bend by 9° 
upon its reduction (Haynes et al., 2002). The bending of the isoalloxazine ring, 
results in the movement of the N5 atom of the flavin towards the binding 
pocket of the enzyme, and consequentially closer to the substrate. This is 
thought to facilitate the movement of electrons between the flavin cofactor and 
the substrate. 
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Figure 7.14 Overlaid structures of oxidized thioredoxin reductaset (orange, pdb code: 
ltde) and reduced thioredoxin reductase (grey, pdb code: 100) showing different 
geometries of FAD molecule. Figure created using UCSF Chimera. 
It is also noticed that there is a hydrogen bond between 02 of the flavin 
(Figure 1.1) and the hydroxyl group of the Tyr-155 residue in dataset five 
(Figure 7.15). The distance between the two atoms was measured to be 2.66 A 
in this structure, which is a suitable distance for the formation of a hydrogen 
bond. The distance between the oxygen of the hydroxyl group of Tyr-155 and 
02 of the FAD molecule in the published oxidized structure of NQO2 was 
measured to be 2.79 A, which is 0.13 A more than that measured in the reduced 
structure (Figure 7.16). The difference in the distance between the flavin and 
the Tyr-155 residue between the oxidized and reduced proteins is 
approximately five per cent of the distance between the flavin and the tyrosine 
residue. This implies either that there is a slight movement of the tyrosine 
residue upon the reduction of the FAD, or that the flattening of the FAD 
molecule caused the movement of the 02 atom closer to the Tyr-155 residue. 
The Tyr-155 residue is conserved in both NQOI and NQO2; it is thought to 
play a role in the electron transport mechanism of NQOI by stabilizing the 
FAD molecule. This is through the transfer of a proton from the hydroxyl 
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group of the Tyr-155 residue to the FAD molecule after its reduction. During 
the reduction of the substrate, a proton is then transferred from the FAD to 
Tyr-155 once again (Figure 1.11) (Li et al., 1995). The decrease in the distance 
between the FAD and tyrosine residue may facilitate the transfer of the proton 
between the flavin and the Tyr-155 residue. 
Figure 7.15 Hydrogen bond between hydroxyl group of Tyr-155 residue and 02 atom of 
FAD molecule. The difference map Feb. 
-Fcalc (blue) is contoured at 3a and 
the composite map, 2Fobs Fca, c, (grey) is contoured at la. Figure created using PyMOL. 
Figure 7.16 Overlaid structures of the oxidized NQO2 (pdb code: IQR2, blue) and 
reduced NQO2 (red) overlaid, showing the distance between hydroxyl group of Tyr-155 
and 02 oxygen of the FAD cofactor. Figure created using PyMOL. 
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7.8.2 Unidentified Electron Density 
The unidentified electron density above the flavin cofactor is thought to be 
caused by an aromatic ring structure due to the dip in the middle of the electron 
density, where the electron density is narrower in the middle than on the edges 
(Figure 7.17). Moreover, the orientation of the electron density above the FAD 
where it lays flat and parallel to the isoalloxazine ring suggests possible n-n 
stacking between the ligand and the flavin cofactor. 
Figure 7.17 Composite map (2Fobs FcaIe) of dataset 2, contoured at la showing 
the dip in the middle of the electron density. Figure was created using PyMOL. 
The connecting electron density between the unidentified ligand and the N5 of 
the FAD molecule is a noteworthy observation and its significance is unclear. 
It may indicate that the ligand is a substrate and that it is undergoing reduction 
by the enzyme during collection of the dataset. The connecting density may be 
the electrons during the transfer process from the cofactor to the substrate. This 
is in agreement with the proposed mechanism of electron transfer between the 
flavin cofactor and the substrate, which suggests that the electron transfer 
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occurs between the N5 of the flavin cofactor to the substrate (Blankenhorn, 
1976). It may also indicate that the ligand is a suicide ligand that binds to the 
flavin cofactor irreversibly during the reduction process and the connecting 
density may then be a covalent bond formed between the substrate and the 
cofactor. 
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The increased interest in nitroaromatic reducing enzymes can be attributed to 
their ability to activate bioreductive anticancer drugs. These enzymes are of 
varied origins, as well as having different biological functions. The bacterial 
nitroreductases have been well studied and characterized and it has been 
demonstrated that they share several structural similarities. One of the 
similarities observed in bacterial nitroreductases is the presence of several 
conserved aromatic residues within the active site, in the vicinity of the flavin 
cofactor. These conserved aromatic residues are thought to form interactions 
with the substrates in the binding pocket and play a role in determining the 
substrate specificity of the different enzymes (Dolores Roldan et al., 2008). It 
was also reported that in other nitroaromatic reducing enzymes, such as old 
yellow enzyme and NQOs, aromatic residues in the active site play different 
roles in their mechanisms of action (Deller et al., 2008, Brown et at., 1998, 
Kohli and Massey, 1998). 
Although bacterial nitroreductases have been well characterized, other 
enzymes sharing the same ability have not been as extensively studied. 
Bioinformatics studies carried in this work on a wide range of enzymes 
reducing nitroaromatic compounds have shown that they may be divided 
according to their general structural conformation and the orientation of 
residues around the active site into four distinct groups. It has been observed 
that all four groups had different aromatic residues conserved in their active 
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sites at different positions relative to the flavin cofactor. It is thought that these 
residues may be involved in the electron transport mechanism from and to the 
cofactor. They may also be involved in the correct orientation of the 
cosubstrate and/or the substrate in the binding pocket and consequently may 
play a role in the cosubstrate or substrate specificity. The identification of the 
conserved residues may aid in the determination of the different mechanisms of 
action of the different classes of enzymes that are able to reduce nitroaromatic 
compounds. Subsequently, this may aid in designing more specific and 
effective drugs for the different enzymes. Furthermore, it may also aid in the 
identification of new enzymes that are capable of reducing nitroaromatic 
compounds and as a result their use in bioreductive anticancer chemotherapy as 
part of either the ADEPT or GDEPT approaches. 
Site directed mutagenesis can be used to determine the exact role of conserved 
aromatic residues in the four identified groups of nitroaromatic reducing 
enzymes. For example, enzyme kinetics can be used to determine the effect of 
the substitution of the aromatic residues on the rate of turnover of various 
cosubstrates as well as substrates. In addition, calculating the disassociation 
constant can be used to determine the change of the affinity of the substrates to 
the enzyme upon the substitution of the aromatic residue. Another approach 
that can be applied to determine the effect of the substitution of the aromatic 
residues is the use of molecular modelling software to simulate the reaction 
between substrates and the mutated enzymes. Similarly, molecular modelling 
software can be used to predict the possible interactions between the substrates 
and the mutated enzymes. Moreover, the effect of the different type of aromatic 
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residues can be also investigated in a similar fashion by replacing the aromatic 
residue of interest with another aromatic residue. 
Previously published results have shown that coenzyme QO is a substrate for 
NQO2 (Boutin et al., 2005). Recently published results have also shown that 
coenzyme Ql and coenzyme Q2 are also substrates for NQO2 (Ferry et al. ). 
Kinetic studies carried out in this work on NQO2 also showed that both 
coenzyme QI and coenzyme Q2 are NQO2 substrates. Further testing of other 
coenzyme Q family members was not possible due to their low aqueous 
solubility. It was observed that the rate of turn over of the tested coenzyme Q 
family members is inversely proportional to the length of the aliphatic side 
chain. This was also reported by the recent study carried out on NQO2 and 
coenzyme Q seris (Ferry et al. ). It is thought that the increase in the size of the 
side chain may affect the binding and correct orientation of the coenzyme Q 
substrates in the binding pocket of NQO2. In addition, GC201 was also 
identified as a noval substrate for NQO2. It was found to have an appreciable 
rate of turn over to CB 1954. More studies are needed to determine the potential 
medicinal use of GC201 as an anti-cancer therapeutic agent upon its reduction. 
Several published structures of reduced flavoprotein showed changes in the 
conformation of the flavin cofactor when compared to their respective oxidized 
structures. Enterobacter cloacae nitroreductase and thioredoxin reductase 
showed an increase in the bend of the isoalloxazine ring of the flavin cofactor 
upon its reduction (Haynes et al., 2002, Lennon et al., 1999). The structure of 
the reduced NQO2 that was determined in this work did not reveal any major 
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conformational changes when compared to the published structure of the 
oxidized NQO2. Contrary to what was expected, a slight flattening of the FAD 
cofactor was observed upon its reduction. Moreover, it was noticed that when 
compared to the published oxidized structure, the distance between an oxygen 
atom from the FAD cofactor and the Tyr- 155 residue is shorter. This is thought 
to facilitate the formation of a hydrogen bond between the oxygen of the FAD 
and the hydroxyl group of the Tyr-155 residue. This observation is in 
agreement with the postulated mechanism of action of NQO2 (Bianchet et al., 
2004). The examination of the catalytic site of the reduced NQO2 structure 
revealed an electron density connecting the N5 nitrogen of the FAD cofactor 
with a potential substrate for NQO2. It is thought that the N5 of the FAD 
cofactor plays an important role in the electron transfer. 
Further investigation needs to be undertaken to determine whether the very thin 
morphology of the plate-like NQO2 crystals is of significant importance in 
changing the behaviour of the ligand in the binding pocket. Given that it may 
be a useful aid in providing a better insight into the mechanism of electron 
transfer between NQO2 and its substrates. This could be done by using X-ray 
crystallography to determine the structure of several NQO2 crystals, showing 
plate-like morphology which are soaked in different known cosubstrates and 
substrates. The binding pocket of the determined structures could then be 
examined to see if the interconnecting density between the different substrates 
and the flavin cofactor is present. Similarly, it will be of interest to test out 
whether the same results could be obtained from other protein crystals showing 
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the same morphology soaked in known substrates. This could provide us with a 
valuable tool in determining the mechanisms of action of different enzymes. 
The better understanding of the mechanism of action of NQO2 and the 
determination of the structure of its reduced form may aid in designing and the 
identification of novel more efficient substrates that can be used in the 
treatment of cancer. The use of sequence and structural alignments may result 
in the identification of novel enzymes that are capable of reducing anticancer 
prodrugs more efficiently or less likely to cause an immunogenic response 
once delivered into the human body. These can then be used in the activation 
of anticancer prodrugs by means of either ADEPT or GDEPT. 
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Appendices 
Al. Amino acid abbreviations 
Alanine Ala A 
Arginine Arg R 
Asparagine Asn N 
Aspartic acid (aspartate) Asp D 
Cysteine Cys C 
Glutamine Gln Q 
Glutamic acid (glutamate) Glu E 
Glycine Gly G 
Histidine His H 
Isoleucine Ile I 
Leucine Leu L 
Lysine Lys K 
Methionine Met M 
Phenylalanine Phe F 
Proline Pro P 
Serine Ser S 
Threonine Thr T 
Tryptophan Trp W 
Tyrosine Try Y 
Valine Val V 
xviii 
Appendices 
A2. Composition of solutions used in experimental procedures 
2xTY: 16 g Tryptone 
10 g Yeast Extract 
10gNaC1 
to 1L H2OMQ 
3X Protein Loading 0.135 M Tris-HCI, pH 6.8 
Buffer: 0.15 M Dithiothreitol 
30% (v/v) Glycerol 
3% (w/v) SDS 
0.03% (w/v) Bromophenol blue 
in H2OMQ 
Coomassie Destaining 25% (v/v) Methanol 
Solution: 25% (v/v) Glacial Acetic acid 
in H2OMQ 
Coomassie Staining 0.25% (v/v) Coomassie Brilliant Blue R250 
Solution: 25% (v/v) Methanol 
25% (v/v) Glacial Acetic acid 
in H2OMQ 
Lysis Buffer: 50 mM Tris-HCI, pH 8 
300 mM NaCl 
SDS Running Buffer: 0.025 M Tris 
0.19 M Glycine 
0.1 % SDS 
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A3. Sequence alignments 
A3. I Alignment of group I protein sequences using Clustal-W2 
PETN 
------------SAEF: LFTPLF: VGAVTAPNRVFMAPLTBLkSIEPGDIPT 3B 
Morph 
------ 
MPDTSFSNPGLFTPLQLGSLSLPNRVIMAPLTF. SF. 
--TPDSVPG 42 
GTN 
-------------MTSLFEPAQAGDIALANRIVMAPLTRNR--SPGAIPN 35 
NemA 
-----MAHHHHHHMPSLFDPLTIGDLTLANRIIMAPLTRAR-AGDTRTPN 44 
XenB 
-------------MTTLFDPIKLGDLELSNRIIMAPLTRCR-ADAGRVPN 36 
Cyclo 
-------------MPTLFDPLTLGDLQSPNRVLMAPLTRGR-ATREHVPT 36 
OYE MSFVF: DFKPQALGDTNLFKPIKIGNNELLHRAVIPPLTRMRALHPGNIPN 50 
XenA 
---------------ALFEPYTLKDVTLRNRIAIPPMCQYM--AEDGMIN 33 
PETN 
-PLMGEYYRQRAS--AGLIISEATQISAQAKGYAGAPGLHSPEQIAAWKK 85 
Morph 
-RLQQIYYGQRAS--AGLIISEATNISPTARGYVYTPGIWTDAQEAGWKG 89 
GTN 
-NLNATYYEQRAT--AGLIVTEGTPISQQGQGYADVPGLYKREAIEGWKK 82 
NemA 
-ALMARYYAERAS--AGLIISEATSVTPQGVGYASTPGIWSPEQVDGWRL 91 
XenB 
-ALMAEYYVQRAS--AGLILSEATSVTPMGVGYPDTPGIWSNDQVRGWAN 83 
Cyclo 
-ELMIEYYTQRAS--AGLIITEATGITQEGLGWPYAPGIWSDEQVEAWKP 83 
OYE FDWAVEYYTQRAQRPGTMIITEGAFISPQAGGYDNAPGVWSEEQMVEWTK 100 
XenA 
-DWHHVHLAGLARGGAGLLWEATAVAPEGRITPGCAGIWSDAHAQAFVP 82 
PETN ITAGVHAEDGRIAVQLWHTGRISHSSIQPGGQAPVSASALNANTRTSLRD 135 
Morph VVEAVHAKGGRIALQLWHVGRVSHELVQPDGQQPVAPSALKAEGAECFVE 139 
GTN ITDGVHSAGGKIVAQIWHVGRISHTSLQPHGGQPVAPSAITAKSKTYIIN 132 
NemA VTDAVHAAGGRIFLQLWHVGRVSDPVFLD-GALPVAPSAIAPGGHVSLVR 140 
XenB VTKAVHGAGGKIFLQLWHVGRISHPSYLN-GETPVAPSALQPKGHVSLVR 132 
Cyclo VTQAVHEAGGRIILQLWHMGRTVHSSFLG-GAKPVSSSATRAPGQAHTYE 132 
OYE IFNAIHEKKSFVWVQLWVLGWAAFPDNLARDGLRYDSASDNVFMDAEQEA 150 
XenA VVQAIKAAGSVPGIQIAHAGRKASANRPWEGDDHIAADDTRGWETIAPSA 132 
PETN 
-ENGNAIRVDTTTPRALELDEIPGIVNDFRQAVANAREAGFDLVELHSAH 184 
Morph FEDGTAGLHPTSTPRALETDGIPGIVEDYRQAAQRAKRAGFDMVEVHAAN 148 
GTN 
-DDGTGAFAETSEPRALTIDDIGLILEDYRSGARAALEAGFDGVEIHAAN 181 
NemA 
------ 
PQRPYVTPRALELDEIPGVVAAFRRGAENARAAGFDGVEVHGAN 184 
XenB 
------PLADFPTPRALETAEIADIVDAYRVGAENAKAAGFDGVEIHGAN 176 
CyC10 
------GKQDYDEARPLSADEIPRLLNDYEHAAKNAMAAGFDGVQIHAAN 176 
OYE 
-----KAKKANNPQHSLTKDEIKQYIKEYVQAAKNSIAAGADGVEIHSAN 195 
XenA 
---IAFGAHLPKVPREMTLDDIARVKQDFVDAARRARDAGFEWIELHFAH 179 
PETN GYLLHQFLSPSSNQRTDQYGGSVENRARLVLEVVDAVCNEWSADRIGIRV 234 
Morph ACLPNQFLATGTNRR. TDQYGGSIENRARFPLEVVDAVAEVFGPERVGIRL 239 
GTN GYLIEQFLKSSTNQRTDDYGGSIENRARFLLEWDAVAEEIGAGRTGIRL 231 
NemA GYLLDQFLQDSANRRTDAYGGSIENRARLLLEWDAAIDVWSAARVGVHL 234 
XenB GYLLDQFLQSSTNQRTDQYGGSLENRARLLLEVTDAAIEIWGAGRVGVHL 226 
Cyclo GYLIDQFLRDNSNVRGDAYGGSIENRIRLLVEVTRRVAETVGAEKTGVRL 226 
OYE GYLLNQFLDPHSNTRTDEYGGSIENRARFTLEVVDALVEAIGHEKVGLRL 245 
XenA GYLGQSFFSEHSNEýTDAYGGSFDNF: SHFLLETLAAVF, EVWPEN---LPL 226 
PETN SP-IGTFQNVD-NGPNEEADALYLIEELAFý: G----- IAYLHMSE----- 272 
Morph TPFLELFGLTD-DEP--EAMAFYLAGELDRRG----- LAYLHFNE----- 276 
GTN SPVTPANDIFE-ADP--QPLYNYWEQLGKRN----- LAFIHWEGATGG 273 
NemA APRGDAHTMGD-SDP--AATFGHVARELGRRR----- IAFLFARE----- 271 
XenB APRADSHDMGD-ANL--AETFTYVARELGKRG----- IAFICSRE----- 263 
Cyclo SPNGDSQGVND-SNP--EPLFSAAAKALDEIG----- IAHLELREP---- 264 
OYE SPYGVFNSMSGGAETGIVAQYAYVAGELEK. R. AKAGKRLAFVHLVEPR--- 292 
XenA TAýFGVLEYDG-c<DEQTLEESIELA? lýF'rAGG----- LDLLSVSVG---- 266 
PETN 
-TDLAGG-KPYSEA-FRQKVREI-FHGVIIGAGAYTAEKAEDLIGK---G 315 
Morph 
-PDWIGGDITYPEG-FREQMRQR-FKGGLIYCGNYDAGRAQARLDD---N 320 
GTN PRDFKQGDKPFDYASFKAAYRNAGGKGLWIANNGYDRQSAIEAVES 
--- 
G 320 
NemA 
--------- 
SFGGDAIGQQLKAA-FGGPFIVNENFTLDSAQAALDA---G 308 
XenB 
--------- 
KEGADSLGPQLKEA-FGGPYIANERFTKDSANAWLAA---G 300 
Cyclo 
--GYEGTFGKADRPPVHPVIRQA-FSRTLILNSDYTLETAQAALAT---G 308 
OYE VTNPFLTEGEGEYEGGSNDFVYSIWKGPVIRAGNFALHPEWREEVK--D 340 
XenA 
-FTIPDTNIPWGPAFMGPIAERVRREAKLPVTSAWGFGTPQLAEAALQAN 315 
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PETN LIDAVAFGRDYIANPDLVAiLQKKAELNPQkPESFYGGGAEGYTDYPSL- 364 
Morph TADAVAFGRPFIANPDLPERFRLGAALNEPDPSTFYGGAEVGYTDYPFLD 370 
GTN KVDAVAFGKAFIANPDLVRRLKNDAPLNAPNQPTFYGGGAEGYTDYPALA 370 
NemA QADAVAWGKLFIANPDLPRRFKLNAPLNEPNAATFYAQGEVGYTDYPALE 358 
XenB KADAVAFGVPFIANPDLPARLKADAPLNEAHPETFYGKGPVGYIDYPTL- 349 
Cyclo EADAITFGRPFLANPDLPHRFAERLPLNKDVMETWYSQGPEGYVDYPTAD 358 
OYE KRTLIGYGRFFISNPDLVDRLEKGLPLNKYDRDTFYQMSAHGYIDYPTYE 390 
XenA QLDLVSVGRAHLADPHWAYFAAKELGVEKAS----- WTLPAPYAHWLE-- 358 
PETN 
Morph 
GTN 
NemA 
XenB 
Cyclo 
OYE 
XenA 
NGHDRLG--- 
Q--------- 
SAA------- 
QK-------- 
EALKLGWDKK 
377 
361 
371 
360 
400 
A3.2 Alignment of group I protein sequences using T-Coffee 
Morph MPDT SFSNPGLFTPLQLGSLSLPNL: VIMAPLThSi<T--PDSVPGh-LQQIYYG- 
OYE MSFVKDFKPQALGDTNLFKPIKIGNNELLHRAVIPPLTRMRALHPGNIPNRDWAVEYYT- 
PETN S------------AEKLFTPLKVGAVTAPNRVFMAPLTRLRSIEPGDIPTP-LMGEYYR- 
XenA 
---------------ALFEPYTLKDVTLRNRIAIPPMCQYMAE-DGMI-NDW-HHVHLAG 
NemA MAHHHH----- HHMPSLFDPLTIGDLTLANRIIMAPLTRARAG-DTRTPNA-LMARYYA- 
GTN 
-------------MTSLFEPAQAGDIALANRIVMAPLTRNRS--PGAIPNN-LNATYYE- 
XenB 
-------------MTTLFDPIKLGDLELSNRIIMAPLTRCRAD-AGRVPNA-LMAEYYV- 
Cyclo 
-------------MPTLFDPLTLGDLQSPNRVLMAPLTRGRAT-REHVPTE-LMIEYYT- 
Morph 
-QRAS--AGLIISEATNISPTARGYVYTPGIWTDAQEAGWKGWEAVHAKGGRIALQLWH 
OYE 
-QRAQRPGTMIITEGAFISPQAGGYDNAPGVWSEEQMVEWTKIFNAIHEKKSFVWVQLWV 
PETN 
-QRAS--AGLIISEATQISAQAKGYAGAPGLHSPEQIAAWKKITAGVHAEDGRIAVQLWH 
XenA LARGG--AGLLWEATAVAPEGRITPGCAGIWSDAHAQAFVPWQAIKAAGSVPGIQIAH 
NemA 
-ERAS--AGLIISEATSVTPQGVGYASTPGIWSPEQVDGWRLVTDAVHAAGGRIFLQLWH 
GTN 
-QRAT--AGLIVTEGTPISQQGQGYADVPGLYKREAIEGWKKITDGVHSAGGKIVAQIWH 
XenB 
-QRAS--AGLILSEATSVTPMGVGYPDTPGIWSNDQVRGWANVTKAVHGAGGKIFLQLWH 
Cyclo 
-QRAS--AGLIITEATGITQEGLGWPYAPGIWSDEQVEAWKPVTQAVHEAGGRIILQLWH 
Morph VGRVSHELVQ----------- PDGQQPVAPSALKAEGAECFVEFEDGTAGLHPTSTPRAL 
OYE LGWAAFPDNLA----------RDGLRYDSASD------NVFMDAEQEAKAKKANNPQHSL 
PETN TGRISHSSIQ----------- PGGQAPVSASALNANTRTSL-RDENGNAIRVDTTTPRAL 
XenA AGRKASANRPWEGDDHIAADDTRGWETIAPSAIAFGA--------------HLPKVPREM 
NemA VGRVSDPVF------------ LDGALPVAPSAIAPGGHVSL-V----- RPQRPYVTPRAL 
GTN VGRISHTSLQ----------- PHGGQPVAPSAITAKSKTYI-INDDGTGAFAETSEPRAL 
XenB VGRISHPSY------------ LNGETPVAPSALQPKGHVSL-V----- RPLADFPTPRAL 
Cyclo MGRTVHSSF------------ LGGAKPVSSSATRAPG------ QAHTYEGKQDYDEARPL 
Morph ETDGIPGIVEDYRQAAQRAKRAGFDMVEVHAANACLPNQFLATGTNRRTDQYGGSIENRA 
OYE TKDEIKQYIKEYVQAAKNSIAAGADGVEIHSANGYLLNQFLDPHSNTRTDEYGGSIENRA 
PETN ELDEIPGIVNDFRQAVANAREAGFDLVELHSAHGYLLHQFLSPSSNQRTDQYGGSVENRA 
XenA TLDDIARVKQDFVDAARRARDAGFEWIELHFAHGYLGQSFFSEHSNKRTDAYGGSFDNRS 
NemA ELDEIPGVVAAFRRGAENARAAGFDGVEVHGANGYLLDQFLQDSANRRTDAYGGSIENRA 
GTN TIDDIGLILEDYRSGARAALEAGFDGVEIHAANGYLIEQFLKSSTNQRTDDYGGSIENRA 
XenB ETAEIADIVDAYRVGAENAKAAGFDGVEIHGANGYLLDQFLQSSTNQRTDQYGGSLENRA 
Cyclo SADEIPRLLNDYEHAAKNAMAAGFDGVQIHAANGYLIDQFLRDNSNVRGDAYGGSIENRI 
Morph RFPLEVVDAVAEVFGPERVGIRLTPFLELFGLTDD---EPEAMAFYLAGELDRRG----- 
OYE ýFTLEVVDALVEAIGHEKVGLRLSPYGVFNSMSGGAETGIVAQYAYVAGELEKRAKAGKR 
PETN FLVLEVVDAVCNEWSADRIGIRVSPIGTFQNVDNGP--NEEADALYLIEELAKRG----- 
XenA r. FLLETLAAVREVWPE-NLPLTA-RFGVL-EYDG-RDEQTLEESI---- ELARRFKA-GG 
NemA kLLLEVVDAAIDVWSAARVGVHLAPRGDAHTMGDS---DPAATFGHVARELGRRR----- 
GTN RFLLEVVDAVAEEIGAGRTGIRLSPVTPANDIFEA---DPQPLYNYVVEQLGKRN----- 
XenB RLLLEVTDAAIEIWGAGRVGVHLAPRADSHDMGDA---NLAETFTYVARELGKRG----- 
Cyclo RLLVEVTRRVAETVGAEKTGVRLSPNGDSQGVNDS---NPEPLFSAAAKALDEIG----- 
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Morph LAYLHF---- NEPDWI------ GGDITYPEG-Fi, EQMRQR-Fh: GGLIYCGNY-DAGRAQA 
OYE LAFVHL---- VEPRVTNP-FLTEGEGEYEGG-SNDFVYSI-WKGPVIRAGNF-ALHPEVV 
PETN IAYLHM---- SETDLA------ GGK-PYSEA-FRQKVRER-FHGVIIGAGAY-TAEKAED 
XenA LDLLSVSVGFTIPDTN 
---- 
IPWGP-AFMGP-IAERVRRE-AKLPVTSAWGFGTPQLAEA 
NemA IAFLFA----RESFG--------G-----DA-IGQQLKAA-FGGPFIVNENF-TLDSAQA 
GTN LAFIHV 
---- 
VEGATGGPRDFKQGDKPFDYASFKAAYRNAGGKGLWIANNGY-DRQSAIE 
XenB IAFICS---- REKEG-------- A----- DS-LGPQLKEA-FGGPYIANERF-TKDSANA 
Cyclo IAHLEL---- REPGYEG---- TFGK-ADRPP-VHPVIRQA-FSRTLILNSDY-TLETAQA 
Morph RLD-DNTADAVAFGRPFIANPDLPERFRLGAALNEPDPSTFYGGAEVGYTDYPFLDNGH- 
OYE REEVKDKRTLIGYGRFFISNPDLVDRLEKGLPLNKYDRDTFYQMSAHGYIDYPTYEEALK 
PETN LIG-KGLIDAVAFGRDYIANPDLVARLQKKAELNPQRPESFYGGGAEGYTDYPS------ 
XenA ALQ-ANQLDLVSVGRAHLADPHWAYFAAKELGVEKAS---WTLPAP--YA---H------ 
NemA ALD-AGQADAVAWGKLFIANPDLPRRFKLNAPLNEPNAATFYAQGEVGYTDYPALES--- 
GTN AVE-SGKVDAVAFGKAFIANPDLVRRLKNDAPLNAPNQPTFYGGGAEGYTDYPAL----- 
XenB WLA-AGKADAVAFGVPFIANPDLPARLKADAPLNEAHPETFYGKGPVGYIDYPT------ 
Cyclo ALA-TGEADAITFGRPFLANPDLPHRFAERLPLNKDVMETWYSQGPEGYVDYPTAD---- 
Morph 
--DRLG 
OYE LGWDKK 
PETN 
-----L 
XenA 
---WLE 
NemA 
----AA 
GTN 
----AQ 
XenB 
-----L 
Cyclo 
----QK 
A3.3 Alignment of group I protein sequences using PROMALS 
Conserv 99 975 79 669777 75 56 77 579 77775 
N, mA MAH-----HHHHHMPSLFDPLTIGDLTLANRIIMAPLTRARAGDT--RTPNALMARYYAERAS--AGLII 61 
Cyclo 
-------------MTTLFDPIKLGDLELSNRIIMAPLTRCRADAG--RVPNALMAEYYVQRAS--AGLIL 53 
XenB 
-------------MPTLFDPLTLGDLQSPNRVLMAPLTRGRATRE--HVPTELMIEYYTQRAS--AGLII 53 
GTN 
-------------MTSLFEPAQAGDIALANRIVMAPLTRNRSP-G--AIPNNLNATYYEQRAT--AGLIV 52 
Morph 
------MPDTSFSNPGLFTPLQLGSLSLPNRVIMAPLTRSRTP-D--SVPGRLQQIYYGQRAS--AGLII 59 
PETN 
------------SAEKLFTPLKVGAVTAPNRVFMAPLTRLRSI-EPGDIPTPLMGEYYRQRAS--AGLII 55 
"; E, MSFVKDFKPQALGDTNLFKPIKIGNNELLHRAVIPPLTRMRALHPGNIPNRDWAVEYYTQRAQRPGTMII 70 
X, " 
--------------- 
ALFEPYTLKDVTLRNRIAIPPMCQYMAE-D--GMINDWHHVHLAGLARGGAGLLV S2 
Consensus eee eee eee hhhhhhhhhhh eee 
Conserv 967 655 6 75 79555 55 7 65 667 556 5 9677 97 57 555 55 
NeniF SEATSVTPQGVGYASTPGIWSPEQVDGWRLVTDAVHAAGGRIFLQLWHVGRVSDPVFLD-GALPVAPSAI 130 
Cyclo SEATSVTPMGVGYPDTPGIWSNDQVRGWANVTKAVHGAGGKIFLQLWHVGRISHPSYLN-GETPVAPSAL 122 
XenB TEATGITQEGLGWPYAPGIWSDEQVEAWKPVTQAVHEAGGRIILQLWHMGRTVHSSFLG-GAKPVSSSAT 122 
GTN TEGTPISQQGQGYADVPGLYKREAIEGWKKITDGVHSAGGKIVAQIWHVGRISHTSLQPHGGQPVAPSAI 122 
Morph SEATNISPTARGYVYTPGIWTDAQEAGWKGVVEAVHAKGGRIALQLWHVGRVSHELVQPDGQQPVAPSAL 129 
PETN SEATQISAQAKGYAGAPGLHSPEQIAAWKKITAGVHAEDGRIAVQLWHTGRISHSSIQPGGQAPVSASAL 125 
"YG TEGAFISPQAGGYDNAPGVWSEEQMVEWTKIFNAIHEKKSFVWVQLWVLGWAAFPDNLARDGLRYDSASD 140 
X., iPý VEATAVAPEGRITPGCAGIWSDAHAQAFVPWQAIKAAGSVPGIQIAHAGRKASANRPWEGDDHIAADDT 120 
Consensus eee hhhhhhhhhhhhhhhh eeeee 
Conserv 57 7 759 565 67 57 9977 77 9 96779 797 
NemA A-PGGHVS------LVRPQRPYVTPRALELDEIPGVVAAFRRGAENARAAGFDGVEVHGANGYLLDQFLQ 193 
CyC10 Q-PKGHVS------LVRPLADFPTPRALETAEIADIVDAYRVGAENAKAAGFDGVEIHGANGYLLDQFLQ 185 
XenB R-APGQAH------TYEGKQDYDEARPLSADEIPRLLNDYEHAAINAMAAGFDGVQIHAANGYLIDQFLR 185 
GTN T-AKSKTYI-INDDGTGAFAETSEPRALTIDDIGLILEDYRSGARAALEAGFDGVEIHAANGYLIEQFLK 190 
Morph K-AEGAECFVEFEDGTAGLHPTSTPRALETDGIPGIVEDYRQAAQRAKRAGFDMVEVHAANACLPNQFLA 193 
PETN N-ANTRTSL-RDENGNAIRVDTTTPRALELDEIPGIVNDFRQAVANAREAGFDLVELHSAHGYLLHQFLS 204 
(ýYF. NVFMDAEQ------EAKAKKANNPQHSLTKDEIKQYIKEYVQAAKNSIAAGADGVEIHSANGYLLNQFLD 188 
}; 
-A R-GWETIA---PSAIAFGAHLPKVPREMTLDDIARVKQDFVDAARRARDAGFEWIELHFAHGYLGQSFFS 
Consensus hhhhhhhhhhhhhhhhhhhh eeeee hhhhh 
Conserv 59 979 9999 799596 7975575 5557 55 7557 
NemA DSANRRTDAYGGSIENRARLLLEVVDAAIDVWSAARVGVHLAPRGDAHTMG---DSDPAATFGHVARELG 260 
Cyclo SSTNQRTDQYGGSLENRARLLLEVTDAAIEIWGAGRVGVHLAPRADSHDMG---DANLAETFTYVARELG 252 
XenB DNSNVRGDAYGGSIENRIRLLVEVTRRVAETVGAEKTGVRLSPNGDSQGVN---DSNPEPLFSAAAKALD 257 
GTN SSTNQRTDDYGGSIENRARFLLEVVDAVAEEIGAGRTGIRLSPVTPANDIF---EADPQPLYNYVVEQLG 265 
Morph TGTNRRTDQYGGSIENRARFPLEVVDAVAEVFGPERVGIRLTPFLELFGLT---DDEPEAMAFYLAGELD 261 
PETN PSSNQRTDQYGGSVENRARLVLEVVDAVCNEWSADRIGIRVSPIGTFQNVDN--GPNEEADALYLIEELA 274 
nYF: PHSNTRTDEYGGSIENRARFTLEVVDALVEAIGHEKVGLRLSPYGVFNSMSGGAETGIVAQYAYVAGELE 254 
EHSNKRTDAYGGSFDNRSRFLLETLAAVREVWPE-NLPLTARFGVLEYDGR---DEQTLEESIELARRFK 
Consensus hhhhhhhhhhhhhhhhhh eeeeee hhhhhhhhhhhhh 
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Conserv 5 567 57576575 
NemA RR----- RIAFLFARESFG-------------- GDAIGQQLKAAFGG-PFIVNENF-TLDSAQAALDAGQ 309 
Cyclo KR----- GIAFICSREKEG-------------- ADSLGPQLKEAFGG-PYIANERF-TKDSANAWLAAGK 301 
XenB EI 
----- 
GIAHLELREPGYEGTF 
------ 
GKADRPPVHPVIRQAFSR-TLILNSDY-TLETAQAALATGE 309 
GTN KR 
----- 
NLAFIHVVEGATGGPRDFKQGDKPFDYASFKAAYRNAGGKGLWIANNGY-DRQSAIF-AVESGK 321 
Morph RR-----GLAYLHFNEPDWIGG-------DITYPEGFREQMRQRFKG-GLIYCGNY-DAGRAQARLDDNT 316 
PETN KR 
----- 
GIAYLHMSETDLAGG 
-------- 
KPYSEAFRQKVRERFHG-VIIGAGAY-TAEKAEDLIGKGL 341 
C! Yi< KRAKAGKRLAFVHLVEPRVTNPFLTE--GEGEYEGGSNDFVYSIWKG-PVIRAGNFALHPEVVREEVKDK 316 
x-. n AG 
----- 
GLDLLSVSVGFTIPDTNIP--WGPAFMGPIAERVRRF-AKL-PVTSAWGFGTPQLAEAALQANQ 
Consensus h eeeee hhhhhhhhhhh eeee hhhhhhhhh 
Conserv 766 95 5677977 75 6 77 667 5 77 999 5 
Nem. P, ADAVAWGKLFIANPDLPRRFKLNAPLNEPNAATFYAQGEVGYTDYPALESAA------- 361 
Cyclo ADAVAFGVPFIANPDLPARLKADAPLNEAHPETFYGKGPVGYIDYPTL----------- 349 
XenF, ADAITFGRPFLANPDLPHRFAERLPLNKDVMETWYSQGPEGYVDYPTADQK-------- 360 
GTN VDAVAFGKAFIANPDLVRRLKNDAPLNAPNQPTFYGGGAEGYTDYPALAQ--------- 371 
Morpl-. ADAVAFGRPFIANPDLPERFRLGAALNEPDPSTFYGGAEVGYTDYPFLDNGHDRLG--- 377 
PE'IN IDAVAFGRDYIANPDLVARLQKKAELNPQRPESFYGGGAEGYTDYPSL----------- 364 
YE RTLIGYGRFFISNPDLVDRLEKGLPLNKYDRDTFYQMSAHGYIDYPTYEEALKLGWDKK 400 
7: ri LDLVSVGRAHLADPHWAYFAAKELGVEK---ASWTLPAPYAHW---- LE---------- 
Consensus eeee hhhhh hhhhhh hhh 
A3.4 Alignment of group II protein sequences using Clustal-W2 
NEC 
-------- 
DIISVAL: liRHSTKAFDASi: KLTAEEAE?; I? ITLLQYSPSSTNS 42 
pnrB 
-------MDTVSLAKRRYTTKAYDASRRIPQATVDALLEQLRHSPSSVNS 43 
FRase 
-----MTHPIIHDLENRYTSKKYDPSKKVSQEDLAVLLEALRLSASSINS 45 
NOX MEATLPVLDAKTAALKRRSIRRYR-KDPVPEGLLREILEAALRAPSAWNL 49 
FrxA 
----MDREQVVALQHQRFAAKKYDPNFFISQrDWEALVEVGPLAPSSIGL 46 
NEC QPWHFIVASTEEGKARVAKSAAGTYVFNEF: 
"MLDASHVVVFCAKTAMDDA 92 
pnrB QPWHFIVADTAEGKALLAKSTAEGYAYNTQKLLDASHVIVFCTRTEMTEE 93 
FRase QPWKFIVIESDAAKQRMHDSFANMHQFNQPHIKACSHVILFANKLSYTRD 95 
NOX QPWRIVVVRDPATKRALREA----- AFGQAHVEEAPVVLVLYADLEDALA 94 
FrxA EPWKMLLLKNERMl'EDLF'PMAWG---- ALFGLEGASHFVIYLARKGVTYD 92 
NEC WLERWDQEEADGiFNTPEAi'AANH'r'GFTYFADMHPVDLKDDDQWMA}: QV 142 
pnrB HLNAVLDQEAADGRFRDEQARAGQNQSRRHYVNLHRFDQKDVQHWMEKQT 143 
FRase DYDWLSKAVADKRITEEQKEAAFASFK--FVELNCDENGEHKAWTKPQA 143 
NOX HLDEVIHPG----- VQGERREAQKQAIQRAFAAMG---QEARKAWASGQS 136 
FrxA SDYVKKVMHEVKKRDYDTNSRFAQIIKNFQENDMKLNSERSLFDWASKQT 142 
NEC YLNVGNFLLGVGAMGLDAVPIEGFDAAILDEEFG---- LKEKGFTSLVVV 188 
pnrB YLALGTALLGAAAHGLDATPIEGFDSKVLDAELG 
---- 
LRERGFTSVVIL 189 
FRase YLALGNALHTLARLNIDSTTMEGIDPELLSEIFA 
---- 
DELKGYECHVAL 189 
NOX YILLGYLLLLLEAYGLGSVPMLGFDPERVRAILG---- LPSR-AAIPALV 181 
FrxA YIQMANMMMAAAMLGIDSCPIEGYDQEKVEAYLEEKGYLNTAEFGVSVMA 192 
NEC PVGHHS-VEDFNATLPKSRLPLSTIVTEC- 216 
pnrB SLGYRS-EADFNAGLNKSRLPASQVFTFL- 217 
FRase AIGYHHPSEDYNASLPKSRKAFEDVITIL- 218 
NOX ALGYPA----- EEGYPSHRLPLERVVLWR- 205 
FrxA CFGYRN----- QEITPKTRWKTEVIYEVIE 217 
A3.5 Alignment of group 11 protein sequences using T-Coffee 
NEC 
--------DIISVALhI'HSTIAFDAS! 'F. LTAEEAEi<IF: TLLQYSPSSTNSQPWHFIVAST 
NOX MEATLPVLDAKTAALKRRSIRRYRKD-PVPEGLLREILEAALRAPSAWNLQPWRIVVVRD 
FRase MTH----- PIIHDLENRYTSKKYDPSKKVSQEDLAVLLEALRLSASSINSQPWKFIVIES 
FrxA MDRE 
---- 
QVVALQHQRFAAKKYDPNRRISQKDWEALVEVGRLAPSSIGLEPWKMLLLKN 
pnrB M-------DTVSLAKRRYTTKAYDASRRIPQATVDALLEQLRHSPSSVNSQPWHFIVADT 
NEC EEGKARVAKSAAGTYVFNER-KMLDASHVVVFCAKTAMD--DAWLERVVDQEEADGRFNT 
NOX PATKRALREA-A 
---- 
FGQA-HVEEAPVVLVLYADLEDA--LAHLDEVIHPGV-QGERRE 
FRase DAAKQRMHDSFANMHQFNQP-HIKACSHVILFANKLSYT--RDDYDVVLSKAVADKRITE 
FrxA ERMKEDLKPM-A---- WGALFGLEGASHFVIYLARKGVTYDSDYVKKVMHE-V-KKRDYD 
pnrB AEGKALLAKSTAEGYAYNTQ-KLLDASHVIVFCTRTEMT--EHLNAVLDQEAADGRFRD 
XX111 
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NEC PEAKAANHKGRTYFADMHHVDLKDDDQWMAKQVYLNVGNFLLGVGAMGLDAVPIEGFDAA 
NOX AQKQAIQ--RAFA--AM---GQEARKAWASGQSYILLGYLLLLLEAYGLGSVPMLGFDPE 
FRase EQKEAAFASF--KFVELNCDENGEHKAWTKPQAYLALGNALHTLARLNIDSTTMEGIDPE 
FrxA TNSRFAQIIKNFQENDMKLNSERSLFDWASKQTYIQMANMMMAAAMLGIDSCPIEGYDQE 
pnrB EQAiAGQNQS6FHYVNLHFFDQF: DVQHWMEi: QTYLALGTALLGAAAHGLDATPIEGFDSI' 
NEC ILDEEFGLiEtGFT------ SLVVVPVGHH-SVEDFNATLPS LPLSTIV-TEC 
NOX kVRAILGLPSkAA------- IPALVALGYP-AEE---- GYPSHRLPLEkVV-LWR 
FRase LLSEIFADELKGYE------ CHVALAIGYHHPSEDYNASLPKSRKAFEDVI-TIL 
FrxA F"VEAYL--EEKGYLNTAEFGVSVMACFGYR-NQE----ITPKTRWF, TEVIYEVIE 
pnrB VLDAELGL: E: GFT------ SVVILSLGY: 
-SEADFNAGLNFS: LPASQVF-TFL 
A3.6 Alignment of group II protein sequences using PROMALS 
Conserv 96 66 656 5696 65699 69 
-------MDTVSLAKRRY'I'TKAYDASRRIPQATVDALLEQLRHSPSSVNSQPWHFIVADTAEGKALLAKS 63 
Nh: 
--------DIISVALKRHSTKAFDASKKLTAEEAEKIKTLLQYSPSSTNSQPWHFIVASTEEGKARVAKS 62 
I M-----THPIIHDLENRYTSKKYDPSKKVSQEDLAVLLEALRLSASSINSQPWKFIVIESDAAKQRMHDS 65 
M----DREQVVALQHQRFAAKKYDPNRRISQKDWEALVEVGRLAPSSIGLEPWKMLLLKNERMKEDLKPM 66 
MEATLPVLDAKTAALKRRSIRRYRK-DPVPEGLLREILEAALRAPSAWNLQPWRIVVVRDPATKRALREA 69 
Consensus hhhhhhhhh hh hhhhhhhhhhhhh eeeeeee hhhhhhhhhh 
Conserv 6666 6 659 
PnrB TAEGYAYNTQKLLDASHVIVFCTRTEMTEEHLNAVLDQEAADGRFRDEQARAGQNQSRRHYVNLHRFDQK 133 
NEC AAGTYVFNERKMLDASHWVFCAKTAMDDAWLERVVDQEEADGRFNTPEAKAANHKGRTYFADMHRVDLK 132 
FPaýý. I FANMHQFNQPHIKACSHVILFANKLSYTRDDYDWLSKAVADKRITEEQKEAAFASFKFV--ELNCDENG 133 
i: ", AWG----ALFGLEGASHFVIYLARKGVTYDSDYVKKVMHEVKKRDYDTNSRFAQIIKNFQENDMKLNSER 132 
NCX AF 
----- 
GQAHVEEAPVVLVLYADLEDALAHLDEVIHPGVQ 
-------- 
GERREAQKQAIQRAFAAMGQE 126 
Consensus hhhhhh hhhhh eeeeee hhhhhhhhhhhhhh hhhhhhhhhhhhhhhhhh hh 
Conserv 99 95 66 6565 6569 95556 96 
PnrP DVQHWMEKQTYLALGTALLGAAAHGLDATPIEGFDSKVLDAELGLR----ERGFTSVVILSLGYRSEADF 199 
NEC DDDQWMAKQVYLNVGNFLLGVGAMGLDAVPIEGFDAAILDEEFGLK----EKGFTSLVVVPVGHHSVEDF 198 
iýsel EHKAWTKPQAYLALGNALHTLARLNIDSTTMEGIDPELLSEIFADE----LKGYECHVALAIGYHHPSED 199 
IxA SLFDWASKQTYIQMANMMMAAAMLGIDSCPIEGYDQEKVEAYLEEKGYLNTAEFGVSVMACFGYRNQEI- 201 
V, X. ARKAWASGQSYILLGYLLLLLEAYGLGSVPMLGFDPERVRAILGL-----PSRAAIPALVALGYPAEEG- 190 
Consensus hhhhhhhhhhhhhhhhhhhhhhh eeee hhhhhhh eeeeeeeee 
Conserv 66 955 
PnrH 
-NAGLNKSRLPASQVFTFL- 217 
NEC 
-NATLPKSRLPLSTIVTEC- 216 
FRasel YNASLPKSRKAFEDVITIL- 218 
I'rxA 
----TPKTRWKTEVIYEVIE 217 
ýj- 
----YPSHRLPLERVVLWR- 205 
Consensus hhhhhh 
A3.7 Alignment of group III protein sequences using Clustal-W2 
Frp 
----------------------- 
MNNTIETILAfIi%SI! iFTAVPITDEQR 27 
NfsA 
----------------------- 
MTPTIELICGHRSIRHFTDEPISEAQP 27 
NitA 
-----------------------MNNTIDTMKNHRSIRQYLDKEVPNDLI 27 
pnrA MSLQDEALKAWQARYGEPANLPAADTVIAQMLQHRSVRAYSDLPVDEQML 24 
NitB 
--------------------------MIDLLKTRRSIRKYKNKEIEKEKV 30 
NbzA 
--------------------MPTSPFIDDLIRDRRAKRGFLDQPVSIEMV 
Frp QTIIQAGLAASSSSMLQWSIV'. VT--DSEKRNELAQFAGNQAYVESAAE 75 
NfsA EAIINSARATSSSSFLQCSSIIRIT--DKALREELVTLTGGQKHVAQAAE 75 
NitA DEIVKSAQAMPNSINGQQTSVIWR--DKKKREKLAELVGNQEYVAKAPV 75 
pnrA SWAIAAAQSASTSSNLQAWSVLAVR--DRERLARLARLSGNQRHVEQAPL 98 
NitB DTLLKAALLAPTSMGKRSWEFIAVT--NKNLISELSTARKMGSQFLKGAP 72 
NbzA KDILSAAP: YAPSSSNTQPWI: CYVITGEAREF, 'ITTAAVEAYRAAPEGLPPE 80 
Frp FLVFCIDYQk-----HATINPDVQADFTELTLIGAVDSGIMAQNCLLAAE 120 
NfsA FWVFCADFNR 
----- 
HLQICPDAQLGLAEQLLLGVVDTAMMAQNALIAAE 120 
NitA FLVFVMDFYRTYLAGEKTGLKQVIHEDIEGILAGSVDVGIALGASVVAAE 125 
pnrA FLVWLVDWSRLRRLARTLQAPTAGIDYLESYTVGVVDAALAAQNAALAFE 148 
NitB LVIVVVENPE------- ATDAYIEDGAIASTLIQVTAHSMGLGSCWCHVR 115 
NbzA YPFFPQPLHEP---- YATFFNSF? GQLGDALGIPR: SDITLzI, FDVE"QF 126 
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Frp SMGLGGVYIGGLFNSAAQVDELLG---LPENSAVLFGMCLGHPD--QNPE 165 
NfsA SLGLGGVYIGGLRNNIEAVTKLLK 
--- 
LPQHVLPLFGLCLGWPA--DNPD 165 
NitA SLGLGTVPIGGIRKMPEEVIEILG---LPKYTFPMVGLVVGYPA--DESH 170 
pnrA AQGLGIVYIGGMRNHPEAMSEELG 
--- 
LPNDTFAVFGMCVGHPDPAQPAE 195 
NitB NRDR----- IDYDTTEAFIKTLLN---IPENLKVECMLGIGYPD---- EE 153 
NbzA FFDAPVGLIFTMDRRLEWASFICYGCFLQNIMLAAKGRGLDTCTQVFWSM 176 
Frp VKPRLPAHWVHENQYQELNLDD--IQSYDQTMQAYYASRTSNQKLSTWS 213 
NfsA LKPRLPASILVHENSYQPLDKGA--LAQYDEQLAEYYLTRGSNNRRDTWS 213 
NitA KKPRVPFESFRHNESYDIKAVEDS-INVYDEQMNKYLKEIGRAEKEINWS 219 
pnrA IKPRLAQSWLHRERYEATEAEAVSVAAYDRRMSDFQHRQQRENR--SWS 243 
NitB =FAYTDEDLALN?: LHYD?: YSF----------------------------- 174 
NbzA QHPVLiTELNLPDDQMWAGMSLG---- WADNSLPENQMS: S MELEEFT 222 
Frp QEVTGi; LAGES---- i, PHILPYLNSr; GLA}; i, 240 
NfsA DHIRRTIIKES---- RPFILDYLHKQGWATL 240 
NitA TFTSTIYQSVY---- YPKVKGAINKQGLKTK 246 
pnrA SQAVERVKGADSLSGRHRLRDALNTLGFGLR 274 
NitB 
------------------------------- 
NbzA TFVHE-------------------------- 227 
A3.8 Alignment of group III protein sequences using T-Coffee 
NitA M----------------------- NN---TIDTMKNHRSIRQYLDFEVPNDLIDEIVKSA 
NitB M----------------------------- IDLLKTRRSIRKYKNKEIEKEKVDTLLKAA 
NfsA M-----------------------TP---TIELICGHRSIRHFTDEPISEAQREAIINSA 
Frp M----------------------- NN---TIETILAHRSIRKFTAVPITDEQRQTIIQAG 
nbzA M----------------------- PTSPFIDDLIRDRRAKRGFLDQPVSIEMVKDILSAA 
PnrA MSLQDEALKAWQARYGEPANLPAADT---VIAQMLQHRSVRAYSDLPVDEQMLSWAIAAA 
NitA QAMPNSINGQQTSVIVVRDKKKREKLAEL------------------------------- 
NitB LLAPTSMGKRSWEFIAVTNKNLISELSTARK----------------------------- 
NfsA RATSSSSFLQCSSIIRITDKALREELVTL------------------------------- 
Frp LAASSSSMLQVVSIVRVTDSEKRNELAQF------------------------------- 
nbzA KYAPSSSNTQPWRCYVITGE-ARERITTAAVEAYRAAPEGLPPEYPFFPQPLHEPYATRF 
PnrA QSASTSSNLQAWSVLAVRDRERLARLARL------------------------------- 
NitA 
------------------------VGNQEYVAKAPVFLVFVMDFYRTYLAGEKTGLKQVI 
NitB 
------------------------MGSQ-FLKGAPLVIVVVEN----------------- 
NfsA 
------------------------ 
TGGQKHVAQAAEFWVFCADFNRHLQICP----- DAQ 
Frp 
------------------------ 
AGNQAYVESAAEFLVFCIDYQRHATINP----- DVQ 
nbzA NSFRGQLGDALGIPRSDITLRRRDVERQFRFFDAPVGLIFTMD----------------- 
PnrA 
------------------------SGNQRHVEQAPLFLVWLVDWSRLRRLARTLQAPTAG 
NitA HEDIEGILAGSVDVGIALGASVVAAESLGLGTVPIGGIRK------- MPEE-VIEILGLP 
NitB 
---PEATDAYIEDGAIASTLIQVTAHSMGLGSCWCH-VRNRDRIDYDTTEAFIKTLLNIP 
NfsA LGLAEQLLLGVVDTAMMAQNALIAAESLGLGGVYIGGLRN------- NIEA-VTKLLKLP 
Frp ADFTELTLIGAVDSGIMAQNCLLAAESMGLGGVYIGGLRN------- SAAQ-VDELLGLP 
nbzA 
---RRLEWASFICYGCFLQNIMLAAKGRGLDTCTQV-------- FWSMQHPVLRTELNLP 
PnrA IDYLESYTVGVVDAALAAQNAALAFEAQGLGIVYIGGMRN------- HPEA-MSEELGLP 
NitA KYTFPMVGLVVGYP--ADESHKKPRVPFESFRHNESYDIKAVED-SINVYDEQMNý: YL'r'E 
NitB ENLKVECMLGIGYP--DEERKAY-------------------------- TDEDL------ 
NfsA QHVLPLFGLCLGWP--ADNPDLKPRLPASILVHENSYQP-LDKG-ALAQYDEQLAEYYLT 
Frp ENSAVLFGMCLGHP--DQNPEVKPRLPAHVVVHENQYQE-LNLD-DIQSYDQTMQAYYAS 
nbzA DDQMVVAGMSLGWA--DNSL----------------------------- PENQM------ 
PnrA NDTFAVFGMCVGHPDPAQPAEIKPRLAQSVVLHRERYEATEAEAVSVAAYDRRMSDFQHR 
NitA IGRAEKEINWSTFTSTIYQS---V-YYPKVKGAINKQG--LK---- TK 
NitB 
--------------------------------ALNKLHYDKY----SK 
NfsA RGSNNRRDTWSDHIRRTIIK---E-SRPFILDYLHKQG--WA---- TR 
Frp RTSNQKLSTWSQEVTGKLAG---E-SRPHILPYLNSKG--LA---- KR 
nbzA 
--------------------------------SISKMELEEFTTFVHE 
PnrA QQRENR-SWSSQAVERVKGADSLSGRHRLRDALNTLG--FG 
---- 
LR 
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A3.9 Alignment of group 111 protein sequences using PROMALS 
Conserv 96 696 96 66 67 696 
Nbza MP 
-------------------- 
TSPFIDDLIRDRRAKRGFLDQPVSIEMVKDILSAAKYAPSSSNTQPWR 50 
Nith 
-------------------------- 
MIDLLKTRRSIRKYKNKETEKEKVDTLLKAALLAPTSMGKRSWE 44 
Nfsý, M----------------------- TPTIELICGHRSIRHFTDEPISEAQREAIINSARATSSSSFLQCSS 47 
I'll M----------------------- NNTIETILAHRSIRKFTAVPITDEQRQTIIQAGLAASSSSMLQVVS 47 
, ..,. 
MSLQDEALKAWQARYGEPANLPAADTVIAQMLQHRSVRAYSDLPVDEQMLSWAIAAAQSASTSSNLQAWS 70 
14 'A M----------------------- NNTIDTMKNHRSIRQYLDKEVPNDLIDEIVKSAQAMPNSINGQQTS 47 
Consensus hhhhhhhh hhh hhhhhhhhhhhhh ee 
Conserv 66 6666 
Nbxa CYVITGEARERITTAAVEA-YRAAPEGLPPEYPFFPQPLHEPYATRFNSFRGQLGDALGIPRSDITLRRR 119 
NiCE3 FIAVTNKNLISELSTARKMGSQFLKGAPLVIVVVENPE-------------------------------- 96 
NfsA IIRITDKALREELVTLTGG-QKHVAQAAEFWVFCADFNRHLQICPDAQLG-------------------- 96 
Frp IVRVTDSEKRNELAQFAGN-QAYVESAAEFLVFCIDYQRHATINPDVQA------ D-------------- 124 
:: )! A VLAVRDRERLARLARLSGN-QRHVEQAPLFLVWLVDWSRLRRLARTLQAP-TAGID 
-------------- 
101 
NtA VIWRDKKKREKLAELVGN-QEYVAKAPVFLVFVMDFYRTYLAGEKTGLK-QVIHE-------------- 
Consensus eeeee hhhhhhhhhhhhh hhhhhh eeeeee hhhhhhhhhhh hhhhh 
Conserv 666 66 996 6 
Nb. t: r DVERQFRFFDAPVGLIFTMDRRLEWASFICYGCFLQNIMLAAKGRGLDTCTQVFWS-------MQHPVLR 182 
tJ_; 6 
----------------------ATDAYIEDGAIASTLIQVTAHSMGLGSCWCHVRNRDRIDYDTTEAFIK 130 
NfsA 
------------------- 
LAEQLLLGVVDTAMMAQNALIAAESLGLGGVYIGGLR------- NNIEAVT 140 
Frp 
------------------- 
FTELTLIGAVDSGIMAQNCLLAAESMGLGGVYIGGLR------- NSAAQVD 140 
aarA 
------------------- 
YLESYTVGVVDAALAAQNAALAFEAQGLGIVYIGGMR------- NHPEAMS 140 
---- 
DIEGILAGSVDVGIALGASVVAAESLGLGTVPIGGIR------- KMPEEVI 169 
Consensus hhhhhhhhhhhhhhhhhhhhhhhhh eeee hhhhh 145 
Conserv 9 69 66 9 66 66 
NLý TELNLPDDQMVVAGMSLGWADNSLP--ENQMSISKMELEEFTTFVHE----------------------- 227 
NH TLLNIPENLKVECMLGIGYPDEERKAY----- TDEDLALNKLHYDKYSK--------------------- 174 
NfsA KLLKLPQHVLPLFGLCLGWPADNPDL------KPRLPASILVHENSYQP--LDKGALAQYDEQLAEYYLT 202 
Frp ELLGLPENSAVLFGMCLGHPDQNPEV------KPRLPAHVVVHENQYQE--LNLDDIQSYDQTMQAYYAS 202 
pn! -A EELGLPNDTFAVFGMCVGHPDPAQPAEI----KPRLAQSVVLHRERYEATEAEAVSVAAYDRRMSDFQHR 234 
u.,; EILGLPKYTFPMVGLVVGYPADESHK------KPRVPFESFRHNESYDIK-AVEDSINVYDEQMNKYLKE 208 
Consensus hh eeeeeeee hhhhhhh hhhhhhhhhhhhhhhh 
Conserv 
Nbz: i 
NilI+ 
NfsA 
F: F 
------------------------------------------ RGSNNRRDTWSDHIRRTIIKE---- SRPFILDYLHKQGWATR 
RTSNQKLSTWSQEVTGKLAGE 
---- 
SRPHILPYLNSKGLAKR 
QQREN--RSWSSQAVERVKGADSLSGRHRLRDALNTLGFGLR 
IGRAEKEINWSTFTSTIYQSV---- YYPKVKGAINKQGLKTK 
hhhhhhhhh hhhhhhhhhh 
240 
240 
274 
246 
Consensus 
A3.10 Alignment of group IV protein sequences using Clustal-W2 
NQO1 
---V", iFALIVLAHSEýTSFNYAM-EAAAAALFGWEVVESDLYAMNFN 47 
NQO2 GAMAGKKVLIVYAHQEPKSFNGSLKNVAVDELSRQGCTVTVSDLYAMNFE 50 
ywrO 
----- 
MKVLVLAFHPN---MEQSVVNRAFADTLKDAPGITLRDLYQEYPD 42 
YieF 
---MSEKLQVVTLLGSLR--KGSFNGMVARTLPKIAPASMEVNALPSIAD 45 
NQO1 PIISRKDITGKLKDPANFQYPAESVLAYKEGHLSPDIVAEQKKLEAADLV 97 
NQO2 PRATDKDITGTLSNPEVFNYGVETHEA-KQRSLASDITDEQKKVREADLV 99 
ywrO 
-------------------------------- 
EAIDVEKEQKLCEEHDRI 60 
YieF IPLYDADVQ------------------- QEEGFPATVEALAEQIRQADGV 76 
NQO1 IFQFPLQWFGVPAILKGWFERVFIGEFAYTYAAMYDKGPFRSKKAVLSIT 147 
NQO2 IFQFPLYWFSVPAILKGWMDRVLCQGFAFDIPGFYDSGLLQGKLALLSVT 149 
ywrO VFQFPLYWYSSPPLLKKWLDHVLLYGWAYGTNG 
---- 
TALRGKEFMVAVS 106 
YieF VIVTPEYNYSVPGGLKNAID------ WLSRLPD---- QPLAGKPVLIQTS 116 
NQO1 TGGSGSMYSLQGIHGDMNVILWPIQSGILHFCG---FQVLEPQLTYSIGH 194 
NQO2 TGGTAEMYTKTGVNGDSRYFLWPLQHGTLHFCG 
--- 
FKVLAPQISFAPEI 196 
ywrO AGAPEEAYQAGGSNHYAISELLRPFQATSNFIG 
--- 
TTYLPPYVFYQAGT 153 
YieF SMGVIGGARCQYHLRQILVFLDAMVMNKPEFMGGVIQNKVDPQTGEVIDQ 166 
NQO1 TPADARIQILEGWKKRLENIWDETPLYFAPSSLFDLNFQAGFLMKKEVQD 244 
NQO2 ASEEERKGMVAAWSQRLQTIWKEEPIPCT--------------------- 225 
ywrO AGKSELAEGATQYREHVLKSF----------------------------- 174 
YieF GTLDHLTGQLTAFGEFIQRVKI 
---------------------------- 
188 
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NQO1 EEYNKkFGLSVGHHLGi_SIPTDNQI}: Anb: 
NQO2 
----------AHWHFGQ------------ 
ywrO 
----------------------------- 
YieF 
----------------------------- 
A3.11 Alignment of group IV protein sequences using T-Coffee 
273 
232 
NQO1 
---V'ýI'ALIVLA--HSE: -TSFNYAM-EAAAAAL: ! 
-ýWEVVESDLYAMNFNPIIS : DI NQ02 GAMAGKKVLIVYA--HQEPKSFNGSLKNVAVDELSRQGCTVTVSDLYAMNFEPFATDF: DI 
YieF 
---MSEKLQVVTLLGSLRKGSFNGMVARTL---- PKIAPASME------- VNALPSIADI 
ywrO 
---M--KVLVLAFHPNMEQSVVNRAFAD-----TLKDAPGITLRDLYQ------------ 
NQO1 TGKLKDPANFQYPAESVLAYKEGHLSPDIVAEQKKLEAADLVIFQFPLQWFGVPAILKGW 
NQ02 TGTLSNPEVFNYGVETHEA-KQRSLASDITDEQKKVREADLVIFQFPLYWFSVPAILKGW 
YieF 
------------PLYDADVQQEEGFPATVEALAEQIRQADGVVIVTPEYNYSVPGGLKNA 
ywrO 
---------- 
EYP---------- DEAIDVEKEQKLCEEHDRIVFQFPLYWYSSPPLLKKW 
NQO1 F---ERVFIGEFAYTYAAMYDKGPFRSKKAVLSITT---- GGSGSMYSLQGIHG-DMNVI 
NQ02 M 
--- 
DRVLCQGFAFDIPGFYDSGLLQGKLALLSVTT 
---- 
GGTAEMYTKTGVNG-DSRYF 
YieF IDWLSRL------------- PDQPLAGKPVLIQTSSMGVIGGARCQYHLR-------- QI 
ywrO L---DHVLLYGWAYGT---- NGTALRGKEFMVAVSA---- GAPEEAYQAGGSNHYAISEL 
NQO1 L---WPIQSGILHFCGF---QVLEPQLTYSIGHTPADARIQILEGWt'KbLENIWDETPLY 
NQ02 L---WPLQHGTLHFCGF---KVLAPQISFAPEIASEEERKGMVAAWSQhLQTIWKEEP-- 
YieF LVFLDAMVMNKPEFMGGVIQNKVDPQTGEVIDQGTLDHLTGQLTAFGEFIQ--------- 
ywr0 L---RPFQ-ATSNFIGT---TYLPPYVFYQAGTAGKSELAEGATQYRE------------ 
NQO1 
NQO2 
YieF 
ywrO 
FAPSSLFDLNFQAGFLMKKEVQDEEKNKKFGLSVGHHLGKSIPTDNQIKARK 
----------------------------------------- 
IPCTAHWHPGQ 
------------------------------------------------RVKI 
----------------------------------------------HVLKSF 
A3.12 Alignment of group IV protein sequences using PROMALS 
Conserv 55 5555 555 
ýw-0 
--M----KVLVLAFHPNMEQ---SVVNkAF'ADT:. KDAPGITLRDLYQEYPDEAI---------------- 45 
! '.. GAMAG-KKVLIVYAHQEPKSFNGSLKNVAVDELSRQGCTVTVSDLYAMNFEPRATDKDITGTLSNPEVFN 69 
----VGRRALIVLAHSERTSFNYAMKEAAAAALKKKGWEVVESDLYAMNFNPIISRKDITGKLKDPANFQ 66 
--MSEKLQVVTLLGSLRKGSFNGMVARTLPKIAPASMEVNALPSIADIPLYDAD---------------- 52 
consensus eeeeee 
hhhhhhhhhhhhhhh eeeee hhh hhhhhh 
Conserv 55 555 59 5555595555559 99 555 
---------------- 
DVEKEQKLCEEHDRIVFQFPLYWYSSPPLLKKWLDHVLLYGWAYGTN---- GTA 95 
YGVETHEAYKQRSLASDITDEQKKVREADLVIFQFPLYWFSVPAILKGWMDRVLCQGFAFDIPGFYDSGL 139 
_ 
YPAESVLAYKEGHLSPDIVAEQKKLEAADLVIFQFPLQWFGVPAILKGWFERVFIGEFAYTYAAMYDKGP 136 
1. F -------VQQEEGFPATVEALAEQIRQADGVVIVTPEYNYSVPGGLKNAIDWLSRLP----------DQP 105 
consensus hhhhhhhh hhhhhhhhhhhh eeeee hhhhhhhhhhhh 
Conserv 5 59 5 55 5 55 95 55 5 
ywrO LRGKEFMVAVSAGAPEEAYQAGGSNHYAISELLRPFQATSNFIGTTYLPPYVFYQAGT----------AG 155 
NQ')? LQGKLALLSVTTGGTAEMYTKTGVNGDSRYFLWPLQHGTLHFCGFKVLAPQISFAPEI----------AS 199 
NýC-. FRSKKAVLSITTGGSGSMYSLQGIHGDMNVILWPIQSGILHFCGFQVLEPQLTYSIGH----------TP 196 
Y'' h LAGKPVLIQTSSMGVIG-----------GARCQYHLRQILVFLDAMVMNKPEFMGGVIQNKVDPQTGEVI 164 
consensus eeeeeee hhh hhh hhhhhhhhhhhhhhhh eeeeee 
Conserv 
ywrO KSELAEGATQYREHVLKSF 
--------------------------------------------------- 
174 
NQO2 EEERKGMVAAWSQRLQTIWKEEPIPCTAHWHFGQ------------------------------------ 233 
NQO1 ADARIQILEGWKKRLENIWDETPLYFAPSSLFDLNFQAGFLMKKEVQDEEKNKKFGLSVGHHLGKSIPTD 266 
F DQGTLDHLTGQLTAFGEFIQRVKI 
---------------------------------------------- 
188 
consensus hhhhhhhhhhhhhhhhhhhhh 
Conserv 
ywrO 
NQO2 
NQo'. NQIKARK 
Y: eF 
_______ 
consensus 
273 
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A4. Ramachandran plots 
A4.1 Rainachandran plot of dataset one 
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Plot statistics 
Residues in most favoured regions [A, B, L) 
Residues in additional allowed regions [a, b, l, p] 
Residues in generously allowed regions [-a, -b, -I, -p] 
Residues in disallowed regions 
Number of non-glycine and non-proline residues 
Number of end-residues (excl. Gly and Pro) 
Number of glycine residues (shown as triangles) 
Number of proline residues 
Total number of residues 
359 90.2% 
37 9.3% 
2 0.5% 
0 0.0% 
398 100.0% 
8 
36 
22 
464 
Based on an analysis of 118 structures of resolution of at least 2.0 Angstroms 
and R-factor no greater than 20%, a good quality model would be expected 
to have over 90% in the most favoured regions. 
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A4.2 Ramachandran plot of dataset two 
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Plot statistics 
Residues in most favoured regions IA, B, L] 
Residues in additional allowed regions [a, b, l, p] 
Residues in generously allowed regions [-a, 
-b, -l, -p] 
Residues in disallowed regions 
Number of non-glycine and non-proline residues 
Number of end-residues (excl. Gly and Pro) 
Number of glycine residues (shown as triangles) 
Number of proline residues 
ýEH 
359 90.2% 
34 8.5% 
4 1.0% 
1 0.3% 
398 100.0% 
8 
36 
22 
Total number of residues 464 
Based on an analysis of 118 structures of resolution of at least 2.0 Angstroms 
and R-factor no greater than 20%, a good quality model would be expected 
to have over 90% in the most favoured regions. 
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A4.3 Ramachandran plot of dataset three 
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Residues in disallowed regions 
Number of non-glycine and non-proline residues 
Number of end-residues (encl. Gly and Pro) 
Number of glycine residues (shown as triangles) 
Number of proline residues 
Total number of residues 
a 
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a 
364 91.5% 
32 8.0% 
2 0.5% 
0 0.0% 
398 100.0% 
8 
36 
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464 
Based on an analysis of 118 structures of resolution of at least 2.0 Angstroms 
and R-factor no greater than 20%, a good quality model would be expected 
to have over 90% in the most favoured regions. 
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A4.4 Ramachandran plot of dataset four 
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Total number of residues 464 
Rased on an analysis of 118 structures of resolution of at least 2.0 Angstroms 
and Rfactor no greater than 20%. a good quality model would be expected 
to have over 90% in the most favoured regions. 
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A4.5 Ramachandran plot of dataset five 
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Residues in additional allowed regions [a, b, ], p] 
Residues in generously allowed regions [-a, 
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Residues in disallowed regions 
Number of non-glycine and non-proline residues 
Number of end-residues (excl. Gly and Pro) 
Number of glycine residues (shown as triangles) 
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361 90.7% 
35 8.8% 
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398 100.0% 
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Total number of residues 464 
Based on an analysis of 118 structures of resolution of at least 2.0 Angstroms 
and R-factor no greater than 20W, a good quality model would be expected 
to have over 90% in the most favoured regions. 
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